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1. Introduction 
1.1. Cartilage  
Cartilage is an avascular, aneural and alymphatic connective tissue, covering the 
articulating ends of long bones. Cartilage is primarily (> 95%) composed of a highly 
organized extracellular matrix (ECM), comprising a collagen II network, 
proteoglycans and non-collagen proteins. Chondrocytes, the unique cell component of 
cartilage, are assumed to be responsible for the production and maintenance of the 
ECM by low-turnover replacement of certain matrix proteins [1]. 
ECM in cartilage consists of a fluid phase composed of high percentage (70-80% by 
wet weight) water and electrolytes (Fig.1). The solid phase of cartilage contains 
collagen fibrils, proteoglycans, and glycoproteins. Collagen is believed to contribute 
mostly to the tensile behaviour of the tissue. Proteoglycans are large molecules with a 
protein backbone named core protein and glycosaminoglycan (GAG) side chains. 
Beside the main proteoglycan-aggrecan, there are several other small proteoglycans, 
such as decorin, biglycan and fibromodulin. The most common types of GAGs are 
chondroitin sulphate and keratan sulphate. Trapped in the collagen network, 
proteoglycans are attached to a molecule of hyaluronan, forming a feathery structure 
called a proteoglycan aggregate. With numerous negatively charged sulphate groups, 
these aggregates attract positive ions in the surrounding fluid phase and lead to 
increased swelling pressures as compared to the outside of this tissue. The collagen 
fibrils in the matrix limit water imbibitions by limiting the degree to separation of 
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glycosaminoglycans. Thus, collagen fibrils and proteoglycans contribute mostly to the 
mechanical characteristics of cartilage [2-4]. 
 
Figure.1 Structure of cartilage 
http://www.bidmc.org/Research/Departments/Radiology/Laboratories/Cartilage.aspx 
 
1.2. Osteoarthritis (OA) 
OA is one of the most important causes of physical disability in adults and ranks 
among the most frequent and cost-intensive chronic diseases in advanced age. In the 
USA, Europe and Japan, the estimated total prevalence of OA ranges from 36% to 48% 
of the population. Due to the growing proportion of older age groups, the estimated 
number of total prevalent cases of OA is expected to grow by 1.1-1.2 % per year [5]. 
27 million Americans have OA, and this arthritis patient number is projected to 
increase to 67 million in 2030. One out of four adults will be affected by arthritis and 
8
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OA will account for most cases. The annual cost of arthritis in the USA economy is 
total $128 billion and OA accounts for much of that. In 2004, over 11 million 
physician visits, 662,000 hospitalizations, and more than 632,000 total joint 
replacements were caused by OA in USA [6]. In Austria, OA resulted in 44,151 
hospitalizations (15,601 men, 28,550 women) in 2000, and the average stay in 
hospital was 16.8 days (man 16 days, woman 17 days) [7]. 
As the most common joint disease in elderly, OA is characterized by progressive loss 
of articular cartilage. Generally, knees, hips, hands, and the spine are the most 
frequently affected sites. The symptoms are often associated with significant 
functional impairment, pain, stiffness, and disability. Traditionally, OA has been 
considered a disease of articular cartilage. Recently, evidence demonstrated that OA 
is not only a disorder of cartilage, but a disease affecting the whole joint, including 
subchondral bone sclerosis, osteophyte formation, and changes in the synovial tissue 
(Fig2.). Various components of the joint are involved in the pathological progression 
of OA, such as the synovial joint lining and peri-articular bone [8, 9]. In contrast to 
rheumatoid arthritis, OA is conventionally not considered a classical inflammatory 
arthropathy, but thought to develop from chronic overuse or injury of the joint. A 
variety of risk factors associated with OA include age, sex, overweight, trauma, 
inflammation diseases of bones or genetic predisposition [7, 10].  
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Figure.2  Healthy and osteoarthritic joint  
http://www.mendmeshop.com/knee/knee_osteoarthritis_causes.php 
 
The etiology of OA is multi-factorial involving both mechanical and biochemical 
factors (Fig.3). Chondrocytes embedded within the negatively charged ECM, serve as 
mechano-sensors and osmo-sensors, and change the metabolism in response to local 
physicochemical alteration of the microenvironment[11]. In OA, a shift in equilibrium 
between anabolic and catabolic activities occurs in cartilage and surrounding joint 
tissues. The metabolic imbalance results in increased cartilage degradation and 
insufficient reparative responses.  
 
1.2.1. Cartilage metabolism in OA 
Degeneration and loss of articular cartilage are characteristic features of OA. The loss 
of articular cartilage is a result of the action of unregulated and overproduced 
proteinases that degrade both proteoglycans and collagens. Matrix metalloproteinases 
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(MMPs) include collagenases (MMP-1, MMP-8, and MMP-13), stromelysin-1 
(MMP-3), the gelatinaseses (MMP-2 and MMP-9) and membrane type 1 MMP 
(MMP14) [1, 12]. Of the collagensases, MMP-13 is assumed to play an important role 
in OA progression because of its preferential ability to degrade native type II collagen 
[11, 12]. MMP-3, MMP-8 and MMP14 are capable of degrading proteoglycans [1]. 
The aggrecanases belong to a family of extracellular proteases known as the 
ADAMTS (a distintergrin and metalloprotease with thrombospondin motifs). 
ADAMTS-4 and ADAMTS-5 are now regarded as the principal aggrecan degrading 
enzymes in cartilage [13]. 
In early OA, there is evidence of increased synthetic activity, which is considered as a 
compensatory response of chondrocyts to regenerate the matrix with cartilage specific 
components including types II, IX, and XI collagens, agggrecan, and type IV collagen 
[8]. The increased levels of cartilage anabolic factors such as bone morphogenetic 
proteins (BMPs) and insulin-like growth factor-α, TGF-ß, and fibroblast growth 
factors provide a possible explanation of the underlying mechanism [11,14,15]. 
However, once the cartilage is severely degraded the chondrocyte is not able to 
maintain or reconstruct the structure of cartilage. Along with the phenotypic 
modulation of the articular OA chondrocytes, the cells stop to expressing aggrecan 
and collagen type II, but start to synthesize collagen types I, III, and V [16]. 
Introduction
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 Figure 3. Molecular and cellular mechanisms of OA [11]  
 
1.2.2. Inflammation and OA 
Traditionally, OA has been classified as a non-inflammatory disease because of the 
absence of neutrophils in the synovium and a systemic manifestation of inflammation. 
However, in the last decade evidence indicated that inflammation contributes to the 
symptoms and the progression of OA. In response to biochemical changes or 
mechanical loading within cartilage, chondrocytes can produce a number of 
inflammatory mediators, which drive predominantly catabolic pathways and inhibit 
matrix synthesis in joint tissue [8].  
Interleukin-1ß (IL-1ß) and tumor necrosis factor-α (TNF-α) are synthesized 
intracellularly as prescursors, converted to mature forms by the IL-1ß-converting 
enzyme (ICE, caspase-1) and the TNF-α-converting enzyme (TACE), respectively. 
12
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An increased production of both cytokines in joint tissues is a characteristic feature of 
OA [17]. IL-1ß and TNF-α stimulate chondrocytes to overexpress MMPs and 
suppress the synthesis of matrix collagen and proteoglycans. In addition, both 
cytokines in an autocrine/paracrine manner stimulate their own production and induce 
chondrocytes and synovial cells to produce other proinflammatory mediators, such as 
chemokines, prostanglandins and nitric oxide (NO). The action of both cytokines is in 
part mediated by activation of the transcription factor nuclear factor-κB(NF-κB). 
IL-1ß and TNF-α increase the synthesis of prostaglandin E2 (PGE2) via the inducing 
the expression or activities of cyclooxygenase(COX)-2, microsomal PGE synthase-I 
and soluble phospholipase A2, and they up-regulate the production of NO via 
inducible nitric oxide synthetase (iNOS, or NOS2). IL-1ß also has the capacity to 
induce IL-6, leukemia inhibitory factor (LIF), and IL-8 and suppress the expression of 
type II collagen (COL-2AI) [8, 18, 19, 20]. (Fig.3)  
Although debate remains regarding the essential role of synovitis in OA, and 
regarding the mechanism underlying the initiation of inflammatory mediators, 
inflammation is a major factor contributing to the exacerbation of dysregulation of 
chondrocyte function and cartilage degradation in OA.  
 
1.2.3. NF-κB signaling pathways in inflammation of cartilage 
Various signaling pathways are involved in the progression of OA. NF-κB signaling 
pathways play a crucial role in inflammatory processes, cartilage degradation, cell 
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proliferation, and angiogenesis in cartilage.  
In mammals, NF-κB dimers are homodimers or heterodimers of 5 different NF-κB 
proteins (RelA/p65, RelB, c-Rel, NFκB1/p105 and NFκB2/p100). NF-κB is present in 
the cytoplasm in an inactive form associated with the inhibitory NF-κB proteins (IκBα, 
IκBβ, IκBε) or the larger precursor proteins p105 (NFκB1) and p100 (NFκB2). 
Phosphorylation of the IκB kinase (IKK) results in nuclear translocation of NF-κB 
and induction of transcription of target genes. The IKK complex consists of two 
serine-threonine kinases, IKKα and IKKβ, and NEMO/IKKγ. The canonical NF-κB 
signaling module immediately reacts to most pro-inflammatory and stress-like 
responses. In this process, IKKβ is both necessary and sufficient to phosphorylate 
IκBα, or IκBβ in an IKKγ-dependent manner [21, 22, 23]. IKKα is specifically 
required for the activation of the so-called non-canonical or alternate NFκB pathway. 
The NF-κB pathway is essential for chondrocytes to express inflammation-related 
genes, including MMP-1, 3 and 13, iNOS/NOS-2, IL-6, IL-1, TNF-α, COX-2, and 
transcription factors such as ELF3/ESE-1 [23]. Evidence suggested that NF-κB and 
the MAP kinase ERK1/2 mediate inhibition of type II collagen and link protein 
expression [24], and mediate MMP-1, 3, and 13 RNA and protein expression [25] 
induced by in IL-1ß or TNF-α. Thus, the NF-κB pathways appear as potential 
therapeutic targets in OA. 
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1.3. Glycobiology of chondrocytes 
 
The ECM of cartilage consists of protein fibers embedded in an amorphous mixture of 
huge glycosylated proteins (proteoglycans), which serve as structural components of 
ECM and play a role in maintaining matrix homeostasis [2]. The protein component 
of proteoglycans is synthesized by ribosomes and translocated into the rough 
endoplasmic reticulum (ER). Then, a core oligosaccharide is added to the protein 
chain, following trimming and processing of monosaccharides, until a core mannose 
structure remains added to the protein chain (Fig.4A). Additional glycosylation of the 
proteoglycan further occurs in the Golgi apparatus in multiple enzymatic steps and is 
a form of co-translational and post-translational modification (Fig.4B). The 
attachment of oligosachharide to asparagine (N-linked) or serine/threonine (O-linked) 
residues confers protection against proteolytic degradation or controls protein folding 
[26-28].  
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A) 
 
B) 
 
Figure 4. A) Glycosylation in ER. B) Glycosylation in Golgi apparatus. The newly 
synthesized protein is shown in the lumen side of the ER membrane. 
http://employees.csbsju.edu/hjakubowski/classes/ch331/cho/glycoproteinshtm.htm 
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Glycosyltransferases (GTs) are a class of enzymes, which are responsible for the 
catalyzation of the glycosylation reactions. In different tissues and cell types, the 
characteristic glycopheotype varies during development and oncogenesis. In addition, 
the glycosylation reaction and expression of GTs can also be regulated by various 
factors such as cytokines and differentiation factors under homeostasis or pathogenic 
conditions. It is well known that altered glycosylation various significantly in cancer 
cells as compared to normal cells [29-31]. Such changes in the cellular 
glycophenotype potentially affect cell functions, such as cellular adhesion, cell 
signaling, and apoptosis [32, 33]. 
Sialic acids are a diverse family of negatively charged sugar units that are typically 
found at the outermost end of glycan chains of all cell types, meditating or modulating 
a variety of normal and pathological processes [34, 35]. In mammals, 20 
sialyltransferases (SiaTs) have been cloned and grouped into four families (ST3GAL, 
ST6GAL, ST6Galnac, ST8Sia) based on linkage (e.g., α-2,3 or α-2,6 linkage in case of 
N-linked glycans in glycoproteins) and acceptor substrate.  The diverse enzymes of 
the SiaT family share the cytidine monophosphate-sialic acid as donor substrate, but 
are distinguished by the oligosaccharide acceptor [36]. Cell surface sialylation has 
been reported to affect osteoclastogenesis, endocytosis in dendritic cells, and adhesion 
properties of human colon cancer cells [37-39].  
Recent studies have documented a relationship between the alteration of glycosylation 
and inflammatory conditions of cartilage. As such, OA was suggested to associate 
with a dysregulation in the hexosamine biosynthesis pathway that could lead to an 
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alteration of the level of o-linked n-acetylglucosamine (O-GlcNAc)-glycosylation in a 
variety of proteins [40]. Yang et al suggested that TNF-α and TGF-ß treatment cause 
specific glycosylation changes related to apoptosis and altered cell proliferation in 
human and bovine chondrocytes [32]. Thus, inflammatory conditions appear able to 
alter the synthesis and activities of glycosyltransferases that synthesize the glycan 
chains of glycoproteins, and these changes in turn can influence the functions of 
glycoproteins. 
 
1.4. Nutraceuticals for OA management 
In general, OA is a progressive disease, and not curable to date. Current treatment 
options are limited to non-pharmacological interventions range from physical exercise 
and weight loss to surgical intervention and symptomatic treatments using 
acetaminophen, oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs) or 
intra-articular glucocorticoid and hyaluronic acid injection to the affected joint [5]. 
The mechanism of cartilage degradation in OA is known as a multifactorial process. 
However, standard pharmacological interventions, such as the use of NSAIDs often 
act in a monomodal way associated with significant adverse effects due to the 
requirement of extended duration of medication. Nutraceuticals and 
phytopharmaceuticals, that usually contain a range of active compounds targeting 
multiple pathways, could provide an alternative to conventional treatment of OA [41, 
42]. Several studies suggest that glucosamine (GlcN), chondroitin sulphate, curcumin, 
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diacerin, s-adenosylmethionine, avocado/soybean unsaponisfiables, and numerous of 
nutraceuticals posses possible analgesic and structure-modifying effects.  
Glucosamin (GlcN) is a natural aminomonosaccharide existing in healthy cartilage. 
D- Glucosamine, the biologically active form, serves as a metabolic precursor for the 
synthesis of proteoglycans, GAG and hyaluronate. It was reported that GlcN sulfate 
stimulates proteolycan production and inhibits IL-1ß- induced NFκB activation in 
human OA chondrocytes and owns mild anti-inflammatory properties [43-45]. Over 
the last 20 years, numerous clinical studies on the use of GlcN as a medical therapy 
for OA were conducted worldwide, but there is conflicting outcome as to its 
effectiveness [46]. 
Curcumin (diferuloylmethane or 1,7-bis(40-hydroxy-30-methoxyphenyl)-1,6- 
heptadiene-3,5-dione) is an active phytochemical component from Indian curry spice 
tumeric (Curcuma longa) and has potent antioxidant, anti-inflammatory, 
anti-carcinogenic and anti-amyloid properties. It has been reported that curcumin is a 
potent inhibitor of NF-κB, c-jun N-terminal kinse (JNK), and signal transducers and 
activators of transcription (STAT) activation by oncostatin M (OSM) and IL-1ß. In 
chondrocytes, it down-regulates the expression of IL-1ß, TNF-α, cyclooxygenase- 2 
(COX2), nitrous oxide systems (NOS), MMPs and chemokines. Further, curcumin is 
able to restore type II collagen and GAG synthesis in chondrocytes[47-50]. Therefore, 
data from recent studies suggested that curcumin may be a novel and safe 
nutraceutical alternative to the first-line used NSAIDs treatment for OA. Nevertheless, 
more information about solubility, application, bioavailability, efficiency and toxicity 
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of curcumin is required and is thus an interesting topic of ongoing research efforts.  
A large number of other nutraceuticals and phytopharmaceuticals are currently widely 
studied. Avocado/soybean unsaponifiables, collage hydrolysates, vitamine D, 
resveratol, extracts from rose hip, ginger and bromelain have also been demonstrated 
to be effective for OA treatments [41, 42]. They could provide alternative for OA 
management, however, further evidence is needed for most of the compounds to draw 
final conclusions regarding their efficacy. 
 
1.4.1. Isolates from Caesalpinia sappan  
Sappan Lignum, the heartwood of Caesalpinia sappan L. (Leguminosae), is known as 
the source of a natural red dye (Fig.5A.). Besides, it has been widely used in oriental 
traditional medicine for improvement of blood circulation, sprains and emmeniopathy 
[51]. Recently, it has also been listed in the 15th edition of the Japanese 
Pharmacopoeia [52]. Different extracts and active compounds isolated from Sappan 
lignum have been reported to possess diverse biological activities including 
antioxidative [53], antiinflammtory [54, 55], antibacterial [56] and anticonvulsive [57] 
effects.  
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A                                     B 
    
Figure 5. A) Sappan lignum used in traditional Chinese medicine B) the structure of Brazilin 
 
Brazilin ((6aS,11bR)-7,11b-Dihydrobenz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol), 
the major compound of Sappan Lignum, was reported to possess anti-inflammatory 
[58], antibacterial [59] and antihepatotoxic effects [60]. In addition, numerous other 
compounds from Sappan Lignum such as prostosappanins A-E or sappanchalcone 
were shown to participate in the different biological activities [61].  
Although brazilin possesses a defined chemical structure (Fig.5B), as well as its own 
IUPAC name and CAS-number, commercially available “brazilin” is mostly an 
extract of sappan wood consisting of several undefined compounds. Hu et al reported 
that brazilin possesses anti-inflammatory actions in macrophages and acts through a 
novel mechanism involving the action of HO-1. In this study, they used a 
commercially available “brazilin” (MP Biomedicals, USA) as pure substance to 
examine the effects of brazilin on LPS-stimulated NO and cytokine production and 
iNOS and PGE2 expression in RAW264.7 macrophages [62]. In preliminary 
experiments, however, we analyzed this product using analytical HPLC and verified 
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that it is actually a multi-component sappan wood extract (data not shown). A similar 
situation was observed in a study of neoflavonoids based on negative ion electrospray 
mass spectrometry [63]. The purchased “brazilin” used in that study was also proved 
as a multi-component sappan wood extract by the manufacturer when contacted. In 
order to obtain chemically pure brazilin, chemical synthesis might represent one 
possibility. Huang et al. reported a unique route to synthesis of (±)-Brazilin using IBX 
[64]. However, this chemical synthesis is highly complex and on inquiry the authors 
claimed that they are currently not able to provide a sample of the purified product. 
Thus, according our experience, the most straightforward way to obtain pure brazilin 
is to isolate it from sappan wood prior to careful identification of its structure.  
Introduction
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1.5. Aim of the thesis 
The present thesis aimed to investigate two separate aspects of inflammation in 
human chondrocytes.  
 
First, we investigated the chondrocyte glycophenotype in different cell models and 
under inflammatory conditions in vitro.  
The study“Lectin binding patterns reflect the phenotypic status of in vitro 
chondrocyte models” aimed to evaluate the glycoprofile of primary human 
chondrocytes as well as the relationship between chondrocyte phenotype and 
glycophenotype by comparing primary chondrocytes and immortalized chondrocytes 
models.  
The study“Phenotype-related differential α-2,6- or α-2,3-sialylation of glycoprotein 
N-glycans in human chondrocytes” aimed to compare the sialylation pattern of 
primary human chondrocytes with immortalized chondrocytes models and one 
chondrosarcoma cell model, and to investigate the effects of IL-1ß and TNF-α on 
primary chondrocyte sialylation.  
The study“IL-1ß and TNF-α alter the glycophenotype of primary human 
chondrocytes in vitro” aimed to investigate the impact of IL-1ß and TNF-α on 
characteristics of chondrocyte glycophenotype focusing on (1) the ratio between 
oligomannosidic, hybrid and complex-type N-glycans, (2) the core fucosylation in 
N-glycans, and (3) the sialylation of N-and O-glycans with regard to linkage type and 
degree of sialylation. 
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As inflammatory events represent interesting targets for the treatment of OA, the 
second part of this thesis evaluated the activities of Caesalpinia sappan extracts (CSE) 
and the isolated compound brazilin in stimulated human chondrocytes and 
macrophages. 
 
The study“Caesalpinia sappan extract inhibits IL1ß mediated over-expression of 
matrix metalloproteinases in human chondrocytes” aimed to investigate the effect of 
CSE on catabolic processes in human OA chondrocytes, particularly regarding the 
expression and activity of major MMPs. 
 
The study“Anti-inflammatory activity of an ethanolic Caesalpinia sappan extract in 
human chondrocytes and macrophages” aimed to elucidate the anti-inflammatory 
activity of CSE in lipopolysaccharide (LPS)-stimulated human macrophages and 
IL-1ß-stimulated human chondrocytes, focusing on the inhibition of gene expression 
of proinflammatory factors such as IL-1ß and TNF-α, and on the interference with NO 
production and NF-κB-mediated COX-2 promoter activation.  
 
The study“Brazilin from Caesalpina sappan inhibits pro-inflammatory mediators 
and metalloproteinase-3 expression in human chondrocytes” aimed to proof the 
hypothesis that brazilin is responsible for previous studies observing 
anti-inflammatory effects of CSE in chondrocytes by determining the effects of 
brazilin on chondrocytes in comparison with CSE. 
24
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Abstract In vitro studies using chondrocyte cell cultures
have increased our understanding of cartilage physiology
and the altered chondrocytic cell phenotype in joint diseases.
Beside the use of primary cells isolated from cartilage
specimens of donors, immortalized chondrocyte cell lines
such as C-28/I2 and T/C-28a2 have facilitated reproducible
and standardized experiments. Although carbohydrate struc-
tures appear of significance for cartilage function, the
contribution of the chondrocyte glycocalyx to matrix
assembly and alterations of the chondrocyte phenotype is
poorly understood. Therefore, the present study aimed to
evaluate the glycoprofile of primary human chondrocytes
as well as of C-28/I2 and T/C-28a2 cells in culture.
First, the chondrocytic phenotype of primary and immor-
talized cells was assessed using real-time reverse tran-
scriptase polymerase chain reaction, immunofluorescence,
and glycosaminoglycans staining. Then, a panel of
lectins was selected to probe for a range of oligosaccha-
ride sequences determining specific products of the O-
glycosylation and N-glycosylation pathways. We found that
differences in the molecular phenotype between primary
chondrocytes and the immortalized chondrocyte cell models
C-28/I2 and T/C-28a2 are reflected in the glycoprofile of the
cells. In this regard, the glycocalyx of immortalized
chondrocytes was characterized by reduced levels of high-
mannose type and sialic acid-capped N-glycans as well as
increased fucosylated O-glycosylation products. In summary,
the present report emphasizes the glycophenotype as an
integral part of the chondrocyte phenotype and points at a
significant role of the glycophenotype in chondrocyte
differentiation.
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Introduction
Beside water, collagen fibers, and other components such
as adhesion proteins and lipids, the extracellular matrix
(ECM) of cartilage consists of numerous glycoproteins and
proteoglycans which function in the maintenance of healthy
cartilage (Knudson and Knudson 2001). The attachment of
oligosaccharide chains to asparagine (N-linked) or serine/
threonine (O-linked) residues represents a common post-
translational modification of proteins potentially influenc-
ing biological processes such as apoptosis, inflammation,
cell signaling, protection against proteolytic degradation,
and protein folding (Knudson and Knudson 2001; Yang et
al. 2007). Furthermore, the protein backbone of major
cartilage proteoglycans is often associated with carbohy-
drate chains such as chondroitin sulfate, heparan sulfate,
and keratan sulfate. Another key molecule required for
matrix assembly is hyaluronan, a large linear glycosamino-
glycan (GAG) composed of a repeating disaccharide (beta-
D-glucuronyl-beta-D-N-acetylglucosamine) without core
protein (Lee and Spicer 2000). It can either be secreted by
chondrocytes into the ECM or stay associated with the
plasma membrane to form a pericellular coat maintaining
cell-substrate adhesion and reducing friction in cartilage. In
general, carbohydrate structures are of fundamental impor-
tance for the functionality of cartilage since the high density
of fixed charges from sulfated glycosaminoglycans (sGAG)
is essential to maintain hydrostatic pressure and gives
cartilage the resistance to bear loads.
In degenerative joint disorders such as osteoarthritis
(OA), the breakdown of the cartilage matrix represents a
major characteristic of the disease process. Typically,
loosening of the tight collagen network as well as the loss
of the interwoven proteoglycan aggregates determine the
initiation and progression of cartilage degeneration (Aigner
and Stove 2003). Being the only vital reactive elements
within the tissue, chondrocytes play a pivotal role in the
loss of cartilage function. It has been shown that increased
matrix catabolisms as well as alterations of the matrix gene
expression profile are important features of chondrocytes
under osteoarthritic conditions (Martin et al. 2001). In vitro
studies using chondrocyte cell cultures have increased our
understanding of cartilage physiology and the altered
chondrocytic cell phenotype in disease (Von der Mark et al.
1977; Martin et al. 2001; Stokes et al. 2002). In particular,
immortalized chondrocyte cell lines such as the C-28/I2 and
T/C-28a2 cell lines have facilitated reproducible and
standardized experiments exploring chondrocyte-specific
responses to stimuli such as cytokines or chondroprotective
agents (Goldring et al. 1994; Oliver et al. 2005; Toegel et
al. 2007b, 2008). Despite their high benefit, however, cell
lines—as expected for cells in constant log-phase growth—
were shown to differ from primary chondrocytes regarding
mRNA profiles and other features of the chondrocyte
phenotype (Finger et al. 2003).
Although carbohydrate structures appear of significance
for cartilage function, the contribution of the chondrocyte
glycocalyx to matrix assembly or alterations of the
chondrocyte phenotype is poorly understood. Hence, the
present study evaluates the glycoprofile of primary human
chondrocytes in culture as well as the relation between
chondrocytic phenotype and glycophenotype by comparing
primary chondrocytes with the immortalized chondrocyte
cell models C-28/I2 and T/C-28a2.
Materials and Methods
The fluorescein-labeled lectins from Triticum vulgare
(wheat germ agglutinin (WGA); molar ratio fluorescein/
protein (F/P)=3.1), Solanum tuberosum (STL; F/P=2.9),
Dolichos biflorus (DBA; F/P=2.2), Arachis hypogaea
(peanut agglutinin (PNA); F/P=5.2), Ulex europaeus
(Ulex europaeus isoagglutinin I (UEA); F/P=2.7) and Lens
culinaris (LCA; F/P=3.8) were purchased from Vector
laboratories (Burlingame, USA) and contained >98% active
conjugate and no free fluorescein. The Mx3000P QPCR
instrument, the StrataScript First-Strand Synthesis System,
and the Brilliant SYBR Green QPCR Master Mix were
from Stratagene (La Jolla, CA). All other chemicals were
obtained from Sigma-Aldrich (St. Louis, MO) unless
otherwise specified.
Isolation and culture of primary human chondrocytes.
Human OA cartilage was obtained during total knee
replacement surgery performed in patients with osteoarthri-
tis (six patients; age 60–68; blood group 0 RhD positive)
with informed consent and in accordance with the terms of
the ethics committee of the Medical University of Vienna
(EK-Nr.: 081/2005). Only cartilage specimens from femoral
condyles and the tibial plateaus showing no visible signs of
pathology were used. Primary chondrocytes were isolated
following standard protocols using 0.2% collagenase II
(Gibco, Carlsbad, CA). Primary chondrocytes were seeded
at high density (105 cells/cm2) and grown to confluence in
an atmosphere of humidified 5% CO2/95% air at 37°C
using Dulbecco’s modified Eagle medium supplemented
with 10% fetal calf serum (Biochrom AG, Berlin,
Germany), 2 μl/ml gentamycin, and 50 μg/ml ascorbate
as culture medium (full medium). For all assays, only
freshly isolated and seeded cells without subculturing were
used.
Culture of immortalized human chondrocytes. The T/C-
28a2 chondrocyte cell line was derived from primary
cultures isolated from costal cartilage from a 15-yr-old
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female by retroviral-mediated transfection with the large T
antigen of Simian virus 49 (Goldring et al. 1994). C-28/I2
represents a cell line obtained after clonal expansion of the
T/C-28 cells. Both cell lines retain chondrocytic morphol-
ogy and maintain continuous proliferation in monolayer
culture (Finger et al. 2003). C-28/I2 and T/C-28a2 cells
were verified to be mycoplasma-free using the Venor GeM
Mycoplasma PCR Detection Kit (Minerva Biolabs, Berlin,
Germany), seeded at 9.3×103 cells/cm2 and maintained in
full medium as described for primary cells.
Lectin binding assay. Immortalized chondrocytes were
cultured in 96-well microplates (Iwaki, Tokyo, Japan).
Confluent monolayers were washed three times with 50 μl
phosphate buffered saline (PBS) using a Columbus washer
(SLT, Salzburg, Austria) prior to incubation with 50 μl of a
dilution series of the respective fluorescein-labeled lectin
(3.125–100 pmol/well in PBS) for 60 min at 4°C. Selected
lectins, associated binding specificities, and target struc-
tures are presented in Table 1. Monolayers were washed
again and the mean cell-bound fluorescence intensity (MFI)
was determined using a Spectra Fluor fluorescence micro-
plate reader (SLT) equipped with Biolise software. Fluo-
rescence emission of the lectin-loaded cell monolayers with
50 μl PBS as supernatant was measured at 535 nm after
excitation at 485 nm. Each experiment was performed in
quadruplicate and control samples consisting of unlabeled
cells were included.
Lectin binding patterns of cultured primary human
chondrocytes were assessed using 50 μl of fluorescein-
labeled lectins (25 pmol/well) following the same procedure.
Flow cytometry. The glycocalyx of primary human chon-
drocytes was assessed directly after isolation from cartilage
specimens and after trypsin treatment (described below)
following recently published protocols (Toegel et al.
2007a). Briefly, 3×105 cells were incubated with 25 pmol
fluorescein-labelled lectins (50 μl) for 5 min at 4°C. After
washing, the cells were resuspended in particle-free PBS
and analyzed using an Epics XL-MCL analytical flow
cytometer (Coulter, FL). The MFI of the relevant cell
population representing the binding of the conjugated lectins
was used to quantify the presence of specific carbohydrate
structures in the glycocalyx of chondrocytic cells. All MFI
values were corrected for autofluorescence of cells.
Specificity of the lectin-chondrocyte interaction. Confluent
monolayers of C-28/I2 and T/C-28a2 cells cultured in 96-
well microplates were washed three times with 50 μl PBS.
Then, 100 μl of a dilution series of the respective
complementary carbohydrate (Table 2) and 50 μl of a
solution containing 25 pmol fluorescein-labeled lectin were
added followed by incubation for 60 min at 4°C. After
washing, the cell-bound fluorescence intensity was deter-
mined by fluorimetry. Each experiment was performed in
quadruplicate and reference values accounting for the
fluorescence maximum (0% inhibition) were determined
using 100 μl PBS instead of the carbohydrate solution.
Specificity of lectin binding to primary OA human
chondrocytes was controlled using the respective comple-
mentary sugars and 25 pmol fluorescein-labeled lectin as
described above. Hyaluronan oligosaccharides used to
characterize the binding specificity of WGAwere generated
by a 24-h digestion of 20 mg hyaluronan (MW∼1,500 kD)
with 439 U of bovine testicular hyaluronidase in 1 ml
digestion buffer (0.1 M phosphate puffer, pH 5.3, 0.15 M
NaCl) at 37°C. It has been reported that the final reaction
product of this digestion consists mainly of tetrasaccharides
(Takagaki et al. 1994).
The binding sites of WGA and PNA were further
evaluated after enzyme-catalyzed hydrolytic removal of
sialic acid residues. Confluent T/C-28a2 monolayers were
treated with 100 μl neuraminidase (Type V; Clostridium
perfringens; 0.05 and 0.1 U/ml in 0.2 M sodium acetate,
pH 5.5) for 60 min at 37°C. Subsequently, the monolayers
were extensively washed with PBS prior to labeling with
50 μl fluorescein-labeled WGA or PNA (50 pmol; 60 min;
4°C). After washing, cell-bound fluorescence intensities
were determined by fluorimetry. Each experiment was
performed in triplicate and control samples consisting of
Table 1. Sources, specificities, and possible target structures at chondrocyte cultures of lectins used
Lectin Source Binding specificity Target structures
WGA Triticum vulgaris/wheat germ N,N′,N″-triacetylchitotriose >
GlcNAc > sialic acid
Hybrid-type N-glycans, keratin sulfate,
hyaluronan, complex oligoantennary glycans
STL Solanum tuberosum/potato Poly-n-acetyllactosamine Keratin sulfate
LCA Lens cultinaris/lentil D-Mannose High-mannose type N-glycan
SNA Sambucus nigra/elder Sialic acido2-6Gal− Sialic acid caps of complex-type N-glycan
DBA Dolichus biflorus/horse gram GalNAc− First step of O-glycosylation pathway
PNA Arachis hypogaea/peanut Galβ1-3GalNAc− Unmodified O-glycan core 1
UEA Ulex europaeus/gorse Fucα1-2Galβ1-4GlcNAc− Fucosylated O-glycan
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unlabelled cells were included. Additional controls were
performed by substituting the neuraminidase with PBS.
Moreover, primary chondrocytes were treated with
0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) for
20 min at 37°C followed by washing with PBS. Then,
flow cytometry using 25 pmol fluorescein-labeled WGA,
L. culinaris agglutinin, and Sambucus nigra agglutinin was
performed as described above.
Immunofluorescence and alcian-blue staining. Confluent
monolayers of C-28/I2 cells, T/C-28a2 cells, and primary
human OA chondrocytes on glass cover slides were washed
with PBS and fixed with 400 μl methanol (10 min, −20°C)
prior to incubation with mouse monoclonal primary anti-
bodies against aggrecan, collagen type I, and collagen type
II (Calbiochem, San Diego, CA) for 60 min at 37°C. Then,
cells were washed using 1% bovine serum albumin (BSA)
in PBS followed by incubation with a fluorescein
isothiocyanate-conjugated antimouse-Ig secondary anti-
body (Dako, Hamburg, Germany) for 30 min at 37°C.
Monolayers were rinsed again, embedded in FluorSave
antifade medium (Calbiochem), and examined using a
Nikon Eclipse 50i fluorescence microscope. Negative
controls were prepared using 1% BSA/PBS instead of the
primary antibodies.
Alcian blue 8GX was dissolved in 3% acetic acid or
0.1 M HCl to prepare 1% alcian blue solutions of pHs 2.5
and 1, respectively. C-28/I2 cells and primary human OA
chondrocytes were seeded in triplicate into six-well plates
and cultured as described above. Upon confluence, cells
were fixed with 10% neutral buffered formalin for 10 min
at room temperature. After washing twice with PBS, cells
were incubated with 3% acetic acid for 10 min. The entire
amount of GAG was stained with alcian blue solution at
pH 2.5, whereas sGAG were stained with alcian blue
solution at pH 1 (Kiernan 2006). After 30 min, cell
monolayers were rinsed five times with PBS prior to
extraction of alcian blue with dimethyl sulfoxide. Absor-
bance was measured in triplicate at 650 nm using a Tecan
Infinite M200 microplate reader (SLT). Finally, absorbance
values were normalized to equal DNA contents as
evaluated using the CyQuant assay (Piana et al. 2007).
Quantitative. RT-PCR. C-28/I2 cells and primary human
OA chondrocytes from three donors were seeded in
duplicate into 12-well microplates. Upon confluence, total
RNA was extracted using the NucleoSpin RNA II Kit
(Macherey-Nagel, Dueren, Germany). Each sample was run
on the Agilent 2100 Bioanalyzer Nano LabChip for quality
control and quantification of total RNA prior to reverse
transcription into cDNA using the StrataScript first-strand
synthesis system. All quantitative reverse transcriptase
polymerase chain reaction (qPCR) reactions for transcripts
from collagen type I (COL1), collagen type II (COL2), and
aggrecan (AGC) were performed in 25 μl reaction mixtures
pursuing protocols published recently (Toegel et al. 2008).
Expression levels were calculated by the equation 2−deltaCt
with respect to glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) as reference gene.
Statistics. Hypothesis tests among two data sets were made
using paired or unpaired Student’s t test. Statistics cross-
comparing several study groups were performed using one-
way analysis of variance with post hoc Tukey test. Values
of p<0.05 were considered significant.
Results
Lectin binding patterns of isolated human chondrocytes.
Figure 1 shows the binding level of isolated human
chondrocytes for WGA, S. tuberosum lectin, L. culinaris
agglutinin, S. nigra agglutinin, and PNA as assessed by
flow cytometry (n=6 donors). Mean ratios between WGA
and L. culinaris agglutinin, S. nigra agglutinin, S. tuber-
osum lectin, and PNA were 0.7, 1.2, 4.1, and 31.1,
respectively. At this, S. nigra agglutinin, S. tuberosum
lectin, and PNA yielded significantly lower binding values
than WGA (p<0.05, paired t test). When primary chon-
drocytes were treated with trypsin-EDTA, a significant drop
in binding of L. culinaris agglutinin and S. nigra agglutinin
Table 2. Competitive inhibition of lectin binding (25 pmol/well) to
confluent C-28/I2 or T/C-28a2 cell monolayers was performed by
addition of increasing amounts of complementary carbohydrate
Lectin + inhibiting sugar IC50
C-28/l2 T/C-28a2
WGA + GlcNAc 1.75 1.1
WGA + triacetylchitotriose 0.005 0.005
WGA + hyaluronan oligosaccharides 0.15 0.32
STL + GlcNAc 15 30
STL + triacetylchitotriose 0.02 0.01
LCA + mannose 2.5 15.3
SNA + sialyllactose 0.46 0.65
UEA + fucose 0.1 0.08
UEA + hyaluronan oligosaccharides – –
PNA + galactosamine 0.18 0.33
IC50 values represent the amount of complementary carbohydrate
necessary for a 50% inhibition of the lectin binding to confluent cell
monolayers. The concentration of hyaluronan oligosaccharides was
calculated based on the molecular weight of hyaluronan of 1,500 kD
prior to enzymatic digestion. Sialyllactose is commercially available
as mixture of α-2,6- and α-2,3-isomers.
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was observed (Fig. 1; p<0.05, paired t test). In contrast,
WGA binding sites were not affected by trypsinization.
Lectin binding patterns of human chondrocyte mono-
layers. The glycoprofile of primary chondrocyte mono-
layers was evaluated using seven fluorescence-labeled plant
lectins (Table 1; Fig. 2). The ranking of bound lectins
remained stable among the donors (PC1-3), with either
WGA or L. culinaris agglutinin exhibiting the highest
binding followed by S. nigra agglutinin, S. tuberosum
lectin, PNA, D. biflorus agglutinin, and U. europaeus
isoagglutinin I. The mean fluorescence intensities among
the three individual donors were 589.3±88.9 for WGA,
393.7±109.9 for S. tuberosum lectin, 608.3±254.5 for L.
culinaris agglutinin, 429.0±167.3 for S. nigra agglutinin,
10.7±4.6 for U. europaeus isoagglutinin I, 23.7±1.1 for D.
biflorus agglutinin, and 119.7±54.2 for PNA. Mean ratios
between WGA and L. culinaris agglutinin, S. nigra
agglutinin, S. tuberosum lectin, PNA, U. europaeus
isoagglutinin I, and D. biflorus agglutinin were 0.9, 1.5,
1.6, 5.7, 64.5, and 24.9, respectively. This indicates a
comparable distribution pattern of lectin binding sites
between freshly isolated cells and confluent chondrocyte
monolayers.
The glycoprofile of immortalized C-28/I2 and T/C-28a2
cells was evaluated in more detail using rising concen-
trations of fluorescence-labeled plant lectins. Resulting
binding curves increased as a function of increasing lectin
concentrations and leveled off between 50 and 100 pmol/
well lectin indicating saturable binding processes for both
cell lines (Figs. 3 and 4). The figures illustrate that the
fluorescence intensity of bound WGA was significantly
higher than that of any other lectin (12.5–100 pmol WGA/
well). At 50 pmol/well, WGA binding was 1.9, 2.5, 2.9,
3.5, 3.9, and 14.3-fold higher than that of S. tuberosum
lectin, L. culinaris agglutinin, PNA, U. europaeus isoag-
glutinin I, S. nigra agglutinin, and D. biflorus agglutinin in
the case of C-28/I2 cells (Fig. 3). In the case of T/C-28a2
cells, ratios of 2.0, 2.8, 7.9, 7.3, 2.8, and 43.6 were
obtained. Together with a direct comparison of the
respective fluorescence intensities, this indicates that
binding levels of PNA, U. europaeus isoagglutinin I, and
D. biflorus agglutinin were significantly lower in T/C-28a2
cells.
In comparison to primary cells, immortalized C-28/I2
chondrocytes bound significantly lower amounts of WGA
and S. tuberosum lectin (both 1.7-fold), whereas no
significant differences were found in case of D. biflorus
agglutinin and PNA. Of note, remarkable differences were
observed for binding levels of L. culinaris agglutinin, S. nigra
agglutinin, and U. europaeus isoagglutinin I, which were
3.5-fold lower, 5.7-fold lower, and 11.7-fold higher in case
of C-28/I2 chondrocytes, respectively (p<0.05).
Specificity of the lectin–chondrocyte interaction. Competi-
tive assays revealed that lectins were inhibited in their
ability to bind to the cell monolayers by increasing amounts
of complementary sugars. From these data, IC50 values were
calculated (Table 2). Due to the low binding of D. biflorus
agglutinin at the chondrocyte glycocalyx, its binding
specificity was only ascertained using excess amounts of
N-acetylgalactosamine. Using free sialic acid as inhibitory
sugar, the preparation of inhibition curves for S. nigra
agglutinin failed (not shown), whereas sialyllactose as
inhibitor markedly inhibited S. nigra agglutinin binding to
chondrocytes, indicating the necessity of 2,6-linked galac-
tose (Gal) residues for specific S. nigra agglutinin binding.
Regarding the specificity of WGA, we found that both
N-acetylglucosamine (GlcNAc) and triacetylchitotriose in-
duced a high degree of inhibition of the interaction between
WGA and the chondrocyte glycocalyx. IC50 values result-
ing from triacetylchitotriose addition, however, were 350
times lower in case of C-28/I2 cells and 220 times lower in
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Figure 1. Flow cytometric analyses of lectin binding by primary
chondrocytes (mean ± standard deviation, n=6) using fluorescein-
labeled WGA, LCA, SNA, STL, and PNA. Chondrocytes isolated by
collagenase II digestion of cartilage specimens and chondrocytes
treated subsequently with 0.25% trypsin-EDTA (20 min, 37°C) are
compared. Significant differences were determined using paired
Student’s t test and marked with asterisks (p<0.05).
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Figure 2. Lectin binding patterns of cultured primary human
chondrocytes isolated from three different patients (PC1–3). Confluent
cell monolayers were incubated with 25 pmol/well fluorescein-labeled
WGA, STL, LCA, SNA, UEA, DBA, and PNA for 60 min at 4°C.
Results were related to an apparent fluorescein/protein ratio of 1
(mean ± standard deviation, n=4).
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case of T/C-28a2 cells as compared to GlcNAc, indicating
the preferred binding of WGA to oligosaccharide structures
(Table 2). Hence, hyaluronidase-digested hyaluronan con-
sisting mainly of hyaluronan tetrasaccharides was prepared
and used as competitive sugar. IC50 values observed with
these oligosaccharides were 11.6-fold lower in case of C-
28/I2 cells and 3.4-fold lower in case of T/C-28a2 cells
compared to the monosaccharide GlcNAc. When hyalur-
onan oligosaccharides were added to U. europaeus isoag-
glutinin I, the low and concentration-independent binding
inhibition indicated that hyaluronan oligosaccharides did
not exert any unspecific interactions.
For further characterization of WGA and PNA binding
specificities, sialic acid residues were enzymatically re-
moved from the chondrocyte glycocalyx. Following neur-
aminidase treatment, binding of PNA significantly
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Figure 3. Saturation analysis of
lectin binding sites on C-28/I2
chondrocyte monolayers with
fluorescein-labeled WGA, STL,
LCA, SNA, UEA, DBA, and
PNA related to an apparent
fluorescein/protein ratio of 1
(mean ± standard deviation, n=
4). Confluent cell monolayers
were incubated with 3.125–
100 pmol/well fluorescein-
labeled lectin in PBS for 60 min
at 4°C. The significant differ-
ences (p<0.05) between WGA
and other lectins at different
concentrations are marked with
asterisks.
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Figure 4. Saturation analysis of lectin binding sites on T/C-28a2
chondrocyte monolayers with fluorescein-labeled WGA, STL, LCA,
SNA, UEA, DBA, and PNA related to an apparent fluorescein/protein
ratio of 1 (mean ± standard deviation, n=4). Confluent cell
monolayers were incubated with 3.125–100 pmol/well fluorescein-
labeled lectin in PBS for 60 min at 4°C. The significant differences (p<
0.05) between WGA and other lectins at different concentrations are
marked with asterisks.
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increased (5.3±0.7-fold at 0.05 U/ml neuraminidase) and
remained constant upon elevation of neuraminidase con-
centration. PNA has been shown to specifically bind
terminal residues of keratan sulfate which are known to
be masked with sialic acid groups (Hoedt-Schmidt et al.
1989). The exposure of these PNA binding sites indicated
the successful removal of sialic acids from the chondrocyte
glycocalyx and suggested the presence of keratan sulfate.
Of note, WGA binding was not significantly affected by
neuraminidase treatment (p=0.14 at 0.1 U/ml neuraminidase).
For primary human chondrocytes, competitive assays
were performed similarly to the cell lines. Specificity of
lectin binding was verified by a continuous decline of
fluorescence intensities after addition of increasing amounts
of the complementary sugars (data not shown).
Phenotypic characterization of primary and immortalized
chondrocytes. In order to associate the evaluated glyco-
phenotype with the general chondrocyte phenotype, the
presence of specific chondrocyte markers at C-28/I2 cells
and primary OA chondrocytes was assessed using qPCR,
immunofluorescence, and GAG analysis. Examination of
genes that encode ECM proteins revealed minimal expres-
sion of AGC and COL2 in C-28/I2 cells (Fig. 5C), whereas
these genes were expressed to a markedly higher extent in
primary chondrocytes (13,996 and 32,951-fold, respectively).
Regarding COL1, comparable mRNA levels were found in
both populations. Of note, COL2 to COL1 ratios, previously
defined as a chondrocyte differentiation index (Martin et al.
2001), were markedly higher in the primary cells (53.6 vs.
0.002) and indicated the difference in the molecular
phenotype between immortalized and primary chondrocytes.
In addition, both cell populations were characterized at the
ECM protein level (Fig. 5A). Primary chondrocytes formed a
dense ECM including the chondrocyte-specific marker
proteins aggrecan and collagen type II, whereas collagen
Figure 5. (A) Matrix formation of primary human chondrocytes was
evaluated by immunofluorescence staining with primary antibodies for
aggrecan (A), collagen type I (B), and collagen type II (C). (B)
Quantification of alcian-blue stainable proteoglycans present in
cultures of immortalized human C-28/I2 chondrocytes and primary
human chondrocytes (PC). Total glycosaminoglycans (GAG) were
stained at pH 2.5, whereas sulfated glycosaminoglycans (sGAG) were
stained at pH 1. Absorbance values were normalized to equal DNA
contents as evaluated using the CyQuant assay. (C) Quantitative
analysis of the mRNA expression of aggrecan (AGC), collagen type II
(COL2), and collagen type I (COL1) in immortalized C-28/I2 cells and
in primary chondrocytes (PC). Expression levels of the PC represent
the mean values of three different patients. mRNA levels of each
target gene were normalized to GAPDH and calculated as 2−deltaCt.
For comparison, target gene ratios between PC and C-28/I2 are
presented.
LECTIN BINDING PATTERNS OF CHONDROCYTES 357
43
Specific topics -Study 1
type I was not present in the ECM of primary chondrocytes.
Consistent with the lack of synthesis and secretion of ECM
by cells in log-phase growth, immortalized C-28/I2 cells did
not stain with either of the antibodies, indicating negligible
amounts of ECM accumulated during culture (not shown).
To evaluate the presence of GAG structures in the
pericellular coat, C-28/I2 cells and primary OA chondro-
cytes were stained with alcian blue. At pH 2.5, alcian blue
stains most polyanions including polycarboxylic acids such
as hyaluronan, whereas at pH 1, only those polyanions that
owe their acidity to sulfate groups (e.g., keratin sulfate) are
stained. The present experiments revealed alcian blue
stainable proteoglycans at the surface of C-28/I2 mono-
layers both at pHs 2.5 and 1 (Fig. 5B). In comparison to C-
28/I2 cells, cultured primary OA chondrocytes revealed
significantly higher amounts of alcian blue stainable
structures at both pHs 2.5 and 1.
Discussion
In this study, we compared the glycophenotype of primary
human chondrocytes and the human chondrocyte cell lines
C-28/I2 and T/C-28a2 in relation to their chondrocytic
molecular characteristics.
The explicit chondrocytic phenotype of the isolated
primary chondrocytes was demonstrated by high expression
of ECM genes, ECM proteins, as well as GAG and sGAG
structures. The basically chondrocytic phenotype of the C-
28/I2 and T/C-28a2 cell lines has been recently demonstrated
by detecting SOX9 mRNA levels and marker genes of
catabolic activity (Finger et al. 2003). Here, we confirmed
the expression of the anabolic marker genes COL2 and
AGC in C-28/I2 cells using qPCR assays. As expected for
cells in constant log-phase growth, however, the expression
of both matrix genes as well as COL2/COL1 ratios were
less than in primary chondrocytes in our study. Moreover,
alcian blue staining and immunofluorescence confirmed the
reduced chondrocytic phenotype of immortalized cell lines
as compared to primary cultures.
The present study highlights that differences in the
molecular phenotype between immortalized and primary
human OA chondrocytes are also reflected in the glyco-
profile of the cells. A panel of lectins was selected to probe
for a range of oligosaccharide sequences determining specific
products of the O-glycosylation and N-glycosylation path-
ways (Liener et al. 1986; Baldus et al. 1996; Yang et al.
2004, 2007). In the O-glycosylation pathways of most cell
types, the primary GalNAc− epitope is converted to the core
1 structure Galβ1-3GalNAc−. These carbohydrate structures
may provide binding sites for D. biflorus agglutinin and
PNA, respectively (Yang et al. 2007). Subsequently, the core
1 structure can be further extended in different ways, e.g., by
fucosylation reactions forming the Fucα1-2Galβ1-4GlcNAc−
residue which can be specifically detected by U. europaeus
isoagglutinin I (Baldus et al. 1996). The present experiments
show that the C-28/I2 and the T/C-28a2 cell lines differ in
their expression of O-linked carbohydrates. The binding
levels of D. biflorus agglutinin, PNA, and U. europaeus
isoagglutinin I were significantly lower for T/C-28a2 cells,
indicating minor biosynthesis of GalNAc− epitopes, core 1
structures, and fucosylation products. The altered glycopro-
file of T/C-28a2 cells might be related to their higher
proliferation rate as compared to C-28/I2 cells (Goldring et
al. 1994; Finger et al. 2003). It has been suggested that the
matrix-producing chondrocytic phenotype is negatively
correlated with proliferative activity (Finger et al. 2003;
Toegel et al. 2008), a fact that might also be reflected in O-
glycan expression patterns. The average biosynthesis of O-
glycans in primary human chondrocytes did not significantly
differ from that of C-28/I2 cells with respect to the amount of
expressed GalNAc− epitopes and core 1 structures. It is
remarkable, however, that the expression of Fucα1-2Galβ1-
4GlcNAc− residues appeared to be markedly reduced in
primary OA chondrocytes.
The biosynthesis of N-linked oligosaccharide chains is
an intricate process involving the transformation of a high-
mannose precursor oligosaccharide to the complex-type
oligosaccharide structure by trimming and modification
(Helenius and Aebi 2001). To account for N-linked
oligosaccharide chains, the binding of L. culinaris aggluti-
nin and S. nigra agglutinin was assessed identifying the
expression of high-mannose type oligosaccharides and
sialylα2-6Gal termini capping some complex-typeN-glycans,
respectively (Akama et al. 2006; Yang et al 2007). No
differences in the expression of these N-glycan structures
were found between C-28/I2 and T/C-28a2 cells. At primary
chondrocytes, the observed susceptibility of S. nigra
agglutinin and L. culinaris agglutinin binding sites to trypsin
treatment (Fig. 1) supports the presence of glycoproteins
with high-mannose and sialyl structures. Of note, primary
OA chondrocytes were characterized by significantly elevat-
ed amounts of high-mannose N-glycans and sialic acid-
capped N-glycans in comparison to the cell lines. This
observation is in line with previous findings (Bernard et al.
1984) showing that chondrocytes produce mature glycopro-
teins such as fibronectin containing oligosaccharides of the
high mannose or hybrid type in contrast to fibroblast
fibronectin, which contains only the complex-type structure.
Therefore, we consider the possibility that the reduced levels
of high-mannose N-glycans in C-28/I2 and T/C-28a2 cells
indicate the altered chondrocytic phenotype of immortalized
cell lines.
Due to the ubiquitous presence of GlcNAc moieties in
the glycocalyx of cells, the target structures of WGA are
difficult to specify. First, possible binding sites could be
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provided by N-linked glycans of the hybrid type. It has
been reported that the binding of WGA to the hybrid-type
N-glycans was mediated by the N,N′-diacetylchitobiose
core portion as well as a GlcNAc residue at the reducing
end (Yamamoto et al. 1981). Also, an interaction of WGA
with keratan sulfate in cultured human chondrocytes
appears conceivable, considering the components of this
sGAG. In contrast to S. tuberosum lectin, however, WGA
has been shown to possess lesser binding affinity for
keratan sulfate in its highly sulfated form (Toda et al. 1981).
Based on the observation that the binding of WGA to the
chondrocyte glycocalyx was higher than that of S. tuberosum
lectin throughout the study, keratan sulfate might not
contribute markedly to the interaction between WGA and
cultured chondrocytes. Similarly, the binding of WGA to
sialic acid residues in the glycocalyx of cultured chondro-
cytes appears negligible in view of stable binding values of
WGA following enzymatic removal of sialic acids. It has to
be underlined that the binding level of WGA was among
the highest of all tested lectins with both immortalized and
primary chondrocytes. Moreover, the low interindividual
variability of WGA binding among different patients might
indicate that the WGA binding sites at the glycocalyx are
part of the basic repertoire of chondrocytes. Recently, it has
been depicted that chondrocytes are surrounded by a
several micrometer-thick hyaluronan coat with gel-like
properties (Cohen et al. 2003). In our study, alcian blue
assays at pH 2.5 suggested high levels of polycarboxylic
acids such as hyaluronan covering cultured human chon-
drocytes. Given the components of hyaluronan, we hypoth-
esize that hyaluronan might represent a target structure for
WGA in the pericellular matrix of cultured chondrocytes.
The resistance ofWGA binding sites against trypsin treatment
(Fig. 1) further supports their localization at a nonprotein
target such as hyaluronan. In spite of a previous study
reporting that WGA does not interact with hyaluronan
(Carlsson et al. 1976), our assumption was corroborated by
a concentration-dependent inhibition of WGA binding using
hyaluronan oligosaccharides. IC50 values observed with
hyaluronan oligosaccharides were several times higher than
those observed with the monosaccharide GlcNAc. Thus,
these data suggest the partial binding of WGA to oligosac-
charide structures of the chondrocyte hyaluronan coat.
In summary, the present report emphasizes the glyco-
phenotype as an integral part of the chondrocyte phenotype
in vitro. In this regard, lectin binding patterns of primary
and immortalized chondrocytes indicate that alterations of
the chondrocytic molecular phenotype are reflected in the
glycophenotype of the cells. In addition to the decreased
production of GAGs, the pattern of O-linked and N-linked
oligosaccharides appears shifted toward reduced levels of
high-mannose type and sialic acid-capped N-glycans as
well as increased fucosylated O-glycosylation products in
immortalized chondrocyte cell lines. A limitation of the
current study is that conclusions regarding the glycophe-
notype of healthy or OA chondrocytes in vivo cannot be
definitely drawn from any in vitro model. Based on the
presented results, however, future studies might aim to
specify the glycoprofile of chondrocytes that is related to
OA. This could further clarify the relevance of the
glycophenotype for chondrocyte function or its signifi-
cance, if any, as a marker for the development of new
chondroprotective agents.
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Summary
Objective: Sialic acids frequently occur at the terminal positions of glycoprotein N-glycans present at chondrocyte surfaces or in the cartilage
matrix. Sialic acids are transferred to glycoproteins in either a-2,3 or a-2,6 linkage by speciﬁc sialyltransferases (SiaTs) and can potentially
affect cell functions and cellematrix interactions. The present study aimed to assess the relationship between the expression of the human
chondrocyte phenotype and the sialylation of chondrocyte glycoprotein N-glycans.
Methods: The transcription of 5 SiaT was quantiﬁed using real-time Reverse transcription polymerase chain reaction (RT-PCR) assays. N-glycan
analysiswas performed using LCeESI-MS. Primary human chondrocyteswere cultured inmonolayer or alginate beads and compared to the chon-
drocyte cell lines C-28/I2 and SW1353. In addition, effects of interleukin-1b (IL-1b) or tumour necrosis factor-a (TNF-a) on primary cells were
assessed.
Results: Primary human chondrocytes predominantly express a-2,6-speciﬁc SiaTs and accordingly, a-2,6-linked sialic acid residues in glyco-
protein N-glycans. In contrast, the preponderance of a-2,3-linked sialyl residues and, correspondingly, reduced levels of a-2,6-speciﬁc SiaTs
are associated with the altered chondrocyte phenotype of C-28/I2 and SW1353 cells. Importantly, a considerable shift towards a-2,3-linked
sialic acids and a-2,3-speciﬁc SiaT mRNA levels occurred in primary chondrocytes treated with IL-1b or tumour necrosis factor-alpha
(TNF-a).
Conclusion: The expression of the differentiated chondrocyte phenotype is linked to the ratio of a-2,6- to a-2,3-linked sialic acids in chondro-
cyte glycoprotein N-glycans. A shift towards altered sialylation might contribute to impaired cellematrix interactions in disease conditions.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Phenotype.Introduction
The extracellular matrix (ECM) of cartilage consists of nu-
merous glycosylated proteins, which contribute to the main-
tenance of its speciﬁc functions1. Beside structural
proteoglycans such as aggrecan transcript (mRNA), and ad-
hesive proteins such as chondroadherin, glycosylated cell
surface receptors, including CD44 and integrins, play critical
roles in the mediation of chondrocyteematrix interactions1e3.
Protein glycosylation, i.e., the attachment of oligosaccharide
chains to asparagine or serine/threonine residues, repre-
sents a common co-translational and post-translational mod-
iﬁcation of proteins, conferring protection against proteolytic
degradation or controlling protein folding. It is known that*Address correspondence and reprint requests to: Stefan Toegel,
Medical University Vienna, Waehringer Guertel 18-20, 1090
Vienna, Austria. Tel: 43-1-4277-55461; Fax: 43-1-4277-9554;
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240carbohydrate chains vary according to tissue and cell type
and are subject to change during development and oncoge-
nesis4e6. In addition, various factors such as cytokines or dif-
ferentiation factors can regulate cellular glycosylation and the
expression of speciﬁc glycosyltransferases7e11. Thus,
changes in the cellular glycophenotype can potentially affect
cell functions such as cell adhesion, cell surface receptor ac-
tivity, and the onset of apoptosis12.
Sialic acids (Neu5Ac in humans) are negatively charged
sugars typically found at the terminal positions of N- and
O-linked oligosaccharides attached to cell surfaces or se-
creted glycoproteins. As a result of their non-reducing termi-
nal position, sialic acids are involved in highly speciﬁc
recognition phenomena, as well as in invasive properties
of cancer cells13e16. The transfer of sialic acids to penulti-
mate galactose or N-acetylgalactosamine groups of glyco-
proteins is mediated by sialyltransferases (SiaTs). The
diverse enzymes of the SiaT family share the cytidine
monophosphate-sialic acid as donor substrate, but are47
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they act and by the linkage type they generate (e.g., a-2,3
or a-2,6 linkage in case of N-linked glycans in glycopro-
teins)16. The expression patterns of SiaTs show remarkable
tissue speciﬁcity and appear to be regulated at the tran-
scriptional level. In particular, the altered expression of a-
2,3- or a-2,6-SiaTs and subsequent effects on cell surface
sialylation have been demonstrated to inﬂuence osteoclas-
togenesis, endocytosis in dendritic cells, and adhesion
properties of human colon cancer cells17e19.
Regarding inﬂammatory and degenerative joint diseases,
recent studies have suggested a relationship between al-
tered glycosylation and disease conditions. It is known that
altered N-glycans of serum immunoglobulin G molecules
contribute to the pathophysiology of rheumatoid arthritis20.
In addition, initial evidence for altered N-glycosylation of car-
tilage tissue has been presented using an animal model of
osteoarthritis21. Despite the signiﬁcance of glycoproteins
for ECM assembly in cartilage tissue, however, little is known
about the regulation of the chondrocyte glycophenotype. Re-
cently, we found that differences in the molecular phenotype
between primary human chondrocytes and chondrocyte cell
lines are reﬂected by speciﬁc cellular lectin-binding pat-
terns22,23. In a further study, Yang and coworkers have
shown that cytokine treatment of human and bovine chon-
drocytes results in speciﬁc glycosylation changes related to
apoptosis and altered cell proliferation12.
Owing to the potential implications of the chondrocyte gly-
cophenotype in the pathophysiology of joint diseases such
as osteoarthritis, we set out to examine the sialylation pro-
cesses in human chondrocytes using a combination of
gene expression and N-glycan structural analyses. We
compared the sialylation pattern of primary human chondro-
cytes with those of immortalized chondrocytes C-28/I2 and
chondrosarcoma cells SW1353, and investigated the ef-
fects of interleukin-1b (IL-1b) and tumour necrosis factor-
alpha (TNF-a) on primary chondrocyte (PC) sialylation.
Our ﬁndings provide new information on N-glycan sialyla-
tion in human chondrocytes and demonstrate that the status
of the chondrocyte phenotype is critically linked to the ratio
of a-2,6- to a-2,3-linked sialic acids of chondrocyte glyco-
protein N-glycans.MethodsHUMAN CHONDROCYTE CULTURESHuman articular cartilage was obtained during total knee replacement sur-
geries in patients with osteoarthritis with informed consent and in accordance
with the terms of the ethics committee of the Medical University Vienna (EK-
Nr.: 081/2005). PCs were isolated according to protocols published previ-
ously22, seeded as high density monolayers (MLs) (105 cells/cm2), and
grown in an atmosphere of humidiﬁed 5% CO2/95% air at 37
C using
Dulbecco’s Modiﬁed Eagle Medium supplemented with 10% fetal calf serum
(Biochrom AG, Germany), 2 ml/ml gentamycin, and 50 mg/ml ascorbate as
culture medium (complete medium). Only freshly isolated cells were plated
for all assays throughout the study. To induce inﬂammatory conditions,
PCs were treated with 10 ng/ml IL-1b or 40 ng/ml TNF-a for the time periods
indicated. Three-dimensional (3D) chondrocyte cultures were established in
alginate beads according to standard procedures and cultured for 3 weeks
as described24. Immortalized chondrocytes C-28/I2, and chondrosarcoma
cells SW1353, were seeded at 9.3 103 cells/cm2 and maintained in com-
plete medium.QUANTITATIVE REAL-TIME PCRChondrocytes were grown in duplicate wells in 12-well tissue culture
plates (Iwaki, Japan) to 90% conﬂuence prior to treatment with cytokines
for 24 h. Total RNA was extracted using the NucleoSpin RNA II Kit
(Macherey-Nagel, Germany). Each sample was run on the Agilent 2100Bioanalyzer Nano LabChip for quality control and quantiﬁcation of total
RNA prior to reverse transcription into cDNA using the high capacity cDNA
reverse transcription kit (Applied Biosystems, Austria).
SYBR-green based qPCR assays for the sialyltransferase transcripts
ST6Gal1 (NM_003032), ST6Gal2 (NM_032528), ST3Gal3 (NM_174963),
ST3Gal4 (NM_006278), and ST3Gal6 (NM_006100) were established. Am-
pliﬁcation efﬁciencies of all primers were between 90 and 105% as evaluated
using dilution series of cDNA prepared from chondrocyte mRNA. Primers
and results of melting curve analyses are shown in Supplementary Table 1
and Supplementary Fig. 1, respectively. qPCR reactions for transcripts
from collagen type I (COL1), collagen type II (COL2) and aggrecan AGC
were performed according to protocols published recently25. mRNA expres-
sion levels were calculated as relative copy numbers considering actual am-
pliﬁcation efﬁciencies and with respect to that of glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) set at 1000. The regulation of a target
gene by cytokines was calculated as quantities relative to the untreated con-
trol group using the MxPro real-time QPCR software, considering both ampli-
ﬁcation efﬁciencies and normalization to GAPDH.PROTEIN ISOLATION AND N-GLYCAN PREPARATIONChondrocytes were seeded in 25 cm2 ﬂasks (Greiner bio-one, Austria)
and allowed to settle for 48 h. Then, the culture medium was changed and
cells were maintained in the presence of 10 ng/ml IL-1b or 40 ng/ml TNF-
a for 5 days. Cells were carefully washed ﬁve times with PBS buffer and
scraped in the presence of 200 ml lysis buffer (containing protease inhibitor).
After centrifugation for 5 min at 12,000 rpm, the pellet was washed once with
PBS buffer and centrifuged again. The combined supernatants were mixed
with three times the volume of acetone (20C for 30 min) to precipitate pro-
teins. Further protein puriﬁcation and glycan isolation was performed using
the ‘in-gel release method’ as described by Rendic et al.26 Brieﬂy, the precip-
itate was dissolved in SDS-PAGE sample buffer and subjected to
SDS-PAGE, but only to the point when the unseparated protein zone had
just entered the separation gel. Free N-glycans were isolated from this
band by trypsin and PNGase F digestion. The released asparagine-linked
glycans were reduced with 50 ml of 1% NaBH4 at room temperature for
4 h. To remove excess salt, the sample was further puriﬁed using a 10 mg
HyperSep Hypercarb SPE cartridge (Thermo Scientiﬁc, USA), according to
previous protocols27.QUANTIFICATION OF OLIGOSACCHARIDES USING LCeESI-MSRecent work on ﬁbrin N-glycans and immunoglobulin glycosylation re-
vealed the ability of porous graphitic carbon (PGC) phases to separate iso-
meric glycans with a subsequent sensitive detection of both neutral and
sialylated glycans by using ESI-MS28,29. The recently established retention
time library of mammalian, diantennary glycans varying in the linkage of si-
alic acid was applied for the structural assignment of the peaks. LCeESI-
MS, using graphitized carbon as the separation phase (PGCeESI-MS),
outperforms other glycan analysis methods including MALDI-TOF or NMR
spectroscopy in terms of minimal sample consumption, minimal sample
preparation, and the reliable qualitative and quantitative recording of neutral,
mono- and di-sialylated structures with concomitant identiﬁcation of isomeric
structures26e28.
Analysis of borohydride-reduced oligosaccharides (from an aliquot equiv-
alent to 2.5 105 cells) by positive-ion LCeESI-MS was performed with
a 100 0.32 mm PGC column (Thermo) and a ﬂow rate of 5 ml/min main-
tained with a Dionex Ultimate 3000 cap ﬂow system, as described re-
cently28,29. Mass analysis was done with a Waters Q-TOF Ultima Global
mass spectrometer with standard ESI-source and MassLynx V4.0 SP4 soft-
ware for evaluation and quantiﬁcation of obtained peak areas. Individual
analyses were averaged, with a mean deviation for the relative glycan quan-
tities of approximately 0.05 units.CELL MORPHOLOGYPCswere seeded on glass cover slips and cultured for 48 h in completeme-
dium. Then, cells were exposed to 10 ng/ml IL-1b or 40 ng/ml TNF-a for up to 5
days. Using conventional light microscopy, cell morphological alterations were
observed with regard to the formation of a spindle-shaped cell conﬁguration,
which is associated with a dedifferentiated ﬁbroblast-like phenotype.CELL PROLIFERATIONPCs of two donors were seeded into 96-well microplates (Iwaki, Japan) and
cultured for 48 h. Then, cells were treated in quadruplicate with 10 ng/ml IL-1b
or 40 ng/ml TNF-a for 24 h. The total number of cells was determined using the
CyQuant assay kit (Molecular Probes, USA) pursuing a modiﬁed protocol30.
Moreover, the rate of proliferation of cells was assessed by incorporation of48
242 S. Toegel et al.: Sialylation of human chondrocytes
Specific topics -Study 2 2-bromodeoxyuridine into theDNAof dividing cells using the colorimetric BrdU
assay (Roche, Germany), according to the manufacturer’s instructions.SULFATED GLYCOSAMINOGLYCAN (sGAG) ASSAYPCs were seeded in triplicate into six-well tissue culture plates (Iwaki,
Japan) and cultured for 48 h prior to treatment with 40 ng/ml TNF-a for 5
days. An improved 1,9-dimethyl-methylene blue (DMMB) colorimetric assay
was performed according to Barbosa et al.31 to assess both cell-associated
sGAG and sGAG released into the culture medium. Absorbance of the sam-
ples was measured at 656 nm and related to equivalent cell numbers, which
were determined using the CyQuant assay kit. The experiment was repeated
twice using cells from different donors.STATISTICSData were exported to the GraphPad Prism statistics software package
(GraphPad Prism Software, USA). The Gaussian distribution of the data
was veriﬁed using the KolmogoroveSmirnov test. Statistics were performed
using one-way analysis of variance (ANOVA) with post-hoc Tukey tests,
cross-comparing all study groups (95% conﬁdence interval) consisting of in-
dependent mean values. P-values <0.05 were considered signiﬁcant.ResultsEXPRESSION PROFILES OF SiaT GENES IN HUMAN
CHONDROCYTE MODELSThe mRNA levels of ﬁve SiaTs were determined with re-
spect to GAPDH in human chondrocytes using qPCR. Table
I shows the SiaT expression levels in PCs cultured as MLs
or in alginate beads (3D), as well as in SW1353 and C-28/I2
cell lines. In general, SiaTs were expressed at low levels in
all cell models. In MLs of PCs (n¼ 10 donors), ST6Gal1
showed the highest abundanceof all evaluatedSiaTs. In com-
parison to ST6Gal1, ST6Gal2 was expressed at more than
400-fold lower levels. In addition, the mRNA levels of the
a-2,3-SiaTs (ST3Gal3, ST3Gal4, and ST3Gal6) were all low
compared to ST6Gal1. Among the a-2,3-SiaTs, ST3Gal4
was the gene with the highest expression level. All in all, the
SiaT expression proﬁle of PCs predicts a sialylation pattern
in which a-2,6-linked sialylation predominates over a-2,3-sia-
lylation. When cultured in alginate beads, PCs expressed
comparable levels of a-2,6-SiaTs and slightly reduced levels
of ST3Gal3 and ST3Gal4 (1.6-fold and 1.9-fold, respectively).
When comparing the chondrosarcoma cell line SW1353 with
PCs, we observed remarkably diminished (2.5-fold) ST6Gal1
expression in SW1353 cells, whereas mRNA levels of
ST3Gal4 were slightly increased. The SiaT proﬁle of C-28/I2
chondrocytes was characterized by almost completely sup-
pressed ST6Gal1 mRNA levels, whereas the a-2,3-SiaT pro-
ﬁle only showed minor alterations in comparison to PCs.
Taken together, primary human chondrocytes are character-
ized by a predominant expression of a-2,6-SiaT, predicting
the preponderant presence of a-2,6-linked terminal sialicTable I
mRNA expression of N-glycan related sialyltransferases (SiaTs).
mRNA levels were quantified using qPCR and expressed as rela-
tive copy numbers with respect to GAPDH set at 1000. PCs cul-
tured in ML or alginate beads (3D) were compared to SW1353
chondrosarcoma cells and immortalized C-28/I2 chondrocytes.
cDNA of PCs from 10 donors was pooled and analyzed in triplicate.
Mean values of the samples are presented
Cells ST6Gal1 ST6Gal2 ST3Gal3 ST3Gal4 ST3Gal6
PC (ML) 17.5 <0.1 3.8 4.7 1.1
PC (3D) 15.8 <0.1 2.3 2.5 1.1
SW1353 6.8 <0.1 1.3 5.8 0.4
C-28/I2 <0.01 0.2 2.2 5.3 1.1acid residues on PC glycoprotein N-glycans. In contrast, im-
mortalized and chondrosarcoma cell models feature a SiaT
expression proﬁle shifted towards a-2,3-SiaTs.SIALYLATION OF CHONDROCYTE GLYCOPROTEIN
N-GLYCANS IN HUMAN CHONDROCYTE MODELSSialylation patterns and linkage types of chondrocyte gly-
coprotein N-glycans were determined using LCeESI-MS.
Figure 1(A) shows the structure of the diantennary H5N4F
glycan and its possible sialylated isomers analyzed in this
study. Both the abbreviated composition and the full struc-
tural description according to the proglycan system are pre-
sented29,32. These glycans were selected for quantiﬁcation
since they represent a common modiﬁcation of cellular pro-
teins and are among the most abundant glycan structures in
the human chondrocyte glycome (own unpublished result).
Moreover, they are practically absent in fetal calf serum-
containing cell culture medium minimizing the risk of me-
dium-dependent glycan structure contamination.
Using LCeESI-MS online analysis via PGC column, we
quantiﬁed free H5N4F1 structures as well as H5N4F1 gly-
cans carrying one or two sialic acid residues in a-2,6- or/
and a-2,3-linkage and compared them across various PC
models. As shown in Fig. 1(B), the proportional distribution
of the different H5N4F1 glycans was strongly dependent on
cell type and culture conditions. In PCs cultured as MLs, the
majority of diantennary glycans carried one a-2,6-linked si-
alic acid (45.4%), whereas only 11.3% were decorated by
one a-2,3-linked sialic acid residue. Among the
S2H5N4F1 glycans, most structures (21.2%) carried both
one a-2,6-linked and one a-2,3-linked sialic acid. In compar-
ison to this mixed type, S2(a-2,6)H5N4F1 and S2(a-
2,3)H5N4F1 structures were generated at 3-fold lower
levels. In 3D-culture systems, PCs expressed a sialylation
pattern characterized by increased levels of H5N4F1
glycans carrying one or two a-2,6-linked sialic acids.
Concomitantly, those structures decorated with one or two
a-2,3-linked sialic acids were produced at reduced levels.
Of note, the sialylation pattern of N-glycans of SW1353
chondrosarcoma cells showed an inverse trend towards
signiﬁcantly reduced S1(a-2,6)H5N4F1 and S2(a-
2,6)H5N4F1 structures and increased S1(a-2,3)H5N4F1
and S2(a-2,3)H5N4F1 glycans. This trend was even inten-
siﬁed in the C-28/I2 cell line, where a-2,6-linked sialylation
was practically absent, while the majority of H5N4F1 gly-
cans (87.8%) carried terminal sialic acids in a-2,3-linkage.
In summary, sialylation patterns of chondrocyte N-glycans
showed alteration towards increased a-2,6-/a-2,3-sialyla-
tion ratios in 3D-culture and decreased a-2,6-/a-2,3-sialyla-
tion ratios in SW1353 and C-28/I2 cells.INFLAMMATORY CYTOKINES INDUCE CHONDROCYTE
DEDIFFERENTIATIONANDASHIFTOFa-2,6-/a-2,3-SIALYLATIONFigure 2 conﬁrms that PCs undergo dedifferentiation un-
der treatment with pro-inﬂammatory cytokines IL-1b and
TNF-a33. Morphological changes of chondrocytes towards
a spindle-shaped ﬁbroblast-like phenotype were observed
after exposure to cytokines [Fig. 2(A)]. Moreover, both
IL-1b and TNF-a reduced chondrocyte proliferation
[Fig. 2(B)] and expression of chondrocyte marker genes
AGC and COL2 [Fig. 2(D)], resulting in decreased COL2/
COL1 ratios34. In addition, TNF-a decreased the production
of both cell-associated and secreted sGAG, further support-
ing cellular dedifferentiation [Fig. 2(C)].49
AB
Fig. 1. Analysis of sialylated and free H5N4F1 glycans in human chondrocytes. (A) Scheme showing all the diantennary N-glycans considered
in this study with the abbreviated composition and the full structural description according to the proglycan system29,32. S stands for sialic acid,
H for hexose, N for N-acetylglucosamine (GlcNAc) and F for fucose. (B) Proportional distribution of free and sialylated H5N4F1 glycans in
human chondrocytes. PCs cultured in ML or alginate beads (3D) are compared to SW1353 chondrosarcoma cells and immortalized C-28/
I2 chondrocytes. PCs from three donors were analyzed in triplicate and respective mean values are presented. The standard deviations
were between 1 and 10% of the mean values for all measurements.
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cans was altered under inﬂammatory conditions, SiaT
mRNA expression and N-glycan sialylation were deter-
mined in PCs (n¼ 6 donors) after treatment with pro-inﬂam-
matory cytokines. Figure 3(A) and (B) shows the log-fold
change of SiaT mRNA levels following IL-1b and TNF-
a treatment, respectively. ST6Gal1 mRNA levels were
markedly reduced under the inﬂuence of the cytokines
(4.7-fold in case of IL-1b and 3.3-fold in case of TNF-a),
whereas the expression of ST3Gal4 was enhanced under
the same conditions (2.8-fold and 3.2-fold, respectively).
ST6Gal2, ST3Gal3, and ST3Gal6 were also subject to re-
duction in the presence of IL-1b or TNF-a. Given the differ-
ent steady-state expression levels of the single SiaTs
(Table I), the contribution of each gene to the entire SiaT
pool is displayed graphically in Fig. 3C. It is obvious that
the a-2,3-SiaTs predominate after exposure of chondro-
cytes to IL-1b or TNF-a. In general, diminished ST6Gal1
and increased ST3Gal4 levels appear to be responsible
for this shift towards reduced a-2,6-/a-2,3-SiaT mRNA ra-
tios under inﬂammatory conditions.
Analysis of N-glycan sialylation using LCeESI-MS con-
ﬁrmed the predicted differential expression of a-2,6- and
a-2,3-sialic acid residues after cytokine treatment. Interest-
ingly, the described shift in SiaT mRNA levels was not imme-
diately followed by a preponderance of a-2,3-linked sialyl
residues in the total of glycoprotein glycans, since no signiﬁ-
cant alteration was detected by LCeESI-MS after 24 h of
cytokine treatment (data not shown). However, followinga5-day exposure of the cells to TNF-a or IL-1b, a correspond-
ing shift of a-2,6- towards a-2,3-linked sialylation was
observed. Figure 4 presents detailed information on the alter-
ation of sialylated H5N4F1 structures in chondrocytes from
three donors, indicating that both S2(a-2,6)H5N4F1 and
S1(a-2,6)H5N4F1 were signiﬁcantly decreased, whereas
those structures containing a-2,3-linked sialic acids (S1(a-
2,3)H5N4F1, S2(a-2,6/a-2,3)H5N4F1, S2(a-2,3)H5N4F1)
were enhanced by both cytokines. The most striking differ-
ences were observed in shift of S1(a-2,6)H5N4F1 and
S2(a-2,3)H5N4F1 glycans under TNF-a exposure, resulting
in a 0.6-fold decrease and 2.5-fold increase, respectively. A
representative LCeESI-MS chromatogram of S2H5N4F1
glycans under the inﬂuence of TNF-a or IL-1b is provided
as Supplementary Fig. 2 and illustrates the underlying
analytic principle, used to compare untreated PCs with cyto-
kine-treated cells. Taken together, alterations of the chondro-
cyte phenotype induced by TNF-a or IL-1b were
accompanied by decreasing a-2,6-/a-2,3-SiaT mRNA ratios
and corresponding shifts of sialylated N-glycans towards
a-2,3-sialylated H5N4F1 structures.Discussion
Sialylation of cell surface glycoproteins plays a key role in
many biological processes, including cellematrix interac-
tions. Although disturbed cellematrix interactions are of fun-
damental importance in the onset of degenerative joint50
AD
B C
Fig. 2. Phenotypic changes of primary human chondrocytes under exposure to inﬂammatory cytokines. (A) Morphological change of chondro-
cytes under exposure to TNF-a for 24 h. (B) Altered cell number (white bars) and proliferation rate (black bars) of chondrocytes treated with
IL-1b and TNF-a. Data are presented as mean valuesSD. (C) Reduced sGAG content in chondrocytes treated with TNF-ameasured in cells
(white bars) and culture medium (black bars). Data are presented as mean valuesSD. (D) Fold-changes of AGC, COL2 and COL1 tran-
scription in human chondrocytes isolated from three donors (PC1, PC2, PC3) and exposed to IL-1b and TNF-a with respect to untreated cells
(control).
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the sialylation patterns in human chondrocytes and their in-
volvement, if any, in cartilage breakdown processes. This
gap in our knowledge may result, at least in part, from the
methodological challenges due to low SiaT transcription
levels and linkage-type speciﬁc glycoprotein N-glycan anal-
ysis in human chondrocytes. Up to the present, evidence for
the sialylation of chondrocytes has been generated using
lectin histochemistry37, lectin-binding studies22, enzyme-
linked lectin assays12,38, and enzyme activity assays12. In
this study, we have employed an advanced approach to
characterize the chondrocyte glycophenotype. Linking to-
gether qPCR and LCeESI-MS techniques, we correlated
quantitatively the gene expression of a-2,6- and a-2,3-spe-
ciﬁc SiaTs with the presence of a-2,6- and a-2,3-linked
sialyl groups in chondrocyte glycoprotein N-glycans.
We here present two lines of evidence indicating that the
chondrocyte phenotype is linked to speciﬁc sialylation pat-
terns of chondrocyte glycoprotein N-glycans. Firstly, thesialylation of various in vitro chondrocyte models with well
known phenotypic differences was investigated. Secondly,
the sialylation of primary human chondrocytes was evalu-
ated after treatment with IL-1b or TNF-a, two cytokines
with pathophysiological signiﬁcance in inﬂammatory joint
diseases.
Despite the value of chondrocytic cell lines, such as the
C-28/I2 and SW1353 cell lines used here, that are used fre-
quently as surrogates for primary human chondrocytes in vi-
tro, they differ markedly from PCs in their molecular
phenotype22,39,40. For instance, the reduced expression of
chondrocyte marker genes such as AGC or COL2, as well
as altered reactivity to IL-1b, may be related to their high
state of proliferation and continuous synthesis of proteins
associated with log-phase growth. The present study clearly
demonstrates that the presence of a-2,6-linked sialyl resi-
dues constitutes a typical feature of the differentiated phe-
notype of primary human chondrocyte cultures, whereas
the abundance of a-2,3-linked sialyl residues is associated51
SA
C
B
Fig. 3. mRNA levels of N-glycan related sialyltransferases in human chondrocytes exposed to pro-inﬂammatory cytokines. PCs were treated in
duplicate with 10 ng/ml IL-1b (A) or 40 ng/ml TNF-a (B) for 24 h and SiaT expression was analyzed in duplicate using qPCR. Expression levels
were log transformed (log base of 2) and alterations with respect to the control group were displayed as log-fold changes. Mean values and SD
of six donors are presented. Asterisks indicate signiﬁcant differences with respect to untreated controls (P< 0.05). (C) Proportional distribution
of SiaT mRNA levels in untreated control cells and under exposure to IL-1b or TNF-a.
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result further supports our recent observation that immortal-
ized cell lines are characterized by a reduced binding of
Sambucus nigra agglutinin (SNA)22. Importantly, differ-
ences in N-glycan sialylation among the chondrocyte cell
models were in correlation with differences in SiaT expres-
sion levels, indicating a crucial role of ST6Gal1 transcription
for the phenotype-speciﬁc sialylation of chondrocyte glyco-
proteins. Our ﬁnding on the preponderant a-2,6-sialylation
of human chondrocytes is in agreement with a previous lec-
tin histochemical study of human knee joints reporting that
chondrocytes in zones IeIV of normal hyaline cartilagewere stained to a higher degree with SNA lectin than with
Maackia amurensis agglutinin37. Interestingly, this feature
distinguishes articular chondrocytes from their progenitor
cells, the mesenchymal stem cells (MSC), which were pre-
viously shown to carry sialic acids predominantly in a-2,3-
linkage41, corresponding to the phenotype of the proliferat-
ing chondrocyte cell lines studied here.
It is tempting to speculate about the physiological rea-
sons underlying the predominant a-2,6-sialylation of chon-
drocyte glycoprotein N-glycans. Homeostasis in cartilage
tissue is maintained by chondrocyteematrix interactions
and the signals that chondrocytes receive in contact with52
Fig. 4. Regulation of H5N4F1 glycan sialylation under IL-1b and
TNF-a exposure. PCs of three donors were cultured separately
for 5 days in the presence of 10 ng/ml IL-1b (grey bars) or 40 ng/
ml TNF-a (black bars). N-glycan sialylation was analyzed in tripli-
cate using LCeESI-MS. Values are meansSD relative to that
of untreated cells (grey bars) set at 1.0.
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ceptor for the glycosaminoglycan hyaluronan (HA), anchor-
ing the proteoglycan network of cartilage to the surface of
chondrocytes. Detailed studies have shown that at least
two of the ﬁve N-glycosylation sites within the HA binding
domain of CD44 can modify binding activity and that both
carry terminal a-2,3-linked sialic acids42,43. Furthermore,
modiﬁcation of CD44 glycosylation by inhibition of N-glycan
biosynthesis or enzymatic cleavage of N-glycans or termi-
nal sialic acids can trigger the activation of CD44-mediated
HA binding in various cells43e46. Therefore, the presence of
terminal a-2,3-linked sialic acid on N-glycans of the CD44
receptor inhibits the binding to HA46. Given the observation
that a-2,6-SiaTs and a-2,3-SiaTs compete for the same lim-
ited pool of N-glycan substrates47,48, it is conceivable that
the predominant expression of a-2,6-SiaTs in human chon-
drocytes facilitates the activation of CD44 receptors, which
in fact is required for a functional matrix assembly of carti-
lage. In contrast, the dominant a-2,3-sialylation of MSC41
may be a physiological requirement for migration and hom-
ing of MSC to sites of condensation and cartilage formation
in the embryo. A similar physiological mechanism has been
proposed recently for hematopoietic stem and progenitor
cells (HSPC)48. In that study, an increased relative abun-
dance of a-2,3-sialylation was found in HSPC whereas
a-2,6-sialylation was prevalent in peripheral blood-derived
CD34þ and CD34 cells. Thus, the authors suggested
that the enriched a-2,3-sialylation of HSPC might constitute
a mechanism to facilitate migration of HSPC from bone
marrow into the circulation.
In recent years, the inﬂammatory component of osteoar-
thritis has been recognized as a decisive factor for the pro-
gression of the disease. The release of cytokines such as
IL-1b or TNF-a from both the synovium and the chondro-
cytes themselves may be involved in the induction of inﬂam-
matory factors, including inducible nitric oxide synthetase,
cyclooxygenase 2, and phospholipase A249e51, as well as
proteinases that promote the destruction of cartilage matrix.
The present work shows that IL-1b and TNF-a induce alter-
ations of the differentiated chondrocyte phenotype and thatthese alterations are associated with a remarkable reorga-
nization of chondrocyte N-glycan sialylation. Strongly en-
hanced ST3Gal4 mRNA levels and the parallel drop of
ST6Gal1 expression result in reduced a-2,6- to a-2,3-sialy-
lation ratios in chondrocyte glycoprotein N-glycans. We
found that this linkage-type remodeling occurred at both
S1H5N4F1 and S2H5N4F glycans, i.e., those H5N4F struc-
tures carrying one or two sialic acid residues. Of note, this
ﬁnding is in line with recent in vivo experiments studying
N-glycans in rabbit cartilage after ligament transection20.
There, it was shown that the amount of S1(a-2,6)H5N4F1
structures signiﬁcantly decreased in cartilage tissues ex-
cised from animals with induced osteoarthritis as compared
to those of healthy animals. It appears noteworthy that the
shift towards reduced a-2,6- to a-2,3-sialylation ratios in hu-
man chondrocytes under exposure to IL-1b and TNF-a, as
observed in our study, is not a general cellular phenome-
non. As reported recently, human endothelial cells respond
to IL-1b, TNF-a, and lipopolysaccharide (LPS) with in-
creased a-2,6-SiaT mRNA levels, increased a-2,6-SiaT en-
zyme activity, and enhanced cellular binding of SNA
lectin52. In contrast, stimulation of human monocyte matura-
tion with TNF-a, IL-1b, LPS, or IFN-g leads to downregula-
tion of both ST6Gal1 and ST3Gal4 transcription19. Thus, it
can be concluded that the effect induced by pro-inﬂamma-
tory molecules on cellular sialylation is strongly dependent
on cell and tissue type. For human chondrocytes we pro-
pose a novel mechanism involving a-2,6-linked sialic acids
that represent a typical structure of the differentiated chon-
drocyte phenotype, whereas the enhanced expression of
a-2,3-linked sialic acids accompanies cellular dedifferentia-
tion induced by IL-1b and TNF-a. In light of the signiﬁcance
of sialic acids in CD44-matrix interactions, a shift towards
a-2,3-sialylation under inﬂammatory conditions may modify
the binding ability of CD44 to the HA substrate, inﬂuencing
cellular anchoring of matrix components and affecting sig-
nal transduction and gene expression53,54. Similarly to
CD44, the b1 subfamily of integrins is substrate of several
glycosyltransferases including ST6Gal155e58. Although
controversial and highly dependent on the cell type, those
studies have demonstrated the relationship between sialy-
lation of b1 integrins and adhesion to ECM components.
Since chondrocytes express a number of different integrins
including a1b1, a2b1, a3b1, a5b1, and a6b1 integrins59, the
altered N-glycan sialylation in the presence of TNF-a or
IL-1b may potentially inﬂuence the binding afﬁnity of these
receptors for their matrix substrates. This hypothesis, how-
ever, still remains to be experimentally proven.
In conclusion, the present report has revealed that the ex-
pression ratio of a-2,6- to a-2,3-linked terminal sialic acids
constitutes a signature of the differentiation status of human
chondrocytes. Whereas a-2,6-linked sialic acids are the typ-
ical structure in primary human chondrocytes, the altered
phenotype observed in chondrocytic cell lines or induced
by IL-1b and TNF-a is associated with abundant a-
2,3-linked sialic acids. This ﬁnding may shed light on the
signiﬁcance of sialylated N-glycan structures for cartilage
homeostasis and enhance our understanding of cartilage
pathophysiology. Future studies clarifying the molecular
basis, as well as the functional consequences of shifting
sialylation patterns in human chondrocyte N-glycans, are
therefore anticipated.Conﬂict of interest
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E-mail address: stefan.toegel@univie.ac.at (S. ToegDespite the signiﬁcance of glycoproteins for extracellular matrix assembly in cartilage tissue, little is
known about the regulation of the chondrocyte glycophenotype under inﬂammatory conditions. The
present study aimed to assess the effect of IL-1b and TNF-a on speciﬁc features of the glycophenotype
of primary human chondrocytes in vitro. Using LC–MS, we found that both cytokines increased overall
sialylation of N- and O-glycans and induced a shift towards a-(2?3)-linked sialic acid residues in chon-
drocyte glycoproteins. These results were supported by quantitative PCR showing increased expression of
a-(2?3) sialyltransferases in treated cells. Moreover, we found that both IL-1b and TNF-a induced a con-
siderable shift from oligomannosidic glycans towards complex-type N-glycans. In contrast, core a-
(1?6)-fucosylation of chondrocyte N-glycans was found to be reduced particularly by TNF-a. In sum-
mary, inﬂammatory conditions induce speciﬁc alterations of the chondrocyte glycophenotype which
might affect cell–matrix interactions or the function of endogenous lectins.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
In recent years, inﬂammatory processes have been recognized
to contribute to the progression of degenerative joint diseases such
as osteoarthritis.1 The release of interleukin-1b (IL-1b) or tumor
necrosis factor-alpha (TNF-a) from joint tissues may be involved
in the induction of pro-inﬂammatory mediators and proteinases
that promote the destruction of cartilage matrix.2 Interestingly, re-
cent studies provide evidence for a relationship between osteoar-
thritic conditions and altered glycosylation of cartilage tissue or
chondrocytes. In an animal model of osteoarthritis, altered N-gly-
cosylation of cartilage has been observed.3 This ﬁnding is in line
with a report showing that cytokine treatment of human and bo-
vine chondrocytes results in speciﬁc glycosylation changes related
to apoptosis and altered cell proliferation.4 Recently, we found that
differences in the molecular chondrocyte phenotype are reﬂected
by speciﬁc cellular lectin-binding patterns.5,6 In a further study
employing quantitative PCR and liquid chromatography–electro-
spray ionization-mass spectrometry (LC–ESI-MS), we demon-
strated that primary human chondrocytes predominantly expressll rights reserved.
artment of Pharmaceutical
nna, Althanstrasse 14, 1090
277 9554.
el).a-(2?6)-sialyltransferases (SiaT) and accordingly, a-(2?6)-linked
sialic acid residues in glycoprotein N-glycans. Upon treatment with
IL-1b or TNF-a, however, an overall shift towards a-(2?3)-sialyla-
tion of diantennary fucosylated N-glycans and towards a-(2?3)-
SiaT mRNA levels was observed in primary chondrocytes.7
To expand our previous work, the present study aimed to inves-
tigate the impact of IL-1b and TNF-a on three characteristics of the
chondrocyte glycophenotype: (1) the ratio between oligomannos-
idic, hybrid and complex-type N-glycans, (2) the core fucosylation
in N-glycans, and (3) the sialylation of N- and O-glycans with re-
gard to linkage type and degree of sialylation.
2. Results and discussion
In osteoarthritis, articular chondrocytes undergo phenotypic
modulation in response to mechanical injury and inﬂammation.2
In addition to changes of cell morphology and marker gene expres-
sion, inﬂammatory conditions induce alterations of the chondrocyte
glycophenotype. As shown in Figure 1, a series of glycosyltransfer-
ases is inducible by pro-inﬂammatory cytokines in primary human
chondrocytes. IL-1b signiﬁcantly down-regulated MAN1C1 (14.3-
fold), MGAT3 (7.1-fold) and ST6GalNAc3 (11.1-fold) mRNA expres-
sion in all three donors (Fig. 1A). Consistently, TNF-a reduced these
genes to a similar extent (12.5-, 4.8-, and 25-fold, respectively)
(Fig. 1B). In contrast, ST3Gal1 was up-regulated 4.1- and 2.7-fold57
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Figure 1. mRNA levels of glycosyltransferases in human chondrocytes exposed to pro-inﬂammatory cytokines. Primary chondrocytes were treated with 10 ng/mL IL-1b (A) or
40 ng/mL TNF-a (B) for 24 h and mRNA expression was analyzed using RT-qPCR. Cytokine-induced alterations of mRNA levels are displayed as relative quantities (mean ± SD;
n = 3 donors) with respect to untreated controls set at 1. *p <0.05 in three cell populations. §p <0.05 in two cell populations.
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1.9-fold higher levels in the presence of TNF-a.
To estimate changes due to cytokine treatment we identiﬁed
the most representative major N-glycan structures for ﬁve differ-
ent criteria (oligomannosidic, hybrid-type, complex-type, degree
of fucosylation and sialylation) by LC-ESI-MS with a graphitized
carbon column (Fig. 2). For oligomannosidic glycans we quantiﬁed# Oligomannosidic Mass H N F S
Man4 - Man9 x x 2
Complex-type
1 A4A4F6 1788.67 5 4 1
2 A4Na6-4F6 2079.76 5 4 1 1
3 A4Na3-4F6 2079.76 5 4 1 1
4 Na6-4Na6-4F6 2370.86 5 4 1 2
5 Na3-4Na6-4F6 2370.86 5 4 1 2
6 Na3-4Na3-4F6 2370.86 5 4 1 2
Hybrid-type (Na3-4 isomers not listed) 
7 Man3Na6-4 1568.57 4 3 1
8 Man4Na6-4 1730.62 5 3 1
9 Man5Na6-4 1892.68 6 3 1
10 Man3Na6-4F6 1714.63 4 3 1 1
11 Man4Na6-4F6 1876.68 5 3 1 1
12 Man5Na6-4F6 2038.73 6 3 1 1
O-glycans
13 A4A-O2   750.29 2 2
14 Na3-4A-O2 1041.39 2 2 1
15 A4Na3-O2 1041.39 2 2 1
16 Na3-4Na3-O2 1332.48 2 2 2
Figure 2. Chondrocyte glycan structures quantiﬁed by LC–ESI-MS. In addition to the st
considered for quantiﬁcation. Regarding the ﬁne structure of O-glycans, we assume the
substances with O-glycans from bovine fetuin.9 Glycans are named according to the ‘prthe amounts of Man4, Man5, Man6, Man7, Man8 and Man9 gly-
cans, whereas hybrid-type glycans were represented by the series
of Man3Na, Man4Na and Man5Na glycans, core a-1,6 fucosylated
as well as unsubstituted. Major complex type structures were
identiﬁed as A4A4F6 glycans (see Fig. 2), either non-, mono- or disi-
alylated. A more detailed analysis concerning sialylation linkage
distribution of the A4A4F6 glycan in human chondrocytes can bemannose
Neu5Acfucose galactose
GlcNAc GalNAc
21
4
7
10
13
β1-4 (or 3)
α2-6
α2-3
3
5
8
11
14
6
9
12
15 16
ructures shown here, hybrid-type N-glycans with a-(2?3)-linked sialic acid were
presence of b-(1?4)-linked galactose on the upper arm from the coelution of these
oglycan’ nomenclature (http://www.proglycan.com).
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Table 2
Glycoprotein N-glycan characteristics in primary human chondrocytes treated with
IL-1b or TNF-a
Oligo-mann. Hybrid Complex Fucosylation Sialylation
CTRL 41.0 13.0 46.0 58.4 68.4
TNF-a 34.4* 12.9 52.7* 51.9§ 71.8§
IL-1b 38.0§ 12.0 50.1§ 56.8 70.3
Data show mean values of cells isolated from 3 donors in percent (2 repeats per
measurement). TNF-a and IL-1b treated cells are compared to untreated controls.
On average, standard deviations were 2.5% of the respective values.
(Oligo.mann. = oligomannosidic structures, hybrid = hybrid-type glycans, com-
plex = complex-type glycans).
* p <0.05 in three cell populations.
§ p <0.05 in two cell populations.
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Proglycan nomenclature (http://www.proglycan.com)).
A considerable shift from oligomannosidic glycans towards
complex-type N-glycans occurred in primary human chondrocytes
under the inﬂuence of IL-1b and TNF-a. While untreated control
cells showed an average of 46% complex type glycans, these struc-
tures increased to 52.7% and 50% after treatment with TNF-a or IL-
1b, respectively (Table 2). This ﬁnding is in line with RT-qPCR re-
sults of MGAT2 expression levels (Fig. 1). Concomitantly, the pro-
portion of oligomannosidic glycans decreased from 41.0% in
control cells to 34.4% after TNF-a and to 38.0% after IL-1b treat-
ment (Table 2). Interestingly, this result appears to be inconsistent
with RT-qPCR results on MAN1C1 and MAN2A1, which both were
markedly decreased in the presence of cytokines (Fig. 1). However,
in both cases only one of the three genes encoding Golgi a-man-
nosidase I and Golgi a-mannosidase II was considered.8 Hybrid-
type structures were detected to represent about 13% in control
samples and no signiﬁcant changes were detected after cytokine
treatment (Table 2). In addition, Figure 3 displays the percent dif-
ferences of oligomannosidic, hybrid-type and complex-type struc-
tures with respect to untreated cells and clearly shows that the
results were reproducible, albeit to a different extent, in cells iso-
lated from three donors.
The degree of fucosylation was analyzed monitoring hybrid-
type glycans. For these structures a contamination by non-fucosy-
lated glycans from the FCS in the cell culture medium can be ex-
cluded. Core a-(1?6)-fucosylation was found to be 58.4% on
average. A signiﬁcant decrease of 6.5% was found for TNF-a treated
cells of two donors (Table 2). For IL-1b on the other hand, fucosy-
lation appeared to be almost unaltered. Similarly, FUT8 mRNA lev-
els were slightly decreased by the cytokines, however, signiﬁcance
levels (p <0.05) were reached in just two of three donors (Fig. 1).
Primary human chondrocytes strongly express the a-(2?6)-
SiaT ST6Gal1 and accordingly, mainly a-(2?6)-linked sialic acid
residues are found on A4A4F6 N-glycans. However, when primary
chondrocytes were treated with IL-1b or TNF-a, a considerable
shift towards the a-(2?3)-SiaT ST3Gal4 occurred.7 LC–ESI-MS
analysis of non-, mono-, and disialylated A4A4F6 N-glycans con-
ﬁrmed the increase of a-(2?3) sialylation on glycoprotein N-gly-
cans of TNF-a treated chondrocytes (Fig. 4). The degree of
sialylation of diantennary (core fucosylated) N-glycans was found
to be 68.4% in the control samples on average and was increased
to 71.8% with TNF-a and 70.3% with IL-1b (Table 2). In case of
TNF-a treated cells, these small changes were signiﬁcant for two
of three donors (Table 2). In summary, the degree of sialylation re-
mained almost unchanged, or just slightly enhanced by treatment
with TNF-a.
Regarding O-glycan sialylation, we observed that the two a-
(2?3) SiaTs ST3Gal1 and ST3Gal2 were expressed at 5 ± 1 and
3 ± 2 molecules/1000 molecules GAPDH, respectively. In compari-
son, the a-(2?6) SiaTs ST6GalNAc1 and ST6GalNAc2 were notTable 1
Primer sequences for qPCR assays
Gene Accession number Forward primer
ST3GAL1 NM_003033 CATCCTCTCGGTCATCTTCTC
ST3GAL2 NM_006927 GGACGGGCACAACTTCATC
ST6GalNAc1 NM_018414 TCTGGCTGTCCTGGTCTTC
ST6GalNAc2 NM_006456 CCAAGTCATCGCCTCCAC
ST6GalNAc3 NM_152996 GATACCATTCTCCTACACATA
ST6GalNAc4 NM_175039 GGCTTTGAGGCGGATGTG
MGAT1 NM_002406 GGTGGAGTTGGTGGGTCATC
MGAT2 NM_002408 CTGCTGCTGGACTCACTTC
MGAT3 NM_002409 ATGGAGGAGAAGAGAATGG
MAN1C1 NM_020379 CCCGCTCAGACACCAAAC
MAN2A1 NM_002372 GACTCTTACTCTCCTGATACC
FUT8 NM_178155 GGTTCAGCGGAGAATAACATdetectable with RT-qPCR and ST6GalNAc3 and ST6GalNAc4 were
expressed at 0.2 ± 0.1 and 3 ± 1 molecules/1000 molecules GAPDH.
Accordingly, a-(2?6) sialylation was practically absent at chon-
drocyte glycoprotein O-glycans as revealed by LC–MS (data not
shown). Upon treatment with IL-1b or TNF-a, the SiaT expression
proﬁle of primary chondrocytes predicted an O-glycan sialylation
pattern characterized by increased a-(2?3)-linked sialylation
(Fig. 1). In fact, ST3Gal1 mRNA levels were markedly up-regulated
under the inﬂuence of the cytokines (4.1-fold in case of IL-1b and
2.7-fold in case of TNF-a), whereas the expression of ST6GalNAc3
was decreased under the same conditions (11.1-fold and 25-fold,
respectively).
LC–MS analysis of O-glycans from chondrocytes revealed
changes in the sialylation of the core 2 O-glycan number 13
(A4A-O, Fig. 2). In untreated chondrocytes, we found 7.4% of the
nonsialylated as well as 44.1% and 49.4% mono- and disialylated
structures, respectively (Table 3). Upon TNF-a treatment, the
amount of disialylated glycans (number 16, Fig. 2) increased to
67% at the expense of non- and monosialo O-glycans. A comparable
increase of sialylation of O-glycans was observed in presence of IL-
1b (Table 3).
Taken together, this study shows that primary human chondro-
cytes display an altered glycophenotype in response to the pro-
inﬂammatory cytokines IL-1b and TNF-a at the mRNA and glycan
level. Regarding the functional consequences of altered glycophe-
notypes, it is noteworthy that the glycosylation of structural pro-
teins and cell surface receptors contributes to the maintenance of
articular cartilage functionality.10 In particular, glycosylated recep-
tors including CD44 and integrins play critical roles in the media-
tion of chondrocyte-matrix interactions which trigger signal
transduction and gene expression.11,12 Increased overall sialylation
as well as shifting sialic acid linkage types could modify chondro-
cyte–matrix interactions or signaling by endogenous lectins. In this
regard, galectins were shown to tolerate a-(2?3) sialylation13,
whereas galectin-1 does not bind sialylated N-glycans with
terminal a-(2?6)-linked sialic acids of the type elaborated byReverse primer Amplicon size
CAGTAGTGGTGCCAGTTCC 93 bp
CAGGTTCTTGGCACTCTCAG 115 bp
TAATGTTCTCTGTGCGTTGATG 95 bp
TCAGAATGCCTCCGTTGC 125 bp
CAG AAGGTCACAGTCCAGTTGC 97 bp
CTGGAAGTAGTGTGAATAGTTGC 96 bp
GAGGAGAGGTCTTGCTTGCC 142 bp
AATGCTGAAAGGAAAGAACACC 147 bp
ATATG GAGGGAAACAGGAGCAAGC 132 bp
TCCGACAGTATTTCTCCAAGG 204 bp
TTC TACCTTGGCTCCGCACTC 104 bp
ATC GACAGCCATAGCCACAGC 98 bp
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Table 3
O-Glycan sialylation in primary human chondrocytes treated with IL-1b and TNF-a
#13 #14 & #15 #16
CTRL 7.4 44.1 49.4
TNF-a 3.3* 29.7* 67.0*
IL-1b 3.8§ 30.8* 66.1*
TNF-a and IL-1b treated cells are compared to untreated controls. Data show mean
values of cells isolated from three donors in percent (two repeats per measure-
ment). In average, standard deviations were 3.5% of the respective values. Numbers
(#13–#16) refer to the O-glycan structures shown in Figure 2.
* p <0.05 in three cell populations.
§ p <0.05 in two cell populations.
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function under inﬂammatory conditions. Similarly, changing
ratios between oligomannosidic and complex-type structures ofglycoproteins might inﬂuence protein folding and stabilization of
functional conformations.15 Based on the present report, future
studies are expected to clarify the functional role of modulated gly-
cosylation in physiological cartilage homoeostasis and joint
disease.3. Experimental
3.1. Cell culture
Primary human chondrocytes were isolated from cartilage spec-
imens as described in detail previously.5,7 The study was per-
formed in accordance with the terms of the ethics committee of
the Medical University Vienna (EK-Nr.: 081/2005). Isolated cells
were grown to conﬂuence in Dulbecco’s Modiﬁed Eagle Medium
supplemented with 10% fetal calf serum (Biochrom AG, Germany)
and 2 lL/mL gentamycin. To induce inﬂammatory conditions, cells60
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periods indicated.
3.2. Quantitative real-time RT-PCR (RT-qPCR)
Chondrocytes were plated on 12-well tissue culture plates (Iwa-
ki, Japan) and grown as described above prior to treatment with
cytokines for 24 h. Total RNA was extracted using the NucleoSpin
RNA II Kit (Macherey-Nagel, Germany) and processed into cDNA
using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Austria).
SYBR-green based RT-qPCR assays for glycosyltransferases were
established following published protocols.16,17 Details on primer
sequences are given in Table 1. All RT-qPCR reactions were per-
formed in 25 lL reaction mixtures containing 1 lL cDNA, 12.5 lL
Brilliant SYBR Green QPCR Master Mix, 100 nM primers, and nucle-
ase-free water to 25 lL, and run in duplicate on a Mx3000P QPCR
system (Stratagene). Melting curves were generated to conﬁrm a
single gene-speciﬁc peak and no-template-controls were included
in each run to control for contaminations. mRNA expression levels
were calculated as relative copy numbers with respect to the
expression of glyceraldehyde-3-phosphate-dehydrogenase (GAP-
DH) set at 1000. The regulation of genes by cytokines was calcu-
lated as quantities relative to the untreated control group using
the MxPro real-time QPCR software.3.3. Protein isolation, glycan preparation, and oligosaccharide
analysis
Chondrocytes were seeded in 25 cm2 ﬂasks (Greiner bio-one,
Austria) and allowed to settle for 48 h. Then, the culture medium
was changed and cells were maintained in the presence of 10 ng/
mL IL-1b or 40 ng/mL TNF-a for 5 days. Protein isolation and N-gly-
can preparation was done after cell lysis by acetone precipitation
and a ‘mini-prep SDS page puriﬁcation’18 of the proteins as de-
scribed in our recent work.7 O-glycans were released by reducing
b-elimination19 and were further analyzed in the same way as
borohydride reduced N-glycans.7,20,21 Porous Graphitized Carbon
was selected as stationary phase for separation of borohydride re-
duced glycans as described recently.20,21 Structural identiﬁcation
and differentiation of isobaric glycans was performed by elution
times. For statistical evaluation, representative major glycan struc-
tures were identiﬁed and evaluated.3.4. Quantiﬁcation of LC–MS peaks
Glycans were detected using an ESI Q-TOF MS from Waters
(Micromass, Q-TOF Ultima Global). A ﬁrst data analysis was per-
formed using a MassLynx 4.0 SP4 Software, where further auto-
matic peak detection and quantiﬁcation was done employing
MassMap (Thermo-Fisher, http://www.massmap.de).3.5. Statistics
RT-qPCR data were exported to the GraphPad Prism statistics
software package (GraphPad Prism Software, USA). Statistics were
performed using one-way analysis of variance (ANOVA) with post
hoc Tukey tests, cross-comparing all study groups (95% conﬁdence
interval). p-values < 0.05 were considered signiﬁcant.
Descriptive statistics and statistical signiﬁcances of LC–MS data
were calculated using SPSS (Statistical Package for the Social Sci-
ences, IBM). One-way ANOVA was performed to evaluate statistical
signiﬁcance. Changes were considered signiﬁcant if their corre-
sponding p values were below p <0.05 (n = 3, 2 repeats).
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Abstract Exacerbated production of matrix metallopro-
teinases (MMPs) is a key event in the progression of
osteoarthritis (OA) and represents a promising target for
the management of OA with nutraceuticals. In this study,
we sought to determine the MMP-inhibitory activity of an
ethanolic Caesalpinia sappan extract (CSE) in human OA
chondrocytes. Thus, human articular chondrocytes isolated
from OA cartilage and SW1353 chondrocytes were stim-
ulated with Interleukin-1beta (IL1b), without or with pre-
treatment with CSE. Following viability assays, the
production of MMP-2 and MMP-13 was assessed using
ELISA, whereas mRNA levels of MMP-1, MMP-2, MMP-3,
MMP-7, MMP-8, MMP-9, MMP-13 and TIMP-1, TIMP-2,
TIMP-3 were quantified using RT-qPCR assays. Chon-
drocytes were co-transfected with a MMP-13 luciferase
reporter construct and NF-kB p50 and p65 expression
vectors in the presence or absence of CSE. In addition, the
direct effect of CSE on the proteolytic activities of MMP-2
was evaluated using gelatin zymography. We found that
CSE significantly suppressed IL1b-mediated upregulation
of MMP-13 mRNA and protein levels via abrogation of the
NF-kB(p65/p50)-driven MMP-13 promoter activation. We
further observed that the levels of IL1b-induced MMP-1,
MMP-3, MMP-7, and MMP-9 mRNA, but not TIMP
mRNA levels, were down-regulated in chondrocytes in
response to CSE. Zymographic results suggested that CSE
did not directly interfere with the proteolytic activity of
MMP-2. In summary, this study provides evidence for the
MMP-inhibitory potential of CSE or CSE-derived com-
pounds in human OA chondrocytes. The data indicate that
the mechanism of this inhibition might, at least in part,
involve targeting of NF-kB-mediated promoter activation.
Keywords Chondrocytes  Osteoarthritis  Caesalpinia
sappan  Matrix metalloproteinase  Tissue inhibitors of
MMP  NFkB
Background
Osteoarthritis (OA), a chronic and degenerative joint dis-
ease, has the highest prevalence and economic impact
among arthritic maladies. Besides mechanical and genetic
factors, pro-inflammatory cytokines such as interleukin-1b
(IL1b) or tumor necrosis factor alpha (TNFa) contribute to
the impaired chondrocyte function and extracellular matrix
(ECM) integrity in OA. Histological examination has
demonstrated the localization of IL1b in the zones of
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degenerated OA cartilage (Saha et al. 1999) as well as in
the synovial membranes and synovial fluids of OA patients
(Smith et al. 1997; Kubota et al. 1997). At the cellular
level, chondrocytes respond to this cytokine via a cascade
of events leading to loss of balance between cartilage
anabolism and catabolism, associated with phenotypic
modulation and activation of the normally quiescent
chondrocytes (Goldring and Marcu 2009; Goldring et al.
2008). In OA cartilage, IL1b and TNFa co-localize with
increased levels of matrix metalloproteinases (MMPs)
(Tetlow et al. 2001), and IL1b was shown to upregulate
MMP expression levels in normal human chondrocytes,
OA chondrocytes, and chondrosarcoma cells (Tetlow et al.
2001; Fan et al. 2005; Mix et al. 2001).
According to their main substrate specificity, proteins of
the MMP family can be divided into collagenases (MMP-1,
MMP-8, MMP-13), gelatinases (MMP-2 and MMP-9),
stromelysins (MMP-3, MMP-10, MMP-11), and membrane
type I MMPs (MMP-14-17). Restriction of the proteolytic
activities of MMPs is mediated by endogenous tissue
inhibitors of MMPs (TIMPs) (Nagase and Woessner 1999).
MMPs play important roles in physiological processes such
as tissue repair, but also become part of destructive disease
processes due both to its overexpression and the excessive
activation of pro-MMPs into their active forms. Interest-
ingly, a recent study by Little et al. demonstrated that
MMP-13-knockout mice were less prone than wild-type
mice to develop tibial cartilage structural damage follow-
ing medial meniscal destabilization surgery in the knee
(Little et al. 2009). Taken together, MMPs might represent
promising targets for therapeutic intervention in OA.
To date, classic therapeutic approaches of OA are still
limited to exercise, palliative drugs or surgical interven-
tion. There is growing awareness, however, that nutritional
factors can positively influence the maintenance of bone
and joint health. Articular cartilage is critically dependent
upon the regular provision of nutrients, vitamins, and
essential trace elements (Goggs et al. 2005). Thus, dietary
supplementation programs and nutraceuticals might pro-
vide long-term benefits to patients with a chronic disease
such as OA. In general, the benefits offered by nutraceu-
ticals are based on the lack of adverse effects and the tar-
geting of multiple signaling pathways addressed by
nutritional compound mixtures such as plant extracts
(Bjorkman 1999). A comprehensive review on current
nutraceuticals for the management of OA has been pub-
lished elsewhere (Ameye and Chee 2006).
Caesalpinia sappan L. (Leguminosae) is distributed in
Southeast Asia, and its dried heartwood (also known as
Sappan wood) has been a traditional ingredient of food or
beverages such as Bir Pletok, a Batavian spice drink. The
extract was shown to lack toxic effects and to possess anti-
atherogenic potential in rats based on its constituent
hematein (Sireeratawong et al. 2010; Oh et al. 2001). In
traditional Chinese medicine, Caesalpinia sappan is known
to promote blood circulation and to possess analgesic or
anti-inflammatory properties (China Pharmacopoeia 2010).
In Japan, Sappan wood was listed in the 15th edition of the
Japanese Pharmacopoeia (2006). A range of constituents
including brazilin, hematoxylin, brazilein, photosappanin
derivatives, flavones, and other homoisoflavonoids has
been isolated from Caesalpinia sappan (Chen et al. 2008;
Washiyama et al. 2009; Xie et al. 2000). Extracts of
Caesalpinia sappan as well as some of their defined con-
stituents have been investigated as functional food,
revealing potential anti-inflammatory (Jeong et al. 2008),
vasorelaxing (Xie et al. 2000), immunosuppressive (Ye
et al. 2006), and hepatoprotective effects (Srilakshmi et al.
2010). At the time of finalizing this manuscript, Sun et al.
published a study demonstrating the efficacy of a Cae-
salpinia sappan extract in an animal model of rheumatoid
arthritis (Sun et al. 2011). Rats treated daily with 1.2, 2.4,
or 3.6 g/kg extract showed reduced signs of paw swelling
and arthritis severity as well as lower levels of proinflam-
matory mediators in the plasma as compared to untreated
animals. The mechanisms underlying these effects, how-
ever, are still not fully understood.
The present study was driven by the hypothesis that the
extract of Caesalpinia sappan (CSE) interferes with cata-
bolic processes in human OA chondrocytes. We cultured
human chondrocytes in the presence of IL1b and examined
the biological effects of CSE co-treatment on the expres-
sion and activity of major MMPs. The results presented
here demonstrate that CSE strongly inhibits chondrocyte
catabolism by suppressing IL1b-induced MMPs mRNA
and protein levels. We further present evidence that CSE
interferes with MMP-13 promoter activation mediated by
NF-kB subunits p50 and p65.
Materials and methods
Preparation and characterization of CSE
The heartwoods of Caesalpinia sappan were collected in
June 2006 in San-Pa-Thong district, Chiang Mai province,
Thailand, and identified by comparison with the voucher
specimen (No. 87-1631) at the Herbarium Section, North-
ern Research Center for Medicinal Plants, Faculty of
Pharmacy, Chiang Mai University, Thailand. Ethanolic
extraction was performed by continuously extracting 30 g
powdered heartwood in 350 ml 96% EtOH for 24 h using a
Soxhlet apparatus. Then, the liquid extract was evaporated
under reduced pressure to yield solid CSE. The composi-
tion of CSE has been described in detail previously (Chen
et al. 2008). For further characterization, 4 batches of CSE
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were analyzed qualitatively using HPLC. Briefly, CSE
samples were dissolved in MeOH (1 mg/ml), filtrated
through a 0.2 lm sterile filter, and analyzed by HPLC
(ICS-3000, Dionex, USA) using a Nucleodur C-18 column
(Macherey–Nagel, D), a PDA-100 detector (Dionex) and a
solvent gradient of MeOH and bidistilled H2O (both con-
taining 2.5% acetic acid). At 280 nm, all 4 batches yielded
congruent chromatograms which were also comparable to
that of the standardized reference Natural Red 24 (MP
Biomedicals, USA, LOT #: R25179), a commercially
available Sappan wood extract (Supplementary Figure 1).
For cell treatment, CSE was dissolved in 96% EtOH
(10 mg/ml) and used in appropriate dilutions for the in
vitro assays. The activity of specific components was not
addressed in the current study.
Cell culture
Human articular cartilage was obtained from intact regions
of femoral condyles and tibial plateaus at the time of total
knee replacement surgery in OA patients with informed
consent and in accordance with the terms of the ethics
committee of the Medical University Vienna (EKNr.:
081/2005). Primary chondrocytes (PCs) were isolated
according to standard protocols (Toegel et al. 2009), see-
ded at 105 cells/cm2, and grown in an atmosphere of
humidified 5% CO2/95% air at 37C using Dulbecco’s
Modified Eagle Medium (DMEM; Gibco, A) supplemented
with 10% fetal calf serum (FCS; Biochrom AG, D) and
gentamycin (complete medium). Only freshly isolated PCs
were used for all assays throughout the study. Human
SW1353 chondrosarcoma cells were seeded at 104 cells/
cm2 and maintained in complete medium, whereas
T/C28a2 immortalized chondrocytes were seeded at 104
cells/cm2 and cultured using DMEM/F12 containing 10%
FCS. Prior to cell treatment, chondrocytes were starved for
6 h in serum-free DMEM containing 2% insulin-transfer-
rin-selenium solution (Gibco, A) (ITS medium). Then,
cells were pretreated for 1 h with CSE or vehicle in ITS
medium followed by the addition of 10 ng/ml IL1b
(Strathmann Biotec, D) and further incubation for the
indicated times.
Viability assay
Primary chondrocytes were seeded at 3 9 103 cells/well
into 96-well microplates (Iwaki, J), serum-starved, and
treated in quadruplicate with serial dilutions of CSE for
72 h. Cell proliferation was evaluated using the MTT-
based EZ4U cell proliferation assay (Biomedica, A) fol-
lowing the manufacturer’s instructions. The experiment
was repeated twice with cells from different donors.
Gelatin zymography
Serum-starved cells were cultured in the presence of 5 lg/
ml CSE for 48 h. Ten microliter of cell culture superna-
tant was mixed with 10 ll Sample buffer (0.5 M Tris–
HCl, 20% Glycerol, 10% SDS, 0.1% Bromophenol Blue)
and incubated for 10 min at room temperature. The
samples were loaded on gelatin (1 mg/ml)—containing
SDS–polyacrylamide gels for electrophoresis with con-
stant voltage (125 V). After running, the gel was incu-
bated in renaturation buffer (2.5% Triton X-100) with
gentle agitation for 30 min at room temperature. After-
ward, the gel was equilibrated for 30 min in developing
buffer (50 mM Tris-Base, 0.2 M NaCl, 5 mM CaCl2,
0.02% Brij35) and then incubated in fresh developing
buffer overnight at 37C. The zymographic activities were
revealed by staining the gel with 0.2% Coomassie Blue.
Gels were destained with a destaining solution (7.5%
acetic acid in 20% ethanol). Areas of protease activity
appeared as clear bands against a dark blue background,
where the substrate digestion by the protease occurred.
Molecular weights were estimated by comparison with
prestained SDS–PAGE markers and a human pro-MMP-2
standard (AnaSpec, USA).
In a different approach, 0.1 lg/ml human pro-MMP-2
(AnaSpec, USA) were mixed with sample buffer and
subjected to gelatine zymography as described above.
Following electrophoresis, the gel was divided into equal
parts, and the individual strips were developed in different
developing buffers containing 5 lg/ml CSE, 10 lg/ml
CSE, or 1 mM EDTA as positive control, respectively
(Albini et al. 2001; Mazzoni et al. 2007).
MMP ELISA
Primary human chondrocytes (n = 3 donors) and SW1353
cells were cultured as described in 12-well plates and
pretreated with 5 lg/ml CSE followed by the addition of
10 ng/ml IL1b. After 48 h, the culture supernatants were
collected, centrifuged, and stored at -80C. ELISA assays
for MMP-2 and MMP-13 were carried out following the
protocols provided by the manufacturer (RayBiotech,
USA).
Quantitative real-time RT-PCR
Primary chondrocytes and SW1353 cells were cultured as
described in 12-well plates and pretreated for 1 h with
5 lg/ml CSE followed by the addition of 10 ng/ml IL1b.
After 6 h, cell monolayers were washed with PBS and total
RNA was extracted using the NucleoSpin RNA II Kit
(Macherey–Nagel, D) according to the manufacturer’s
instructions. On-column DNase digestion was performed
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for all samples during the isolation process. To quantify
and control for the integrity of the isolated RNA prepara-
tions, each sample was run on the Agilent 2100 Bioana-
lyzer Nano LabChip prior to reverse transcription of equal
RNA quantities into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, A). RNA
integrity numbers (RINs) were found to range from 7.8 to
10 for all samples.
SYBR green-based RT-qPCR assays for MMP-1, MMP-
2, MMP-3, MMP-7, MMP-8, MMP-9, and MMP-13 as well
as TIMP-1, TIMP-2, and TIMP-3 were established
according to previously published protocols (Toegel et al.
2007, 2008). Details on primer sequences are given in
Table 1. Amplification efficiencies of all primers were
evaluated using dilution series of cDNA prepared from
chondrocyte mRNA. All RT-qPCR reactions were per-
formed in 25-ll reaction mixtures containing 1 ll cDNA,
12.5 ll SensiMix SYBR Green Master Mix (GenXpress,
A), 100 nM primers (Metabion, D), and nuclease-free water
to 25 ll and run in duplicate on an Mx3000P QPCR system
(Stratagene, USA). Melting curves were generated to con-
firm a single gene-specific peak and no-template-controls
were included in each run to control for contaminations.
The regulation of target genes was calculated as quan-
tities relative to the untreated control group using the
MxPro real-time QPCR software, considering both ampli-
fication efficiencies and normalization to GAPDH as ref-
erence gene. In preceding experiments, the expression
stability of 5 candidate reference genes (GAPDH, ACTB,
HPRT1, SDHA, B2M) was determined in human chon-
drocytes and SW1353 cells treated with 5, 10, and 20 lg/
ml CSE, as described above. Then, the expression stabili-
ties were evaluated using the geNorm software (Vande-
sompele et al. 2002), and GAPDH was selected as stable
reference gene under the experimental conditions of this
study.
We declare that the current study has adhered to the
minimal guidelines for the design and documentation of
qPCR experiments as recently outlined by Bustin et al.
(2010). A qPCR checklist listing all relevant technical
information has been provided for the reviewers to assess
the technical adequacy of the used qPCR protocols (Sup-
plementary Table 1).
Transfection and reporter assays
The MMP-13 promoter sequence spanning -1007/?27 bp
of the human MMP13 promoter was prepared by PCR and
cloned into the pGL2-Basic luciferase reporter vector (Pro-
mega; USA) as previously described (Ijiri et al. 2005). The
expression vectors encoding the NF-kB p50 and p65 subunits
were previously described (Grall et al. 2005). The sequences
of all constructs were confirmed by DNA sequencing.
Transient transfection experiments were carried out in
T/C-28a2 cells using LipofectAMINE PLUSTM Reagents
(Invitrogen; USA). Cells were seeded in 24-well tissue
culture plates and cultured to 80% confluence. Transfec-
tions were carried out in serum-free antibiotic-free medium
using no more than 325 ng of plasmid DNA, including
300 ng of reporter constructs and 25 ng of expression
vectors or pCI empty vector (control). After incubation for
1 h at 37C with the transfection mixture, cells were
treated with 1 ml of serum-free medium containing CSE or
caffeic acid phenethyl ester (CAPE; Calbiochem, D) and
incubation was continued for 23 h. Cell lysates were pre-
pared using the Reporter Lysis Buffer (Promega), and
luciferase activities were determined by chemilumines-
cence assay using the LMaxII384 luminometer (Molecular
Devices, USA) and the Luciferase Assay Substrate (Pro-
mega). Data are representative of two independent exper-
iments performed in triplicate and expressed as fold change
versus control.
Table 1 Details on primers for RT-qPCR
Gene Accession number Forward primer Reverse primer Amplicon size (bp) Efficiency (%)
MMP1 NM_002421 CTGGAATTGGCCACAAAGTT TCCTGCAGTTGAACCAGCTA 144 93.9
MMP2 NM_004530 TGACGGTAAGGACGGACTC ATACTTCACACGGACCACTTG 124 91.3
MMP3 NM_002422 GGTGTGGAGTTCCTGATGTTG AGCCTGGAGAATGTGAGTGG 184 99.9
MMP7 NM_002423 GAGTGCCAGATGTTGCAGAA TCTCTTTGCCCCACATGTTT 156 106.9
MMP8 NM_002424 TCTGCAAGGTTATCCCAAGG ACCTGGCTCCATGAATTGTC 154 95.3
MMP9 NM_004994 CTGGGCAGATTCCAAACCT TACACGCGAGTGAAGGTGAG 170 91.9
MMP13 NM_002427 TCAGGAAACCAGGTCTGGAG TGACGCGAACAATACGGTTA 196 102.3
TIMP1 NM_003254 AATTCCGACCTCGTCATCAG GTTGTGGGACCTGTGGAAGT 195 100.3
TIMP2 NM_003255 GTAGTGATCAGGGCCAAAGC GGGGGCCGTGTAGATAAACT 153 101.9
TIMP3 NM_000362 GTACCGAGGCTTCACCAAGA ACCTCTCCACGAAGTTGCAC 164 95.9
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Statistics
Data were exported to the GraphPad Prism statistics software
package (GraphPad Prism Software, USA). The Gaussian
distribution of the data was verified using the Kolmogorov–
Smirnov test. Statistics were performed using one-way
analysis of variance (ANOVA) with post hoc Tukey tests,
cross-comparing all study groups (95% confidence interval).
P-values \0.05 were considered significant.
Results
Cytotoxicity
Aiming to test the potential use of CSE as MMP inhibitor
in chondrocytes, we first evaluated the cytotoxic effects of
the extract on primary human chondrocytes using an MTT-
based viability assay. As shown in Fig. 1, CSE concen-
trations up to 20 lg/ml did not induce cytotoxicity in
chondrocytes, whereas 40 lg/ml CSE significantly reduced
viability (47.0 ± 2.2%). In the subsequent assays, there-
fore, we used the concentrations of CSE below 20 lg/ml.
CSE does not directly modify gelatinolytic activities
Previous work has suggested that MMP-2 is involved in
both the physiological collagen turnover in articular carti-
lage and the matrix degradation in OA cartilage (Duerr
et al. 2004). Using gelatin zymography, the present study
confirms that chondrocytes isolated from OA cartilage, as
well as SW1353 cells (data not shown), express functional
pro-MMP-2 (Fig. 2a). In contrast, bands corresponding to
MMP-9 activity were hardly detectable (data not shown),
reflecting the differences in MMP-2 and MMP-9 mRNA
levels (Table 2). The images also indicate that the activity
of MMP2 was not affected in primary chondrocytes treated
with 5 lg/ml CSE (Fig. 2a). Similarly, when added to the
buffer during zymography development, CSE did not
substantially affect the enzymatic activity of recombinant
MMP-2, whereas the addition of EDTA completely abro-
gated the gelatinolytic activity (Fig. 2b).
CSE inhibits IL1b -stimulated production of MMP-13
In order to investigate the effect of CSE on MMP-13 and
MMP-2 protein levels produced by human chondrocytes,
supernatants of treated cell cultures were collected and
subjected to ELISA. We observed that neither IL1b nor
CSE significantly modified the expression of MMP-2 in
primary or SW1353 cells (data not shown). In contrast,
MMP-13 levels were significantly up-regulated in both
SW1353 and primary cells after treatment with IL1b
(Fig. 3). Pretreatment of SW1353 cells with 5 lg/ml CSE
significantly reduced IL1b-stimulated MMP-13 production
from 6.7 ± 1.6 to 2.5 ± 1.4 pg/ml, which was comparable
to the levels found in untreated cells (1.2 ± 0.5 pg/ml;
P [ 0.05). In primary chondrocytes, CSE significantly
reduced IL1b-stimulated MMP-13 levels from 16.3 ± 1.4
to 13.1 ± 2.7 pg/ml (P \ 0.05; n = 3 donors).
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Fig. 1 Cell viability of primary chondrocytes treated with CSE.
Serum-starved primary chondrocytes were treated for 72 h with
varying concentrations of CSE (up to 40 lg/ml). Cell-viability was
evaluated using a MTT-based proliferation assay. The experiment
was repeated twice with cells from different donors, and each
experimental condition was set up in quadruplicate. Mean values and
standard deviations are given with respect to untreated cells (100%
viability). *indicates significant differences with respect to untreated
controls (P \ 0.05)
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Fig. 2 CSE does not directly interfere with the gelatinolytic activity
of MMP-2. a Cell culture supernatants of primary chondrocytes
isolated from 2 patients (PC1 and PC2) were treated and subjected to
gelatine zymography as described in Materials and Methods. Lane 1
shows the activity of a recombinant human pro-MMP-2. Lanes 2 and
4 show the supernatants of untreated chondrocytes, whereas lanes 3
and 5 present the supernatants of the chondrocytes treated with 5 lg/
ml CSE, respectively. b Recombinant human pro-MMP-2 was
subjected to gelatine zymography and developed separately in
different developing buffers containing 5 lg/ml CSE, 10 lg/ml
CSE or 1 mM EDTA
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CSE inhibits gene expression of MMPs,
but not of TIMPs
To evaluate the effects of CSE on MMP and TIMP
expression in human chondrocytes, mRNA levels of 7
MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-13) and 3 TIMPs (TIMP-1, TIMP-2, TIMP-
3) were quantified using RT-qPCR (Table 2). In agreement
with previous reports (Fan et al. 2005), MMP-3 was the
most abundant (12.1 ± 12.2 molecules/molecules GAP-
DH) of the MMPs analyzed in human OA primary chon-
drocytes, with MMP-7 and MMP-8 showing the lower
expression levels. The expression levels of TIMP-1, TIMP-
2, and TIMP-3 were relatively higher compared with most
MMPs, with lower expression of TIMP-3 (Table 2).
Interestingly, the SW1353 cell line showed a different
MMP and TIMP expression profile as compared to primary
cells (Table 2), with MMP-2 being the most abundant (0.22
molecules/molecule GAPDH) and very low levels of
MMP-1, MMP-3, and MMP-13 mRNA.
IL1b up-regulated the expression of a number of MMPs in
SW1353 cells, including MMP-1 (Fig. 4a, 64.0 ± 3.1 fold),
MMP-3 (Fig. 4c, 27.4 ± 0.8 fold), MMP-7 (Fig. 4d, 3.2 ±
0.1 fold), MMP-8 (Fig. 4e, 6.3 ± 1.1 fold), MMP-9 (Fig. 4f,
1.8 ± 0.1 fold), and MMP-13 (Fig. 4g, 71.4 ± 1.1 fold).
Preincubation of SW1353 cells with CSE suppressed the
IL1b-induced mRNA levels of these MMPs in a dose-
dependent manner. Of note, 5 lg/ml CSE strongly inhibited
the expression of MMP-1 (Fig. 4a), MMP-3 (Fig. 4c), and
MMP-13 (Fig. 4g) mRNA as compared to IL1b-treated cells
(P \ 0.05), and 10 lg/ml CSE further down-regulated the
expression of these genes to levels comparable to control
cells (P [ 0.05). In addition, 5 lg/ml of CSE reduced the
IL-1b-induced MMP-7 (Fig. 4d), MMP-8 (Fig. 4e), and
MMP-9 (Fig. 4f) expression to basal levels. Regarding
MMP-2 gene expression, no alterations were observed in
SW1353 cells under the experimental conditions of this study
(Fig. 4b).
In keeping with those observations, the results obtained
with human OA primary chondrocytes (n = 3; PC1,2,3)
further confirmed those obtained in SW1353 cells, as shown
in Table 3. Namely, despite minor inter-individual differ-
ences, IL1b significantly increased mRNA levels of MMP-
1, MMP-3, MMP-7, MMP-9, and MMP-13 in all 3 cell
populations. At 5 lg/ml, CSE significantly suppressed the
IL1b-mediated upregulation of MMP-3, MMP-7, MMP-9,
and MMP-13 in all cell populations and that of MMP-1 in 2
out of 3 donors. Similar to the results in SW1353 cells,
Table 2 mRNA expression levels of MMPs and TIMPs in SW1353 cells and primary chondrocytes
MMP1 MMP2 MMP3 MMP7 MMP8 MMP9 MMP13 TIMP1 TIMP2 TIMP3
SW1353 0.001 0.22 0.004 0.0003 0.000004 0.0001 0.00003 0.06 0.13 0.01
PC1 0.21 0.01 26.0 0.0000003 0.00003 0.000837 0.031 0.51 0.16 0.05
PC2 0.29 0.09 3.4 0.0000367 0.00006 0.000015 0.023 0.67 2.38 0.36
PC3 0.25 0.01 7.0 0.0000437 0.00008 0.000005 0.018 0.73 0.04 0.01
Mean PC 
(n=3) 0.25 0.04 12.1 0.00003 0.00006 0.0003 0.024 0.64 0.86 0.14
SD 0.04 0.05 12.2 0.00002 0.00002 0.0005 0.007 0.11 1.32 0.19
mRNA levels were quantified using RT-qPCR and expressed as number of molecules per molecules of GAPDH. Articular chondrocytes were
isolated from cartilage specimens of 3 donors (PC1, PC2, PC3) and cultured and analyzed separately. Mean values and standard deviations (SD)
of the 3 primary cell populations are also presented
Fig. 3 CSE inhibits IL1b-stimulated MMP-13 production in human
chondrocytes. Primary chondrocytes (PC) were isolated from 3
donors and cultured and analyzed separately. Serum-starved SW1353
cells and PC were pretreated with 5 lg/ml CSE followed by the
coincubation with 10 ng/ml IL1b for 48 h. MMP-13 concentration
was determined in the cell culture supernatants using ELISA. Mean
values and standard deviations from 2 independent experiments
(SW1353) and from 3 donors (PC) are given. *indicates significant
differences with respect to cells treated with IL1b only (P \ 0.05).
#indicates significant differences with respect to untreated controls
(P \ 0.05)
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10 and 20 lg/ml CSE reduced the IL-1b-induced MMP
mRNA expression to basal levels. Expression of MMP-2
and MMP-8 were only slightly altered in the presence of
IL1b and CSE (P \ 0.05 in 1 out of 3 donors).
Since the balance between MMP and TIMP activities
determines cartilage degradation in OA [Nagase and Wo-
essner 1999), we examined the effect of 5 lg/ml CSE on the
gene expression of TIMP-1, TIMP-2, and TIMP-3 in IL1b-
treated chondrocytes (Fig. 5). In primary cells, neither IL1b
nor 5 lg/ml CSE regulated the mRNA levels of any of the
TIMPs (Fig. 5a, b, c). In SW1353 cells, however, TIMP-1
and TIMP-3 mRNA levels were up-regulated by IL1b
2.1 ± 0.3 fold and 3.0 ± 0.1 fold, respectively. Treatment
with 5 lg/ml CSE reduced only TIMP-3 mRNA levels
significantly in SW1353 cells (Fig. 5d).
These results suggest that CSE is a potent inhibitor of
IL1b-mediated MMP transcription in human chondrocytes,
whereas it appears not to interfere with TIMP gene
expression.
CSE inhibits MMP-13 promoter activation
It has been shown that IL1b-induced MMP gene expression
is mediated by diverse signaling pathways and transcription
Fig. 4 CSE inhibits IL1b-
mediated MMP transcription in
SW1353 cells. Serum-starved
SW1353 cells were pretreated
with 5, 10, or 20 lg/ml of CSE
followed by the addition of
10 ng/ml IL1b. After 6 h of
incubation, total RNA was
isolated and mRNA levels of
a MMP-1, b MMP-2, c MMP-3,
d MMP-7, e MMP-8, f MMP-9,
and g MMP-13 were quantified
using RT-qPCR and expressed
as fold change with respect to
untreated controls. Mean values
and standard deviations are
given. *indicates significant
differences with respect to cells
treated with IL1b only
(P \ 0.05). #indicates
significant differences with
respect to untreated controls
(P \ 0.05)
Genes Nutr
123
Author's personal copy
73
Specific topics -Study 4
factors, including NF-kB (Vincenti and Brinckerhoff
2002; Marcu et al. 2010). To further explore the mechanism
underlying suppression of MMP transcription by CSE,
human T/C-28a2 chondrocytes were co-transfected with a
MMP-13 reporter construct and p65/p50 expression vec-
tors in the presence or absence of CSE. As shown in
Fig. 6, p65/p50 overexpression transactivated the
pGL2B(-1007/?27)MMP-13 construct by 7.1 ± 1.5 fold,
and CSE reversed the p65/p50-driven MMP-13 promoter
transactivation in a concentration-dependent manner.
Whereas 5 lg/ml CSE significantly inhibited MMP-13
promoter activity by about 65%, 10 lg/ml CSE com-
pletely blocked the p65/p50-mediated promoter activation,
re-establishing levels comparable to those in the untreated
control (P [ 0.05).
For comparison, additional experiments using CAPE
were performed (Fig. 6). CAPE dose-dependently reduced
the p65/p50-dependent promoter activation at a concen-
tration of 0.5 lg/ml (P \ 0.05) and re-established control
levels at 2.5 lg/ml.
Discussion
The present study shows for the first time that CSE inhibits
MMP expression in human chondrocytes in vitro. As our
data demonstrate, pretreatment of primary chondrocytes
with CSE effectively suppressed the IL1b-mediated
upregulation of MMP-1, MMP-3, MMP-7, MMP-9, and
MMP-13 at the level of gene expression involving NFkB
signaling.
Since exacerbated production and activation of MMPs is
associated with rheumatoid arthritis and OA, MMPs rep-
resent promising pharmacological targets for the treatment
of arthritic diseases (Jacobsen et al. 2010). Strategies for
MMP inhibition include direct MMP inhibition (by TIMPs,
small molecule MMP inhibitors, or antibodies) and indirect
MMP inhibition targeting signaling pathways that lead to
MMP expression. Although considerable progress has been
made in the development of direct MMP inhibitors, severe
off-target effects, poor bioavailability and efficacy are
frequently associated with their use in clinical trials
Table 3 Regulation of MMP transcription by IL1b and CSE in primary chondrocytes
Ctrl IL-1b
?CSE 5 lg/ml ?CSE 10 lg/ml ?CSE 20 lg/ml
MMP-1 PC1 1.00 ± 0.10 5.76 ± 0.26* 1.83 ± 0.03** 0.91 ± 0.07** 0.78 ± 0.06**
PC2 1.00 ± 0.18 15.4 ± 0.01* 10.12 ± 0.45** 2.21 ± 0.22** 0.91 ± 0.10**
PC3 1.00 ± 0.15 4.24 ± 0.28* 3.63 ± 0.18 3.10 ± 0.06** 1.27 ± 0.09**
MMP-2 PC1 1.00 ± 0.06 1.46 ± 0.06* 1.05 ± 0.09** 0.97 ± 0.05** 0.83 ± 0.02**
PC2 1.00 ± 0.02 1.17 ± 0.05 1.08 ± 0.15 1.06 ± 0.13 0.82 ± 0.02
PC3 1.00 ± 0.09 1.24 ± 0.03 1.23 ± 0.04 1.55 ± 0.08** 1.06 ± 0.08
MMP-3 PC1 1.00 ± 0.01 3.16 ± 0.01* 1.35 ± 0.02** 1.08 ± 0.01** 0.84 ± 0.01**
PC2 1.00 ± 0.01 8.37 ± 0.25* 3.71 ± 0.09** 1.12 ± 0.01** 1.05 ± 0.04**
PC3 1.00 ± 0.01 4.74 ± 0.02* 3.12 ± 0.02** 3.48 ± 0.02** 1.15 ± 0.01**
MMP-7 PC1 1.00 ± 0.46 10.40 ± 1.06* 5.56 ± 0.92** 1.97 ± 1.60** 3.41 ± 0.02**
PC2 1.00 ± 0.47 8.19 ± 0.26* 2.41 ± 0.27** 3.15 ± 1.33** 2.14 ± 0.82**
PC3 1.00 ± 0.19 4.45 ± 0.17* 3.02 ± 0.12** 2.78 ± 0.06** 3.04 ± 0.11**
MMP-8 PC1 1.00 ± 0.57 1.29 ± 0.02 1.92 ± 0.22 0.65 ± 0.35 1.32 ± 0.58
PC2 1.00 ± 0.06 2.11 ± 0.33* 1.69 ± 0.35 1.02 ± 0.02** 0.57 ± 0.11**
PC3 1.00 ± 0.02 1.44 ± 0.13 1.14 ± 0.03 2.04 ± 0.26 0.89 ± 0.17
MMP-9 PC1 1.00 ± 0.01 1.89 ± 0.28* 1.11 ± 0.04** 0.85 ± 0.16** 1.03 ± 0.10**
PC2 1.00 ± 0.04 10.29 ± 1.28* 2.64 ± 0.36** 0.66 ± 0.16** 0.54 ± 0.06**
PC3 1.00 ± 0.37 7.65 ± 1.48* 3.76 ± 1.15** 1.22 ± 0.14** 2.15 ± 0.18**
MMP-13 PC1 1.00 ± 0.17 13.22 ± 0.07* 1.39 ± 0.03** 0.72 ± 0.04** 0.64 ± 0.05**
PC2 1.00 ± 0.01 10.42 ± 0.37* 2.71 ± 0.23** 1.11 ± 0.03** 0.85 ± 0.01**
PC3 1.00 ± 0.02 4.65 ± 0.40* 2.80 ± 0.24** 4.42 ± 0.54 1.20 ± 0.01**
Primary chondrocytes were isolated from 3 donors (PC1, PC2, PC3) and cultured and analyzed separately. Serum-starved cells were pretreated
with 5 to 20 lg/ml CSE followed by stimulation with 10 ng/ml IL1b for 6 h. mRNA levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-13 were quantified using RT-qPCR and expressed as fold change with respect to untreated controls. Mean values and standard
deviations are given. * indicates significant differences with respect to untreated controls (P \ 0.05). ** indicates significant differences with
respect to cells treated with IL1b only (P \ 0.05)
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(Clutterbuck et al. 2009). Thus, indirect MMP inhibition
using nutraceuticals or plant-derived phytopharmaceuticals
might provide a promising alternative to present thera-
peutic approaches. In this context, curcumin, resveratrol, or
green tea catechins have already been investigated
regarding their MMP-inhibitory actions (Shakibaei et al.
2007; Lee and Moon 2005; Annabi et al. 2007).
The results presented here suggest that Caesalpinia
sappan-derived phytochemicals might be developed as
nutraceuticals for the management of arthritic diseases. In
this context, the strong inhibitory action of CSE on the
IL1b-mediated overexpression of MMP-1, MMP-3, and
MMP-13 appears of particular interest. Exacerbated pro-
duction and activation of the collagenases, MMP-1 and
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Fig. 5 Regulation of TIMP transcription by IL1b and CSE in
SW1353 cells and primary chondrocytes. a–c Primary chondrocytes
were isolated from 3 donors (PC1, PC2, PC3) and cultured and
analyzed separately. Serum-starved cells were pretreated with 5 lg/
ml CSE followed by the addition of 10 ng/ml IL1b. After 6 h of
incubation, the mRNA levels of TIMP-1 (a), TIMP-2 (b), and TIMP-3
(c) were quantified using RT-qPCR and expressed as fold change with
respect to untreated controls (white bars). Gray bars represent IL1b-
treated cells, whereas black bars represent cells pretreated with CSE.
d TIMP-1, TIMP-2, and TIMP-3 mRNA levels were quantified in
SW1353 cells under exposure to IL1b and CSE as described. Mean
values and standard deviations are given. *indicates significant
differences with respect to cells treated with IL1b only (P \ 0.05).
#indicates significant differences with respect to untreated controls
(P \ 0.05)
Fig. 6 Effect of CSE or CAPE on MMP-13 promoter activity.
T/C28a2 chondrocytes, cotransfected with a MMP-13 luciferase
reporter construct and p50 and p65 expression vectors, were treated
with CAPE (gray bars) or CSE (black bars) in a dose-dependent
manner. Both CAPE and CES inhibited the NF-kB(p65/p50)-driven
MMP-13 promoter activation. #indicates significant differences with
respect to cells transfected with the MMP-13 reporter construct and
the pCI empty vector (P \ 0.05). *indicates significant differences
with respect to cells co-transfected with the MMP-13 promoter and
the p65/p50 expression vectors (P \ 0.05)
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MMP-13, in articular chondrocytes are known to promote
the cleavage of collagen triple helices allowing further
degradation by other MMPs (Nagase and Woessner 1999).
Supporting the role of MMP-13 in connective tissue deg-
radation, Neuhold et al. (2001) reported that transgenic
mice overexpressing MMP-13 show signs of articular
cartilage degradation and exhibit joint pathology similar to
that found in OA. Our results confirm that IL1b represents
a potent inflammatory stimulus that leads to overexpression
of MMP-1, MMP-3, and MMP-13 mRNA in primary and
SW1353 chondrocytes. Interestingly, the upregulation of
these genes by IL1b was more pronounced in SW1353
cells than in primary OA chondrocytes; however, when
cultured in the presence of 5–20 lg/ml CSE, the effect of
IL1b was suppressed in both cell models and the expres-
sion of MMP-1, MMP-3, and MMP-13 mRNA was down-
regulated to levels found under control conditions. The
relevance of the RT-qPCR data was further verified by
ELISA, demonstrating reduced MMP-13 protein levels in
chondrocytes treated with CSE. In contrast, however, the
transcription of TIMPs was not affected by the presence of
CSE. Of note, CSE treatment did not totally block the
expression of MMPs but rather inhibited IL1b-induced
MMP overexpression. In this regard, CSE might be
advantageous over other MMP inhibitors, since total MMP
inhibition not only impairs physiological ECM remodeling,
but may also affect cellular signaling to which MMPs
contribute (Clutterbuck et al. 2009). In this context, it is
noteworthy that CSE did not directly influence the gela-
tinolytic activity of MMP-2 under the experimental con-
ditions of this study.
In a first attempt to elaborate the mechanism underly-
ing the MMP-inhibitory action of CSE, we focused on the
role of NF-kB in MMP-13 promoter activation. It is well
established that IL1b, once bound to its type 1 receptor,
activates NF-kB dimers by triggering phosphorylation and
subsequent degradation of the inhibitory kB proteins
(Daheshia and Yao 2008). The most prevalent activated
NF-kB dimer is the heterodimer RelA (p65)/p50, which
can bind to sites in NF-kB-dependent promoters regulat-
ing the transcription of response genes (Roman-Blas and
Jimenez 2006). Mengshol et al. have assessed the role of
NF-kB in MMP-13 transcription in chondrocytes and
found that, besides JNK and p38, NF-kB signaling is
required for the IL1b-mediated induction of MMP-13
(Mengshol et al. 2000). Although the promoter of MMP-
13 does not contain consensus NF-kB binding sites
(Burrage et al. 2006), the link between NF-kB activation
and MMP-13 induction has been further demonstrated in
a previous study on the effect of hyaluronan oligosac-
charides in articular chondrocytes (Ohno et al. 2006). We
show here that, indeed, NF-kB p65/p50 overexpression
leads to MMP-13 promoter transactivation and that CSE
suppresses the p65/p50-driven MMP-13 promoter activa-
tion, thereby suggesting that CSE’s MMP-inhibitory
actions are related to its blockade of the NF-kB signaling.
Furthermore, the comparison to CAPE, a chemically
defined specific inhibitor of NF-kB (Natarajan et al.
1996), revealed that CSE was only about 4 times less
active in our assay. Our results go along with previous
reports demonstrating that CSE and its constituents
interfere with NF-kB signaling in different cell types.
Namely, Bae et al. (2005) showed that brazilin, the main
component of CSE, inhibited the DNA binding activity of
NF-kB and AP-1 in LPS-stimulated mouse macrophages.
In addition, protosappanin A was shown to target the
NF-kB pathway in rat heart tissue (Wu et al. 2010).
Therefore, our results suggest that CSE contains one or
more active components that may act as potent inhibitors
of NF-kB in human chondrocytes.
To date, the bioavailability of specific components of
CSE has not been elaborated and it remains elusive whe-
ther the doses of CSE used in this study are representative
for physiologically active concentrations. Despite this lack
of specific knowledge, the efficacy of CSE in diverse in
vivo models supports the apparent bioavailability of CSE
components at therapeutically effective doses (Sun et al.
2011; Oh et al. 2001). Moreover, the present study dem-
onstrates that CSE affects human chondrocytes in vitro at
concentrations that are comparable to those of well-known
dietary antioxidants including ascorbic acid, curcumin, or
resveratrol (Csaki et al. 2009; Graeser et al. 2009). Similar
to curcumin and resveratrol, CSE appears to exert its
effects on chondrocytes via mechanisms targeting NFkB
signaling. Interestingly, recent data have explored the dif-
ferent molecular targets of curcumin and resveratrol as well
as their synergistic chondroprotective effects (Csaki et al.
2009). In this context, it might be of interest to further
investigate the synergism between CSE components and
other dietary antioxidants regarding the modulation of
biomarkers of inflammation in cultured chondrocytes.
Conclusion
In summary, this study suggests that CSE or CSE-derived
compounds may be beneficial as indirect MMP inhibitors
for the future management of degenerative or inflammatory
joint diseases. We present evidence that CSE effectively
suppresses IL1b-mediated overexpression of major MMPs
in human chondrocytes in vitro. More specifically, CSE
inhibits the de novo synthesis of MMP-1, MMP-3, MMP-7,
MMP-9, and MMP-13 at the gene expression level without
affecting the expression of TIMPs. Further, we showed that
the molecular mechanism underlying MMP-13 inhibition
by CSE involves, at least in part, the interference with the
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NF-kB (p65/p50)-driven MMP-13 promoter transactiva-
tion. Future studies should therefore aim to define CSE’s
actions in the context of arthritic diseases and to further
delineate the molecular mechanisms evoked by CSE and its
specific constituents both in vitro and in vivo.
Acknowledgments This research was supported partially by
National Institutes of Health (NIH) grant R01-AG022021 (Mary B
Goldring), an Arthritis Foundation Postdoctoral Fellowship (Miguel
Otero), and the graduate program ‘‘Molecular Drug Targets’’ spon-
sored by the University of Vienna (Shengqian Q Wu).
Conflict of interest The authors declare that they have no conflict
of interest.
References
Albini A, Morini M, D’Agostini F, Ferrari N, Campelli F, Arena G,
Noonan DM, Pesce C, De Flora S (2001) Inhibition of
angiogenesis-driven Kaposi’s sarcoma tumor growth in nude
mice by oral N-acetylcysteine. Cancer Res 61:8171–8178
Ameye LG, Chee WSS (2006) Osteoarthritis and nutrition. From
nutraceuticals to functional foods: a systematic review of the
scientific evidence. Arthr Res Ther 8:R127
Annabi B, Currie JC, Moghrabi A, Be´liveau R (2007) Inhibition of
HuR and MMP-9 expression in macrophage-differentiated HL-
60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk
Res 31:1277–1284
Bae IK, Min HY, Han AR, Seo EK, Lee SK (2005) Suppression of
lipopolysaccharide-induced expression of inducible nitric oxide
synthase by brazilin in RAW 264.7 macrophage cells. Eur J
Pharmacol 513:237–242
Bjorkman DJ (1999) Current status of nonsteroidal anti-inflammatory
drug (NSAID) use in the United States: risk factors and
frequency of complications. Am J Med 107:3S–8S
Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metallopro-
teinases: role in arthritis. Front Biosci 11:529–543
Bustin SA, Beaulieu JF, Huggett J, Jaggi R, Kibenge FSB, Olsvik PA,
Penning LC, Toegel S (2010) MIQE pre´cis: practical implemen-
tation of minimum standard guidelines for fluorescence-based
quantitative real-time PCR experiments. BMC Mol Biol 11:74
Chen YP, Liu L, Zhou YH, Wen J, Jiang Y, Tu PF (2008) Chemical
constituents from Sappan Lignum. J Chin Pharm Sci 17:82–86
China pharmacopoeia commission (2010) The Chinese Pharmaco-
poeia. Medical science press, Beijing
Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A
(2009) Targeting matrix metalloproteinases in inflammatory
conditions. Curr Drug Targets 10:1245–1254
Csaki C, Mobasheri A, Shakibaei M (2009) Synergistic chondropro-
tective effects of curcumin and resveratrol in human articular
chondrocytes: inhibition of IL-1beta-induced NF-kappaB-med-
iated inflammation and apoptosis. Arthr Res Ther 11:R165
Daheshia M, Yao JQ (2008) The interleukin 1beta pathway in the
pathogenesis of osteoarthritis. J Rheumatol 35:2306–2312
Duerr S, Stremme S, Soeder S, Bau B, Aigner T (2004) MMP-2/
gelatinase A is a gene product of human adult articular
chondrocytes and is increased in osteoarthritic cartilage. Clin
Exp Rheumatol 22:603–608
Fan Z, Bau B, Yang H, Soeder S, Aigner T (2005) Freshly isolated
osteoarthritic chondrocytes are catabolically more active than
normal chondrocytes, but less responsive to catabolic stimulation
with interleukin-1b. Arthr Rheum 52:136–143
Goggs R, Vaughan-Thomas A, Clegg PD, Carter SD, Innes JF,
Mobasheri A, Shakibaei M, Schwab W, Bondy CA (2005)
Nutraceutical therapies for degenerative joint diseases: a critical
review. Crit Rev Food Sci Nutr 45:145–164
Goldring MB, Marcu KB (2009) Cartilage homeostasis in health and
rheumatic diseases. Arthr Res Ther 11:224
Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y (2008) Defining
the roles of inflammatory and anabolic cytokines in cartilage
metabolism. Ann Rheum Dis 67:75–82
Graeser AC, Giller K, Wiegand H, Barella L, Boesch Saadatmandi C,
Rimbach G (2009) Synergistic chondroprotective effect of alpha-
tocopherol, ascorbic acid, and selenium as well as glucosamine
and chondroitin on oxidant induced cell death and inhibition of
matrix metalloproteinase-3—studies in cultured chondrocytes.
Molecules 15:27–39
Grall FT, Prall WC, Wei W, Gu X, Cho JY, Choy BK, Zerbini LF,
Inan MS, Goldring SR, Gravallese EM, Goldring MB, Oettgen P,
Libermann TA (2005) The Ets transcription factor ESE-1
mediates induction of the COX-2 gene by LPS in monocytes.
FEBS J 272:1676–1687
Ijiri K, Zerbini LF, Peng H, Correa RG, Lu B, Walsh N, Zhao Y,
Taniguchi N, Huang XL, Otu H, Wang H, Wang JF, Komiya S,
Ducy P, Rahman MU, Flavell RA, Gravallese EM, Oettgen P,
Libermann TA, Goldring MB (2005) A novel role for GADD45-
beta as a mediator of MMP-13 gene expression during chondro-
cyte terminal differentiation. J Biol Chem 280:38544–38555
Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM (2010) To
bind zinc or not to bind zinc: an examination of innovative
approaches to improved metalloproteinase inhibition. Biochim
Biophys Acta 1803:72–94
Jeong IY, Chang HJ, Park YD, Lee HJ, Choi DS, Byun MW, Kim YJ
(2008) Anti-inflammatory activity of an ethanol extract of
Caesalpinia sappan L. in LPS-induced RAW 264.7 cells. J Food
Sci Nutr 13:253–258
Kubota E, Imamura H, Kubota T, Shibata T, Murakami K (1997)
Interleukin 1 beta and stromelysin (MMP3) activity of synovial
fluid as possible markers of osteoarthritis in the temporoman-
dibular joint. J Oral Maxillofac Surg 55:20–27
Lee B, Moon SK (2005) Resveratrol inhibits TNF-alpha-induced
proliferation and matrix metalloproteinase expression in human
vascular smooth muscle cells. J Nutr 135:2767–2773
Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z,
Shah M, Thompson EW (2009) Matrix metalloproteinase
13-deficient mice are resistant to osteoarthritic cartilage erosion
but not chondrocyte hypertrophy or osteophyte development.
Arthr Rheum 60:3723–3733
Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB (2010) NF-
kappaB signaling: multiple angles to target OA. Curr Drug
Targets 11:599–613
Mazzoni A, Mannello F, Tay FR, Tonti GA, Papa S, Mazzotti G, Di
Lenarda R, Pashley DH, Breschi L (2007) Zymographic analysis
and characterization of MMP-2 and -9 forms in human sound
dentin. J Dent Res 86:436–440
Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff
CE (2000) Interleukin-1 induction of collagenase 3 (matrix
metalloproteinase 13) gene expression in chondrocytes requires
p38, c-Jun N-terminal kinase, and nuclear factor kappa B:
differential regulation of collagenase 1 and collagenase 3. Arthr
Rheum 43:801–811
Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB,
Brinckerhoff CE (2001) A synthetic triterpenoid selectively
inhibits the induction of matrix metalloproteinases 1 and 13 by
inflammatory cytokines. Arthr Rheum 44:1096–1104
Genes Nutr
123
Author's personal copy
77
Specific topics -Study 4
Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Biol
Chem 274:21491–21494
Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB
(1996) Caffeic acid phenethyl ester is a potent and specific
inhibitor of activation of nuclear transcription factor NF-kappa
B. Proc Natl Acad Sci USA 93:9090–9095
Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, Turner
J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P,
DeGennaro LJ (2001) Postnatal expression in hyaline cartilage
of constitutively active human collagenase-3 (MMP-13) induces
osteoarthritis in mice. J Clin Invest 107:35–44
Oh GT, Choi JH, Hong JJ, Kim DY, Lee SB, Kim JR, Lee CH, Hyun
BH, Oh SR, Bok SH, Jeong TS (2001) Dietary hematein
ameliorates fatty streak lesions in the rabbit by the possible
mechanism of reducing VCAM-1 and MCP-1 expression.
Atherosclerosis 159:17–26
Ohno S, Im HJ, Knudson CB, Knudson W (2006) Hyaluronan
oligosaccharides induce matrix metalloproteinase 13 via tran-
scriptional activation of NFkappaB and p38 MAP kinase in
articular chondrocytes. J Biol Chem 281:17952–17960
Roman-Blas JA, Jimenez SA (2006) NF-kB as a potential therapeutic
target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil
14:839–848
Saha N, Moldovan F, Tardif G, Pelletier JP, Cloutier JM, Martel-
Pelletier J (1999) Interleukin-1-b-converting enzyme/caspase-1
in human osteoarthritic tissues: localization and role in the
maturation of interleukin-1b and interleukin-18. Arthr Rheum
42:1577–1587
Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A
(2007) Suppression of NF-kappaB activation by curcumin leads
to inhibition of expression of cyclo-oxygenase-2 and matrix
metalloproteinase-9 in human articular chondrocytes: implica-
tions for the treatment of osteoarthritis. Biochem Pharmacol
73:1434–1445
Sireeratawong S, Piyabhan P, Singhalak T, Wongkrajang Y,
Temsiririrkkul R, Punsrirat J, Ruangwises N, Saraya S,
Lerdvuthisopon N, Jaijoy K (2010) Toxicity evaluation of
sappan wood extract in rats. J Med Assoc Thai 93:S50–S57
Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M
(1997) Synovial membrane inflammation and cytokine produc-
tion in patients with early osteoarthritis. J Rheumatol 24:365–
371
Srilakshmi VS, Vijayan P, Raj PV, Dhanaraj SA, Chandrashekhar HR
(2010) Hepatoprotective properties of Caesalpinia sappan Linn.
heartwood on carbon tetrachloride induced toxicity. Indian J Exp
Biol 48:905–910
Sun SQ, Wang YZ, Zhou YB (2011) Extract of the dried heartwood of
Caesalpinia sappan L. attenuates collagen-induced arthritis.
J Ethnopharmacol Article, in press
Tetlow LC, Adlam DJ, Woolley DE (2001) Matrix metalloproteinase
and proinflammatory cytokine production by chondrocytes of
human osteoarthritic cartilage: associations with degenerative
changes. Arthr Rheum 44:585–594
The Society of Japanese Pharmacopoeia (2006) The Japanese
Pharmacopoeia, 15th edn. Hirokawa Publishing, Tokyo
Toegel S, Huang W, Piana C, Unger FM, Wirth M, Goldring MB,
Gabor F, Viernstein H (2007) Selection of reliable reference
genes for qPCR studies on chondroprotective action. BMC Mol
Biol 8:13
Toegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, Gabor F,
Viernstein H (2008) Comparison between chondroprotective
effects of glucosamine, curcumin, and diacerein in IL-1b stimu-
lated C-28/I2 chondrocytes. Osteoarthr Cartil 16:1205–1212
Toegel S, Plattner VE, Wu SQ, Chiari C, Gabor F, Unger FM,
Goldring MB, Nehrer S, Viernstein H, Wirth M (2009) Lectin
binding patterns reflect the phenotypic status of in vitro
chondrocyte models. In Vitro Cell Dev Biol Anim 45:351–360
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F (2002) Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol 18:3
Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of
collagenase (MMP-1, MMP-13) genes in arthritis: integration of
complex signaling pathways for the recruitment of gene-specific
transcription factors. Arthr Res 4:157–164
Washiyama M, Sasaki Y, Hosokawa T, Nagumo S (2009) Anti-
inflammatory constituents of Sappan Lignum. Biol Pharm Bull
32:941–944
Wu J, Zhang M, Jia H, Huang X, Zhang Q, Hou J, Bo Y (2010)
Protosappanin A induces immunosuppression of rats heart
transplantation targeting T cells in grafts via NF-kappaB
pathway. Naunyn Schmied Arch Pharmacol 381:83–92
Xie YW, Ming DS, Xu HX, Dong H, But PP (2000) Vasorelaxing
effects of Caesalpinia sappan involvement of endogenous nitric
oxide. Life Sci 67:1913–1918
Ye M, Xie WD, Lei F, Meng Z, Zhao YN, Su H, Du LJ (2006)
Brazilein, an important immunosuppressive component from
Caesalpinia sappan L. Int Immunopharmacol 6:426–432
Genes Nutr
123
Author's personal copy
78
Specific topics -Study 4
GJ
A
c
S
C
a
b
c
d
e
a
A
R
R
A
A
K
O
I
C
C
C
C
1
d
h
v
b
0
dARTICLE IN PRESS ModelEP-7037; No. of Pages 9
Journal  of Ethnopharmacology xxx (2011) xxx– xxx
Contents lists available at SciVerse ScienceDirect
Journal  of  Ethnopharmacology
journa l h o me  page: www.elsev ier .com/ locate / je thpharm
nti-inﬂammatory  activity  of  an  ethanolic  Caesalpinia  sappan  extract  in  human
hondrocytes  and  macrophages
hengqian  Q.  Wua,b, Miguel  Oteroc, Frank  M.  Ungera, Mary  B.  Goldringc,  Ampai  Phrutivorapongkuld,
atharina Chiari e,  Alexander  Kolbe,  Helmut  Viernsteina,  Stefan  Toegela,c,e,∗
Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, 1090 Vienna, Austria
Department of Pharmacology and Toxicology, University of Vienna, 1090 Vienna, Austria
Laboratory of Cartilage Biology, Research Division, Hospital for Special Surgery, Weill Cornell Medical College, New York, USA
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand
Department of Orthopedics, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 14 February 2011
eceived  in revised form 25 July 2011
ccepted 14 September 2011
vailable online xxx
eywords:
steoarthritis
nﬂammation
hondrocytes
aesalpinia sappan
ytokine
OX-2
a  b  s  t  r  a  c  t
Ethnopharmacological  relevance:  Caesalpinia  sappan  is  a common  remedy  in  Traditional  Chinese  Medicine
and  possesses  diverse  biological  activities  including  anti-inﬂammatory  properties.  Osteoarthritis  (OA)  is
a  degenerative  joint  disease  with  an  inﬂammatory  component  that  drives  the  degradation  of cartilage
extracellular  matrix.  In order  to provide  a scientiﬁc  basis  for the  applicability  of Caesalpinia  sappan  in
arthritic  diseases,  the  present  study  aimed  to assess  the  effects  of  an  ethanolic  Caesalpinia  sappan  extract
(CSE)  on  human  chondrocytes  and  macrophages.
Materials and methods:  Primary  human  chondrocytes  were  isolated  from  cartilage  specimens  of  OA
patients.  Primary  cells,  SW1353  chondrocytes  and  THP-1  macrophages  were  serum-starved  and  pre-
treated  with  different  concentrations  of  CSE  prior  to  stimulation  with  10 ng/ml  of interleukin-1beta
(IL-1)  or lipopolysaccharide  (LPS).  Following  viability  tests,  nitric  oxide  (NO)  and  tumor  necrosis  factor-
alpha  (TNF-)  were  evaluated  by Griess  assay  and  ELISA,  respectively.  Using  validated  real-time  PCR
assays,  mRNA  levels  of  IL-1, TNF-,  inducible  nitric  oxide  synthase  (iNOS),  and  cyclooxygenase-2  (COX-
2)  were  quantiﬁed.  SW1353  cells  were  cotransfected  with  a COX-2  luciferase  reporter  plasmid  and  nuclear
factor-kappa-B  (NF-B)  p50  and  p65  expression  vectors  in  the  presence  or absence  of  CSE.
Results: CSE  dose-dependently  inhibited  the  expression  of  pro-inﬂammatory  cytokines  IL-1  and  TNF-
in  IL-1-stimulated  chondrocytes  and  LPS-stimulated  THP-1  macrophages.  CSE  further  suppressed  the
synthesis  of  NO in primary  OA  chondrocytes  by  blocking  iNOS  mRNA  expression.  The  inhibition  of  COX-2
transcription  was found  to be related  with  the  CSE  inhibition  of the  p65/p50-driven  transactivation  of
the  COX-2  promoter.
Specific topics - Study 5Conclusions:  The  present  report  is ﬁrst  to  demonstrate  the  anti-inﬂammatory  activity  of CSE  in  an  in  vitro
cell  model  of joint  inﬂammation.  CSE  can  effectively  abrogate  the  IL-1-induced  over-expression  of
inﬂammatory  mediators  at the  transcriptional  level  in  human  chondrocytes  and  macrophages,  most
likely  by inhibiting  NF-B  (p65/p50)  signaling.  Blockade  of IL-1-induced  NF-B  signaling  and  its  down-
stream  pro-inﬂammatory  targets  by  CSE  may  be beneﬁcial  for  reducing  cartilage  breakdown  in arthritis.. Introduction
Osteoarthritis (OA) ranks among the major causes of physical
isability of elderly patients, thus representing a critical factor inPlease cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
ealth economics. In contrast to rheumatoid arthritis, OA is con-
entionally not considered a classical inﬂammatory arthropathy,
ut thought to develop from chronic overuse or injury of the joint.
∗ Corresponding author at: Tel.: +43 1 40400 7653; fax: +43 1 40400 7641.
E-mail  address: stefan.toegel@meduniwien.ac.at (S. Toegel).
378-8741/$ – see front matter ©  2011 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jep.2011.09.011© 2011 Elsevier Ireland Ltd. All rights reserved.
However, evidence has accumulated that, besides mechanical and
genetic factors, inﬂammatory processes within joint tissues con-
tribute to the OA onset and progression. Chondrocytes, the unique
cell component of articular cartilage, are embedded in a highly
organized extracellular matrix (ECM), comprising collagen type II
ﬁbrils and proteoglycans, which confer to the cartilage structural
rigidity and protective resiliency (Goldring and Marcu, 2009). Inty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
response to mechanical or biochemical stress, chondrocytes over-
express pro-inﬂammatory mediators such as interleukin-1beta
(IL-1) and tumor necrosis factor-alpha (TNF-) that will, in an
autocrine/paracrine manner, stimulate their own  production and
79
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Nomenclature
OA Osteoarthritis
CSE ethanolic Caesalpinia sappan extract
IL-1 interleukin-1 beta
LPS  lipopolysaccharide
NO nitric oxide
TNF- tumor necrosis factor- alpha
iNOS inducible nitric oxide synthase
COX-2  cyclooxygenase-2
NF-B nuclear factor-kappa-B
ECM extracellular matrix
MMPs  matrix metalloproteinases
ADAMTS a disintegrin and metalloproteinase with throm-
bospondin motifs
PGE2 prostaglandin E2
NSAIDs nonsteroidal anti-inﬂammatory drugs
DMEM Dulbecco’s modiﬁed Eagle’s medium
FCS fetal calf serum
PMA  phorbol 12-myristate 13-acetate
RT-qPCR quantitative real-time RT-PCR
ITS insulin–transferrin–selenium
RIN RNA integrity numbers
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
ACTB beta actin
HPRT1 hypoxanthine phosphoribosyl-transferase I
SDHA succinate dehydrogenase complex, subunit A
B2M beta-2-microglobulin
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nduce the expression of matrix-degrading proteinases, including
atrix metalloproteinases (MMPs) and a disintegrin and metal-
oproteinase with thrombospondin motifs (ADAMTS) (Bonnet and
alsh, 2005; Goldring and Goldring, 2007). Recently, it has been
emonstrated that mediators such as prostaglandin E2 (PGE2)
Gosset et al., 2010) or nitric oxide (NO) (Tsuruda et al., 2004) play
ey roles in the induction of MMPs  in an inﬂammatory context. In
ddition to the chondrocytes, macrophages that have inﬁltrated the
A synovium contribute to inﬂammation and matrix degradation
n OA tissues (Benito et al., 2005; Bondeson et al., 2006). Therefore,
nﬂammatory mediators represent potential targets for OA disease
odiﬁcation.
The mechanism of cartilage degradation in OA is known to be a
ultifactorial process. However, standard pharmacological inter-
entions, such as the use of nonsteroidal anti-inﬂammatory drugs
NSAIDs), often act in a monomodal way that is frequently asso-
iated with signiﬁcant adverse effects (Fendrick and Greenberg,
009). Although considerable progress has been made in the devel-
pment of novel strategies, such as the use of direct MMP  inhibitors,
o clinically effective inhibitor exists to date. Thus, novel, safe and
ffective anti-inﬂammatory agents are demanded for the therapy
f arthritic diseases. Nutraceuticals and phytopharmaceuticals that
sually contain a range of active compounds targeting multiple
athways could provide an alternative to conventional treatment
f OA (Clutterbuck et al., 2009). A comprehensive review on cur-
ent nutraceuticals for the management of OA has been published
lsewhere (Ameye and Chee, 2009).
Sappan Lignum, the heartwood of Caesalpinia sappan L. (Legu-
inosae), is the source of a natural red dye. In traditional
hinese medicine, Sappan wood has sweet, salty, and neutralPlease cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
haracteristics, and is associated with the heart, liver and spleen
eridians. Traditionally, it is applied as an aqueous decoction
nd prescribed to invigorate the blood system, promote menstru-
tion, reduce pain and swelling (Chinese Pharmacopoeia, 2010). PRESS
macology xxx (2011) xxx– xxx
Additionally,  Sappan wood has been medicinally recommended
due to its astringent or diuretic properties, as well as for certain
skin diseases (Sireeratawong et al., 2010). Recently, it has also
been listed in the 15th edition of the Japanese Pharmacopoeia
(Japanese Pharmacopoeia, 2006). Different extracts and active com-
pounds isolated from Sappan lignum have been reported to possess
diverse biological activities including antioxidative (Budami et al.,
2003), anti-inﬂammtory (Jeong et al., 2008), antibacterial (Xu and
Lee, 2004) and anticonvulsive (Baek et al., 2000) effects. Brazilin,
the major compound of Sappan Lignum, was  reported to have
anti-inﬂammatory (Hikino et al., 1977; Washiyama et al., 2009),
antibacterial (Batubara et al., 2010), and antihepatotoxic effects
(You et al., 2005). In addition, numerous other compounds from
Sappan Lignum such as prostosappanins A–E or sappanchalcone
have also been shown to display some of the different biological
activities (Liu et al., 2009). To our knowledge, however, Caesalpinia
sappan has not been evaluated in the context of OA, and the effects
of Caesalpinia sappan derived isolates on OA chondrocytes and syn-
ovial macrophages are unknown.
The present study, therefore, aimed to elucidate the anti-
inﬂammatory activity of an ethanolic Caesalpinia sappan extract
(CSE) in lipopolysaccharide (LPS)-stimulated human macrophages
and IL-1-stimulated human chondrocytes. Particular focus was  on
the inhibition of gene expression of proinﬂammatory factors such
as IL-1 and TNF-, and on the interference with NO production
and NF-B-mediated COX-2 promoter activation.
2. Materials and methods
2.1.  Plant material and extraction
The  heartwoods of Caesalpinia sappan were collected in June
2006 in San-Pa-Thong district, Chiang Mai  province, Thailand, and
identiﬁed by comparison with the voucher specimen (No. 87-1631)
at the Herbarium Section, Northern Research Center for Medicinal
Plants, Faculty of Pharmacy, Chiang Mai  University, Thailand. Pow-
dered heartwood (30 g) was extracted with 95% ethanol (350 ml)
for 24 h using a Soxhlet apparatus and the resulting extract was
concentrated under vacuum to yield a solid extract (5.5 g).
2.2. Characterization of the extract
Four batches of CSE were characterized by HPLC (ICS-3000,
Dionex, USA) with a Nucleodur C-18 column (Macherey-Nagel, D)
and a PDA-100 detector (Dionex) set at 280 nm.  The eluent sys-
tem consisted of a 45 min  gradient program from 10% to 100%
methanol (containing 2.5% acetic acid) at a ﬂow rate of 0.8 ml/min.
All 4 batches yielded congruent chromatograms, which were also
comparable to that of Natural Red 24 (MP  Biomedicals, USA,
LOT #: R25179), a commercially available Sappan wood extract
(Supplementary Figs. 1A and B).
Brazilin was  isolated from CSE using preparative HPLC (Shi-
madzu, Japan) with a reversed-phase C18 column (Polygoprep C18,
12 , 25 mm × 250 mm,  Austria) monitored at 280 nm. The eluent
system consisted of a 45 min  gradient program from 10% to 100%
methanol (containing 1.25% acetic acid) at a ﬂow rate of 22 ml/min
and a column temperature of 50 ◦C. The fraction at a reten-
tion time of about 20 min  was collected in repeated preparative
HPLC separations. These fractions were further concentrated under
reduced pressure and then freeze-dried to give a white compound
Specific topics - Study 5ty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
which rapidly oxidized to a red-brown powder. In accordance
with Chen et al. (Chen et al., 2008), the isolated compound was
identiﬁed as brazilin ((6aS,11bR)-7,11b-dihydro-6H-indeno[2,1-
c]chromene-3,6a,9,10-tetrol) using 1H NMR  (Bruker Avance 500
80
ARTICLE IN PRESSG ModelJEP-7037; No. of Pages 9
S.Q. Wu  et al. / Journal of Ethnopharmacology xxx (2011) xxx– xxx 3
Table  1
Details on RT-qPCR primers.
Gene symbol Primer sequences Efﬁciency Amplicon size NM-number
IL-1 Fw: CCTATTACAGTGGCAATGAGGATG
Rv:  AGTGGTGGTCGGAGATTCG
95.1% 132bp NM 000576
TNF-  Fw: TCAGCAAGGACAGCAGAGG
Rv:  CAGTATGTGAGAGGAAGAGAACC
96% 126bp NM 000594
iNOS  Fw: GTTCTCACGGCACAGGTCTC
Rv:  GCAGGTCACTTATGTCACTTATC
94.6% 127bp NM 000625
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Specific topics - Study 5COX-2  Fw: CCGAGGTGTATGTATGAGTGTG
Rv:  TGTGTTTGGAGTGGGTTTCAG
nstrument, Bruker, USA). The HPLC chromatogram of brazilin is
hown in Supplementary Fig. 1C.
.3. Cell cultures
In  accordance with the terms of the ethics committee of the
edical University Vienna (EK-Nr.: 081/2005) and following the
uidelines of the Declaration of Helsinki and Tokyo, primary human
hondrocytes were enzymatically isolated from articular cartilage
f OA patients undergoing knee replacement surgery following
stablished protocols (Toegel et al., 2009, 2010). Isolated chon-
rocytes were seeded at a density of 105/cm2 and cultured in
ulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco, A) containing
0% fetal calf serum (FCS; Biochrom AG, D) and 2 l/ml gentamycin
Biochrom AG, D) in a humidiﬁed atmosphere of 5% CO2/95% air at
7 ◦C. For all assays, only freshly isolated and seeded cells with-
ut subculturing were used. The human chondrosarcoma cell line
W1353 (ATCC, USA) was cultured at a density of 104/cm2 under
he same conditions as described above and passaged by incuba-
ion with 0.25% trypsin-EDTA. The human monocytic cell line THP-1
ATCC, USA) was maintained in RPMI 1640 medium supplemented
ith 10% FCS, 4 mM L-glutamine, and 104 U/ml penicillin (Gibco, A)
n a humidiﬁed atmosphere of 5% CO2/95% air at 37 ◦C. Cells were
ifferentiated into macrophages in the above medium containing
 ng/ml phorbol 12-myristate 13-acetate (PMA) over 24 h. After
ashing once, cultures were changed to medium without PMA  for
4 h and then used for further studies.
.4. Cytotoxicity assay
The  cytotoxicity of CSE was assessed in primary human
hondrocytes and THP-1 cells using an MTT-based test (EZ4U,
iomedica, A) following the manufacturer’s instructions. Brieﬂy,
 × 103 cells/well were seeded in quadruplicate in 96-well
icroplates (Iwaki, J) and cultured with various concentrations of
SE (0.625–40 g/ml) for 3 days. The absorbance was  recorded by
 Spectraﬂuor Fluorometer (Tecan, A) at 450 nm with 620 nm as
eference wave length.
.5.  Griess assay
Primary  human OA chondrocytes (n = 3 donors) were seeded
n 96-well microplates and analyzed separately. Upon conﬂu-
ncy, cells were preincubated with CSE at three concentrations
10 g/ml, 5 g/ml or 2.5 g/ml) for 1 h prior to coincubation
ith 10 ng/ml IL-1 (Miltenyi Biotec, D) for 24 h. The amount
f accumulated nitrite derived from NO metabolism was deter-
ined in the cell culture supernatant by mixing with an equal
olume of Griess reagent (1% sulphanilamide in 0.1 N HCl and 0.1%
-1-naphthylethylenediamine dihydrochloride in equal parts).Please cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
bsorbance was measured at 544 nm with reference to 690 nm with
 Spectraﬂuor Fluorometer. Nitrite concentrations were calculated
sing a NaNO2 standard curve (0–100 M in cell culture medium).
 nitrite standard reference curve was established for each assay.96.5% 136bp NM 000963
2.6. Quantitative real-time RT-PCR (RT-qPCR)
4 × 105/well primary human OA chondrocytes or 4 × 104/well
SW1353 cells were seeded in 12-well microplates (Iwaki, J).
Upon 90% conﬂuency, medium was  changed to DMEM contain-
ing 2% insulin–transferrin–selenium (ITS; Gibco, A) and incubated
overnight prior to treatment. Chondrocytes were preincubated
with CSE (5, 10, or 20 g/ml) or 10 M dexamethasone (Sigma,
A) for 1 h and then incubated for a further 6 h in the presence of
10 ng/ml IL-1. In a different set of experiment, cells were pre-
treated with 10 g/ml Natural Red 24 (NR24). Cells without any
treatment were used as control. THP-1 cells were seeded in 12-well
microplates at 3 × 105 per well. After differentiation with PMA  (see
above), cells were preincubated with 5 g/ml CSE for 1 h and then
co-treated for an additional 2 h with 10 ng/ml LPS.
Total RNA was extracted from each sample using the NucleoSpin
RNA II Kit (Macherey-Nagel, D) according to the manufacturer’s
instructions. To quantify and control for the integrity of the iso-
lated RNA preparations, each sample was run on the Agilent 2100
Bioanalyzer Nano LabChip prior to reverse transcription of equal
RNA quantities into cDNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, A). RNA integrity numbers
(RIN) were found to range from 7.8 to 10 for all samples.
qPCR analyses of IL-1, TNF-, iNOS and COX-2 mRNA were
performed using primer sets described in Table 1. Primers for ref-
erence genes were used as previously described (Toegel et al.,
2007). Ampliﬁcation efﬁciencies of all primers were evaluated
using dilution series of cDNA prepared from chondrocyte mRNA.
All qPCR reactions were performed in 25 l reaction mixtures con-
taining 1 l cDNA, 12.5 l SensiMix SYBR Green Mix  (GenXpress, A),
100 nM primers (Metabion, D), and nuclease-free water to 25 l,
and run in duplicate on an Mx3000P QPCR system (Stratagene,
USA). Melting curves were generated to conﬁrm a single gene-
speciﬁc peak and no-template-controls were included in each run
to control for contaminations.
The  regulation of target genes was  calculated as quantities
relative to the untreated control group using the MxPro real-
time QPCR software, considering both ampliﬁcation efﬁciencies
and normalization to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as reference gene. In preliminary experiments, the
expression stabilities of 5 candidate reference genes (GAPDH, beta
actin (ACTB), hypoxanthine phosphoribosyl-transferase I (HPRT1),
succinate dehydrogenase complex, subunit A (SDHA), beta-2-
microglobulin (B2 M))  were determined under the experimental
conditions described above. Then, the expression stabilities were
evaluated using the geNorm software (Vandesompele et al., 2002)
and GAPDH was selected as a stable reference gene under the exper-
imental conditions of this study.
We declare that the current study has adhered to the minimal
guidelines for the design and documentation of qPCR experimentsty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
as recently outlined by Bustin et al. (2010). A qPCR checklist listing
all relevant technical information has been provided for the review-
ers to assess the technical adequacy of the used qPCR protocols
(Supplementary Table 1).
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Fig. 1. Cytotoxic effect of CSE in differentiated THP-1 cells and primary chon-
drocytes. Cells were incubated for 72 h with various concentrations of CSE
(0.625–40  g/ml) and the viability was determined using MTT-based assays. Each
Specific topics - Study 5
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.7. TNF-  ˛ ELISA
4  × 105/well primary human OA chondrocytes from donors
n = 2 donors) or 4 × 104/well SW1353 cells were seeded in 12-well
icroplates. Upon 90% conﬂuency, culture medium was  changed to
MEM containing 2% ITS and cultured overnight. After 1 h prein-
ubation with 5 g/ml CSE, the cells were treated with 10 ng/ml
L-1 for an additional 48 h. Chondrocytes without any treatment
ere used as control. The TNF- concentration in the cell culture
upernatants was measured using the Human TNF alpha ELISA
eady-SET-Go! Kit (eBioscience, USA), as described by the man-
facturer.
.8. Transfections and reporter assays
The pXP2-COX2-Luc reporter construct, containing
170/ + 103 bp of the human COX2 promoter, and the NF-kB
50 and p65 expression vectors were described previously (Grall
t al., 2005). The sequences of all constructs were conﬁrmed by
NA sequencing.
Transient transfection experiments were performed in SW1353
ells using LipofectAMINE PLUS Reagent (Invitrogen, A). Cells were
eeded in 24-well plates at 104 cells/cm2 in DMEM/F12 containing
0% FCS. Transfections were carried out in serum-free medium with
 total of no more than 325 ng of plasmid DNA, including 300 ng
f luciferase reporter construct and 25 ng per well of expression
ector or empty backbone (control). Brieﬂy, plasmid DNA was  incu-
ated for 15 min  at room temperature with 6 l Plus Reagent and
4 l serum-free DMEM/F12. Following incubation, LipofectAMINE
eagent (4 l) in 96 l serum-free medium was added to each reac-
ion mixture and the incubation was continued for an additional
0 min  at room temperature. Then, the transfection mixture was
ombined with 300 l of serum-free medium and the lipid-nucleic
cid complex (500 l) was  added drop-wise to the cell monolayer
ielding a total volume of 1 ml.  After incubation for 1 h at 37 ◦C, 1 ml
f serum-free medium containing CSE was added to each well and
ncubation was continued for 23 h. Cell lysates were prepared using
he Reporter Lysis Buffer (Promega, USA) and luciferase activities
ere determined by chemiluminescence assay using the LMaxII384
uminometer (Molecular Devices, USA) and the Luciferase Assay
ubstrate (Promega). Data are representative of two independent
xperiments performed in triplicate and expressed as fold-change
ersus unstimulated control.
.9.  Statistical analysis
Data  were exported to the GraphPad Prism statistics software
ackage (GraphPad Prism Software, USA). The Gaussian distri-
ution of data was veriﬁed using the Kolmogorov–Smirnov test.
tatistics were performed using one-way analysis of variance
ANOVA) with post hoc Tukey tests, cross-comparing all study
roups (95% conﬁdence interval). p-Values < 0.05 were considered
igniﬁcant.
. Results
.1. Effect of CSE on cell viability
As  shown in Fig. 1, signiﬁcant cytotoxicity of CSE was observed
t concentrations higher than 40 g/ml and 10 g/ml in pri-Please cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
ary chondrocytes and THP-1 cells, respectively. The subsequent
xperiments were therefore performed using CSE concentrations
ot higher than 20 g/ml for experiments carried out using
uman primary chondrocytes and at 5 g/ml for treatment of
HP-1 cells.value represents the mean ± SD. *Signiﬁcant differences as compared to untreated
cells  (p < 0.05).
3.2. Effect of CSE on IL-1  ˇ and TNF-  ˛ mRNA in THP-1 cells
In  THP-1 macrophages, 10 ng/ml LPS induced an 11.9 ± 0.6 fold
and 60.2 ± 7.2 fold upregulation of IL-1 (Fig.  2A) and TNF-
(Fig. 2B) mRNA levels, respectively. Pretreatment with 5 g/ml
CSE signiﬁcantly inhibited the upregulation of both cytokines in
THP-1 macrophages. In the case of TNF-, CSE pretreatment down-
regulated the mRNA expression to levels comparable to control
cells (Fig. 2B).
3.3.  Effect of CSE on IL-1  ˇ and TNF-  ˛ expression in chondrocytes
As  shown in Fig. 3A, IL-1 gene expression in SW1353 chondro-
cytes was  upregulated by 45.3 ± 2.5 fold following stimulation with
10 ng/ml recombinant IL-1. CSE, however, markedly suppressed
the effect caused by IL-1 in  a concentration-dependent manner.
At 10 and 20 g/ml, CSE completely blocked the IL-1-induced
IL-1 mRNA level, re-establishing expression levels comparable
to untreated cells. The TNF- mRNA level (Fig. 3B) was strongly
increased 325 ± 9 fold by 10 ng/ml IL-1, whereas pre-treatment
with 10 or 20 g/ml CSE signiﬁcantly reduced this effect. In addi-
tion, comparable results regarding the impact of CSE on IL-1 and
TNF- mRNA expression were obtained in primary chondrocytes
(Table 2). Interestingly, the upregulation of IL-1 and TNF- mRNA
expression caused by IL-1 was considerably higher in primary
chondrocytes than in SW1353 cells. Nevertheless, the stimulated
expression of IL-1 and TNF- mRNA was clearly abrogated by
CSE treatment in a dose-dependent manner. The validity of the
assay was  veriﬁed using 10 M dexamethasone, a widely used anti-
inﬂammatory glucocorticoid, as positive control. Dexamethasone
substantially suppressed the IL-1-mediated upregulation of IL-1
and TNF- mRNA levels in primary chondrocytes isolated from 3
donors (p < 0.05; data not shown).
Interestingly, also NR24 down-regulated TNF- mRNA levels
in IL-1 stimulated primary chondrocytes (Supplementary Fig. 2).
Even more importantly, the inhibitory effects mediated by NR24
were signiﬁcantly less pronounced than those mediated by CSE
(p < 0.05). This fact might be explained by the lower concentra-
tion of brazilin found in NR24 as compared to CSE (Supplementary
Fig. 1).
The production of TNF- was measured in the culture super-
natants of chondrocytes using ELISA. As shown in Fig. 4, 24 hty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
treatment with IL-1 (10 ng/ml) caused a 3.6 fold and 9.1 fold
increase of TNF- expression in SW1353 chondrocytes and primary
human chondrocytes, respectively. Pretreatment of both cell types
with 5 g/ml CSE signiﬁcantly suppressed the IL-1-induced TNF-
82
ARTICLE IN PRESSG ModelJEP-7037; No. of Pages 9
S.Q. Wu  et al. / Journal of Ethnopharmacology xxx (2011) xxx– xxx 5
0
5
10
15
*
LPS   -                 +                   +
CSE -                 -                   +
#
#
A
F
ol
d 
ch
an
ge
0
20
40
60
80
LPS   -                +               +
CSE -                -               +
*
#
B
F
ol
d 
ch
an
ge
0
1
2
3
LPS   -                +              +
CSE -                -               +
C
F
ol
d 
ch
an
ge
F  cells
I levels
v p < 0.0
p
p
I
d
F
s
c
Specific topics - Study 5ig. 2. CSE regulates IL-1 (A), TNF- (B) and iNOS (C) mRNA in THP-1 cells. THP-1
L-1 alone or following pretreatment with 5 g/ml CSE. The alterations of mRNA 
ersus controls. ∗Signiﬁcant differences compared to cells treated only with IL-1 (Please cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
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roduction. As such, 5 g/ml CSE reduced the IL-1-induced TNF-
roduction in primary cells from 19.1 ± 1.1 pg/ml to 5.4 ± 3.8 pg/ml.
n both SW1353 and primary cells, the TNF- production was
own-regulated to basal levels.
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3.4.  Effect of CSE on NO production and on iNOS expression
Nitrite, the stable metabolite of NO, was measured using
the Griess assay in primary chondrocytes. Stimulation with
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niﬁcant differences compared to untreated cells (p < 0.05).
83
ARTICLE IN PRESSG ModelJEP-7037; No. of Pages 9
6 S.Q.  Wu  et al. / Journal of Ethnopharmacology xxx (2011) xxx– xxx
Table  2
CSE  regulates IL-1, TNF-, iNOS and COX-2 mRNA in primary chondrocytes. Cells were preincubated with 5, 10 or 20 g/ml CSE for 1 h prior to stimulation with 10 ng/ml
IL-1 for 6 h. The alteration of mRNA levels was  analyzed using RT-qPCR. Data from 3 donors (PC1, 2, 3) are presented as relative quantities (mean ± SD) as compared to
controls.
Control IL-1 IL-1+5 g/ml CSE IL-1+10 g/ml CSE IL-1+20 g/ml CSE
IL-1
PC1  1.00 ± 0.04 218.94 ± 6.95# 2.66 ± 0.01* 0.43 ± 0.06* 0.52 ± 0.11*
PC2 1.00 ± 0.03 8359.31 ± 113.81# 752.09 ± 68.18 * 15.29 ± 1.73* No Cq
PC3  1.00 ± 0.01 910.01 ± 8.26# 229.19 ± 41.38 255.77 ± 2.32* 12.93 ± 1.06*
TNF-
PC1  1.00 ± 0.78 468.07 ± 27.37# 4.82 ± 0.63* 3.68 ± 0.69* 7.64 ± 0.86*
PC2 1.00 ± 0.03 1013.48 ± 136.44# 128.52 ± 4.63* 22.13 ± 0.30* 37.0 ± 5.16*
PC3 1.00 ± 0.02 1786.13 ±  200.57# 501.60 ±  51.84*# 154.04 ±  16.61*# 28.88 ± 4.92*
iNOS
PC1 1.00 ± 0.04 659.17 ± 28.86# 48.86 ± 4.04* 1.22 ± 0.01* 0.19 ± 0.02*
PC2 1.00 ± 0.10 20014.19 ± 4442.74# 3297.77 ± 96.27*# 163.84 ± 18.30* 0.88 ± 0.05*
PC3 1.00 ± 0.11 7363.67 ± 644.13# 2952.28 ± 14.37# 4047.04 ± 666.50*# 123.64 ± 9.61*
COX-2
PC1  1.00 ± 0.01 96.10 ± 2.23# 21.39 ± 2.28*# 9.61 ± 0.53*# 2.93 ± 0.40*
PC2 1.00 ± 0.04 121.84 ± 36.81# 71.07 ± 7.26# 23.19 ± 0.32* 9.07 ± 1.26*
PC3 1.00 ± 0.13 304.77 ±  11.33# 134.24 ±  9.35*# 128.23 ±  3.58*# 28.36 ± 0.92*#
∗ Signiﬁcant differences compared to cells treated only with IL-1 (p < 0.05).
# Signiﬁcant differences compared to untreated cells (p < 0.05).
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Fig. 4. CSE regulates IL-1-induced TNF- production  in SW1353 and primary
chondrocytes.  After 1 h preincubation with 5 g/ml CSE, cells were treated with
10 ng/ml IL-1 for additional 48 h. TNF- levels in the cell culture medium were
analyzed  using ELISA assay. Primary cells were isolated from 2 donors and analyzed
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Specific topics - Study 5eparately.  Data are presented as relative quantities (mean ± SD) compared to con-
rols. ∗Signiﬁcant differences compared to cells treated only with IL-1 (p < 0.05).
Signiﬁcant differences compared to untreated cells (p < 0.05).
L-1 resulted in a 16.3 ± 4.9 fold increase of nitrite accumulationPlease cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
hereas pretreatment with CSE caused a concentration-dependent
eduction  of nitrite accumulation (Fig. 5). 5 g/ml and 10 g/ml
SE signiﬁcantly suppressed the IL-1-induced NO production to
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ig. 5. CSE regulates IL-1-stimulated NO production in primary chondrocytes.
rimary  cells were isolated from 3 donors and analyzed separately. Cells were incu-
ated with 2.5, 5 and 10 g/ml CSE for 1 h prior to coincubation with 10 ng/ml IL-1
or 24 h. The nitrite concentration in the culture medium was  measured using the
riess assay. Data are presented as relative quantities (mean ± SD) compared to con-
rols. ∗Signiﬁcant differences compared to cells treated only with IL-1 (p < 0.05).
Signiﬁcant differences compared to untreated cells (p < 0.05).basal levels. At 2.5 g/ml, CSE did not exert a statistically signif-
icant effect in this assay. For correlation, RT-qPCR was  performed
to quantify iNOS mRNA levels in IL-1-stimulated SW1353 and
primary chondrocytes as well as in LPS-stimulated THP-1 cells. As
shown in Fig. 3C and Table 2, 10 ng/ml IL-1 markedly stimulated
iNOS expression in SW1353 cells and primary chondrocytes,
respectively. Pretreatment with CSE dose-dependently suppressed
iNOS expression to control levels, supporting the results obtained
with the Griess assay. A similar, albeit not signiﬁcant, trend was
also observed in THP-1 cells (Fig. 2C).
3.5. Effect of CSE on COX-2 transcription via p65/p50-mediated
COX-2 promoter activation
As  shown in Fig. 3D, IL-1-induced COX-2 expression was  sig-
niﬁcantly reduced by CSE pretreatment in SW1353 chondrocytes.
Accordingly, IL-1-induced COX-2 mRNA levels were reduced in a
dose-dependent manner by CSE in human primary chondrocytes
(Table 2). Previous studies have shown that IL-1 activates COX-
2 expression via NF-B signaling in different cell types, including
chondrocytes (Crofford et al., 1997; Allport et al., 2000; Thomas
et al., 2000). Therefore, in order to elucidate the mechanism under-
lying COX-2 suppression by CSE, SW1353 cells were co-transfected
with a COX-2 reporter construct and NF-B p65/p50 expression
vectors in the presence or absence of CSE. As shown in Fig. 6, the
basal COX-2 promoter activity was reduced by 2.5 and 5 g/ml
CSE, although the differences were not statistically signiﬁcant.
Overexpression of the NF-B subunits p50 and p65 signiﬁcantly
enhanced the COX-2 promoter activity (3.4 ± 0.7 fold, p < 0.05)
whereas the p65/p50-driven COX-2 transactivation was  dose-
dependently suppressed by CSE (0.5–10 g/ml), indicating that the
anti-inﬂammatory effects of CSE are, at least in part, derived from
its actions on NF-B signaling.
4.  Discussion
It  is now accepted that inﬂammatory processes play a role
in the pathophysiology of OA. Indeed, different studies have
shown that joint tissue cells, including synovial ﬁbroblasts, syn-
ovial macrophages and chondrocytes, produce proinﬂammatory
cytokines, chemokines and other proinﬂammatory mediators that
will in turn result in an inﬂammatory environment that drives the
upregulation of cartilage-degrading MMPs  and ADAMTSs (Tsurudaty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
et al., 2004; Bondeson et al., 2006).
Using human OA chondrocytes and THP-1 macrophages, the
present study demonstrates for the ﬁrst time that CSE is a
potent inhibitor of proinﬂammatory mediators in the context
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Fig. 6. CSE inhibits p65/p50-mediated COX-2 promoter activation in chondrocytes. SW1353 chondrocytes were transfected with the pXP2 luciferase construct containing
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Specific topics - Study 5he −170/ + 103 COX-2 promoter or cotransfected with NF-B p50 and p65 express
wo  independent experiments. #Signiﬁcant differences with respect to cells transfe
ifferences with respect to cells co-transfected with the COX-2 promoter and the p
f joint inﬂammation. Several lines of evidence have previously
emonstrated the anti-inﬂammatory potential of Caesalpinia sap-
an extracts and their isolated compounds. In LPS-stimulated
AW264.7 mouse macrophages, Hu and coworkers found that
razilin, the main constituent of CSE, suppressed the release of
L-1, TNF-, NO, and PGE2 and they suggested that these effects
re mediated by Heme oxygenase-1 (Hu et al., 2009). Washiyama
t al. compared seven compounds isolated from a methanolic
xtract of Sappan lignum in mouse macrophage-like J774.1 cells
nd demonstrated inhibitory effects on the expression of inﬂam-
atory mediators (Washiyama et al., 2009). More importantly,
n vivo data from mouse and rat models further support our ﬁnd-
ngs on the anti-inﬂammatory activity of Caesalpinia sappan isolates
Shen et al., 2007; Washiyama et al., 2009). Only recently, a 70%
thanolic extract of Caesalpinia sappan has been evaluated in a
uman cell model of TNF--stimulated umbilical vein endothe-
ial cells (Lee et al., 2010). Our present study extends these results
o human macrophages and shows that CSE down-regulates IL-1
nd TNF- mRNA levels in activated THP-1 cells. This result is of
nterest since synovial macrophages are known to contribute to the
athogenic cascade that leads to OA and rheumatoid arthritis as a
ajor source of inﬂammatory cytokines and reactive oxygen inter-
ediates (Bondeson et al., 2006). Targeting macrophages using
nti-inﬂammatory phytopharmaceuticals may, therefore, repre-
ent a strategy to alleviate synovitis and deleterious mediators in
he synovial ﬂuid.
Besides  synovial macrophages, OA chondrocytes are a promis-
ng target of anti-inﬂammatory agents. Our present results clearly
ocument that the addition of CSE effectively suppresses the over-
xpression of IL-1 and TNF- in stimulated OA chondrocytes as
ell as SW1353 cells in vitro, indicating that CSE contains one or
ore active components that may  act as potent anti-inﬂammatory
gents in human chondrocytes. Most likely, brazilin ((6aS,11bR)-
,11b-Dihydro-6H-indeno[2,1-c]chromene-3,6a,9,10-tetrol) con-
ributes to the described anti-inﬂammatory action of CSE. In the
resent study, we have isolated brazilin from CSE and identiﬁedPlease cite this article in press as: Wu, S.Q., et al., Anti-inﬂammatory activi
and  macrophages. J. Ethnopharmacol. (2011), doi:10.1016/j.jep.2011.09.01
ts structure using 1H NMR. Interestingly, we found that CSE sup-
ressed the IL-1-mediated upregulation of TNF- mRNA levels to
 signiﬁcantly higher extent than NR24. This ﬁnding correlates with
he lower content of brazilin in NR24 as demonstrated using HPLCctors. Data shown are means of triplicate measurements of luciferase activity from
ith the COX-2 reporter construct and the pCI empty vector (p < 0.05). ∗Signiﬁcant
0 expression vectors (p < 0.05).
analysis  and supports the role of brazilin in the anti-inﬂammatory
action of CSE in human chondrocytes.
One of the biological messengers associated with inﬂammation
is NO. NO is biosynthesized endogenously from l-arginine by nitric
oxide synthases and can activate transcription factors or protein
kinases in a cGMP-dependent manner. Although NO might also
regulate physiological processes in chondrocytes, including colla-
gen type X expression and alkaline phosphatase activity, several
reports have shown that OA chondrocytes overexpress iNOS and
that the resulting excess NO production by OA chondrocytes is a
contributing factor to OA cartilage degradative processes (Studer
et al., 1999; Abramson, 2008). Experiments in other cell types have
indicated that the anti-inﬂammatory activity of CSE involves the
reduction of NO synthesis via inhibition of iNOS mRNA expression
(Bae et al., 2005; Washiyama et al., 2009). The latter led us to explore
the action of CSE in human OA chondrocytes where, in agreement
with the aforementioned reports, we demonstrated that the pres-
ence of the extract abrogates IL-1-mediated NO production by
suppressing iNOS transcription. This suggests that CSE might allevi-
ate deleterious effects associated with over-expression of NO such
as the inhibition of collagen and proteoglycan synthesis and the
induction of apoptosis (Abramson, 2008).
Furthermore, inﬂammatory cytokines increase the production
of prostaglandins via the induction of COX-2 and microsomal
PGE synthase 1 (Abramson and Attur, 2009). Attur and coworkers
reported that PGE2 decreased proteoglycan synthesis and enhanced
matrix degradation in OA cartilage explants (Attur et al., 2008). RT-
qPCR results reported in the present study indicate that CSE is able
to attenuate IL-1-induced COX-2 mRNA expression in SW1353
and primary chondrocytes. This result correlates well with stud-
ies on CSE and brazilin in mouse macrophages, demonstrating that
the potential anti-inﬂammatory effects of the agents involve the
inhibition of PGE2 production (Hong et al., 2002; Sasaki et al.,
2007). Aiming to further elucidate the mechanisms underlying the
anti-inﬂammatory action of CSE in chondrocytes, we focused on
the role of NF-B in COX-2 promoter activation. The NF-B sig-ty of an ethanolic Caesalpinia sappan extract in human chondrocytes
1
naling is activated by pro-inﬂammatory stimuli including IL-1
and TNF-. Activated NF-B subunits, such as the RelA (p65)/p50
heterodimer, are translocated to the nucleus, where they bind to
target DNA sequences and regulate the expression of a number of
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enes, including COX-2, iNOS, IL-1 and TNF-. The COX-2 pro-
oter contains at least four putative NF-B binding sites and it has
een shown that NF-B modulates COX-2 expression in different
ell types, including epithelial cells, rheumatoid synoviocytes and
rticular chondrocytes (Crofford et al., 1997; Allport et al., 2000;
homas et al., 2000). In the present study, co-transfection experi-
ents utilizing a COX-2 promoter luciferase construct and p65/p50
xpression vectors in the presence or absence of CSE, revealed that
SE strongly inhibited the p65/p50-driven COX-2 transactivation in
 dose-dependent manner. This result suggests that CSE interferes
ith the DNA binding activity of NF-B subunits, thereby blocking
OX-2 transcription. This ﬁnding is in agreement with a previous
tudy by Bae et al. showing that brazilin inhibited the DNA binding
ctivity of NF-B and AP-1 in LPS-stimulated mouse macrophages
Bae et al., 2005).
Finally,  it should be noted that the present study is limited in
erms of its in vitro experimental design and that extrapolations
o in vivo conditions should be carried out with caution. Future
tudies should aim to deﬁne the in vivo actions of CSE using animal
odels of arthritic diseases, and to further delineate the molecular
echanisms evoked by CSE and its speciﬁc constituents. As any
ther phytochemical drug, CSE or CSE-derived compounds will also
equire rigorous toxicological and pharmacokinetic testing as well
s clinical veriﬁcation of the ﬁndings obtained in vitro.
.  Conclusion
In this study, we demonstrated that CSE possesses anti-
nﬂammatory activity in human macrophages and OA
hondrocytes. In these cells, CSE substantially suppresses the
xpression of inﬂammatory mediators including IL-1 and TNF-
t the mRNA level. In addition, we show that the anti-inﬂammatory
ctions of CSE involve, at least in part, the inhibition of NO produc-
ion via iNOS downregulation as well as the inhibition of COX-2
romoter activation by interfering with the canonical NF-B
p65/p50) signaling pathway. Therefore, we suggest that CSE or
SE-derived compounds should be further developed as therapeu-
ically effective agents or lead structures for future treatment of
nﬂammation in OA.
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1. Introduction 
 
Osteoarthritis (OA) is one of the most frequent and cost-intensive chronic disabling 
diseases in the elderly. Characterized by progressive degradation of cartilage, OA is 
traditionally not considered as a classical inflammatory athropathy. However, 
overexpression of inflammatory mediators including interleukin 1ß (IL-1ß), tumor 
necrosis factor (TNF-α), nitric oxide (NO) and prostaglandins contributes to 
dysregulations of chondrocyte function and remodelling of ECM. The action of these 
mediators drives catabolic pathways, inhibits matrix synthesis via the inductions of 
degradative proteases (matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)), and promotes cellular 
apoptosis [1, 2, 3]. To date, the aetiology of OA remains to be defined and the process 
of clinically detectable OA is irreversible. In general, pharmacological and 
non-pharmacological approaches, the operations, focus on the relief of symptoms, 
such as reduction of pain, inflammation, and stiffness. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) are currently the most widely recommended pharmacological therapy. 
However, the application of NSAIDs is also well associated with the risk of 
gastro-intestinal or cardiovascular adverse effects [4]. As alternatives to conventional 
medicine, a new class of agents has been reported to improve joint health, including 
glucosamine sulphate, chondroitin sulphate, avocado/soybean unsaponifiables, 
curcumin, diacerein and numerous plant products [5]. Although the clinical efficacy 
of these agents remains to be confirmed [6], they are widely available and generally 
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well-tolerated.  
Sappan Lignum, the heartwood of Caesalpinia sappan L. (Leguminosae), has been 
widely used in oriental traditional medicine for improvement of blood circulation, 
sprains, and emmeniopathy [7]. Different extracts and active compounds, such as 
brazilin, brazilein, prostosappanins A-E, sappanchalcone from extracts have been 
reported to possess diverse biological activities including antioxidative [8], 
antiinflammtory [9, 10], and antibacterial [11, 12] effects. Brazilin, the major 
constituent of Sappan lignum, has been reported to show anti-inflammatory [10], 
antibacterial [12], and antihepatotoxic effects [13] in diverse cell types. In a previous 
study, we performed assays to clarify the anti-inflammatory activities of an ethanolic 
extract of sappan lignum (CSE) in an osteoarthritic cell model containing human 
chondrocytes and macrophages [14]. We presented evidence that the CSE inhibits 
chondrocyte catabolism via suppression IL-1ß-induced MMPs mRNA and protein 
levels [15]. Moreover, we explored part of the mechanisms underlying the 
anti-inflammatory effects and supposed that the inhibitory effects on MMPs are 
mediated by inhibiting Nuclear factor –κB (NF-κB)(p65/p50) signalling.  
The present study aims to proof the hypothesis that brazilin is responsible for the 
recently observed anti-inflammatory effects of CSE in chondrocytes. Therefore, we 
isolated brazilin from CSE, identified the chemical structure, and determined the 
effects of brazilin on chondrocytes in comparision with CSE. 
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2. Material and methods 
 
2.1. Brazilin Isolation 
CSE isolation from Sappan lignum was described in our previous study [14, 15]. 
3.25g CSE were extracted by stirring in100ml water at room temperature for 24h. The 
supernatant was filtered and freeze-dried to give 1.69g extract as an orange powder. 
The resulting extract was dissolved in water in a concentration of 10 mg/ml. Further 
separation was conducted using preparative high-performance liquid chromatography 
(HPLC, Schimadzu, Japan) with a reversed – phase C18 column (Polygoprep C18, 
12µ, 25mm x 250mm, Austria) monitored at 280nm. The eluent system consisted of a 
45 min gradient program from 10% to 100% methanol (containing 1.25% acetic acid) 
at a flow rate of 22 ml/min; column temperature 50°C. The fraction with retentions 
time at about 20min was collected in repeated preparative HPLC separation. These 
fractions were further concentrated under vacuum and then freeze-dried to give a 
white compound which easily oxidized to a red-brown powder. 
 
2.2. Analytic HPLC  
The fraction was characterized by HPLC (ICS-3000, Dionex, USA) with a Nucleodur 
C-18 column (Macherey-Nagel, D) and a PDA-100 detector (Dionex) set at 280 nm. 
The eluent system consisted of a 45 min gradient program from 10% to 100% 
methanol (containing 2.5% acetic acid) at a flow rate of 0.8 ml/min and column 
temperature 50°C. 
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 2.3. Brazilin Identification –NMR (Nuclear magnetic resonance) 
The 
1
H NMR and 
13
C NMR spectra were recorded from CDCl3 solutions on a Bruker 
Avance 500 instrument (Bruker, USA)500 MHz for 
1
H, 125 MHz for 
13
C) at 25°C 
using a 5 mm direct detection broadband observe probe and deuterium lock. The 
center of the solvent signal was used as an internal standard which was related to 
tetramethylsilane with 7.26 ppm (
1
H) and 77.0 ppm (
13
C). The recording conditions 
were the following: 
1
H NMR: pulse angle 30°, acquisition time 5 s, digital resolution 
0.2 Hz/data point, spectral width 16 ppm, relaxation delay 5 s; broad-band decoupled 
13
C-NMR spectra: pulse angle 30°, acquisition time 2 s, digital resolution 0.5 Hz/data 
point, spectral width 220 ppm, relaxation delay 2 s, exponential multiplication with 
1.0 Hz line broadening factor before FT. Full and unambiguous assignment of (almost) 
all 
1
H and 
13
C NMR resonances was achieved by combined application of standard 
NMR spectroscopic techniques
[x]
 such as APT, COSY, TOCSY, NOESY (1 s mixing 
time), gs-HSQC
[y]
 and gs-HMBC
[z]
 using standard Bruker software. 
 
2.4. Biological activity assays 
2.4.1. Cell culture 
In accordance with the terms of the ethics committee of the Medical University 
Vienna (EK-Nr.: 081/2005) and following the guidelines of the Declaration of 
Helsinki and Tokyo, primary human chondrocytes were enzymatically isolated from 
articular cartilage of OA patients undergoing knee replacement surgery following 
93
Specific topics - Study 6
established protocols [16]. Isolated chondrocytes were seeded at a density of 10
5
/cm
2
 
and cultured in Dulbecco‟s modified Eagle‟s medium (DMEM; Gibco, A) containing 
10% fetal calf serum (FCS; Biochrom AG, D) and 2 μl/ml gentamycin (Biochrom AG, 
D) in a humidified atmosphere of 5% CO2/95% air at 37°C. For all assays, only 
freshly isolated and seeded primary cells without subculturing were used. The human 
chondrosarcoma cell line SW1353 (ATCC, USA) was cultured at a density of 10
4
/cm
2
 
under the same conditions as described above and passaged by incubation with 0.25% 
trypsin-EDTA.  
 
2.4.2. Cytotoxicity assay 
The cytotoxicity of Brazilin was assessed in primary human chondrocytes cells using 
an MTT-based test (EZ4U, Biomedica, A) following the manufacturer‟s instructions. 
Briefly, 3x10
3 
cells/well were seeded in quadruplicate in 96-well microplates (Iwaki, J) 
and cultured with various concentrations of brazilin 0.625-40 µg/ml) for 3 days. The 
absorbance was recorded by a Spectrafluor Fluorometer (Tecan, A) at 450 nm with 
620 nm as reference wave length.  
 
2.4.3. Quantitative real-time RT-PCR (RT-qPCR) 
4x10
5 
primary human OA chondrocytes or 4x10
4
 SW1353 cells were seeded in 
12-well microplates (Iwaki, J). Upon 90% confluency, medium was changed to 
DMEM containing 2% Insulin-Transferrin-Selenium (ITS; Gibco, A) and incubated 
overnight prior to treatment. Chondrocytes were preincubated with Brazilin (5, 10, or 
94
Specific topics - Study 6
20 µg/ml) or 5 µg/ml CSE for 1 h and then incubated for a further 6 h in the presence 
of 10 ng/ml IL-1ß (Miltenyi Biotec, D). Untreated cells were used as control.  
Total RNA was extracted from each sample using the NucleoSpin RNA II Kit 
(Macherey-Nagel, D) according to the manufacturer‟s instructions. To quantify and 
control for the integrity of the isolated RNA preparations, each sample was run on the 
Agilent 2100 Bioanalyzer Nano LabChip prior to reverse transcription of equal RNA 
quantities into cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, A). RNA integrity numbers (RIN) were found to range from 7.8 
to 10 for all samples.  
qPCR analyses of TNF-α, COX-2 and MMP3 mRNA were performed as previously 
described[14,16]. Primer sets described in Table 1. We declare that the current study 
has adhered to the minimal guidelines for the design and documentation of qPCR 
experiments as recently outlined by Bustin et al [17]. 
 
2.4.4. ELISA 
4x10
5
 Primary human OA chondrocytes or 4 x 10
4
 SW1353 cells per well were 
seeded in 12-well microplates. Upon 90% confluency, culture medium was changed 
to DMEM containing 2% ITS and cultured overnight. After 1 h preincubation with 
different concentrations of brazilin, the cells were treated with 10 ng/ml IL-1ß for an 
additional 48 h. Untreated chondrocytes were used as control. The TNF-α, PGE-2, 
and MMP3 concentrations in the cell culture supernatants were measured using the 
Human TNF alpha ELISA Ready-SET-Go! Kit (eBioscience, San Diego, CA), the 
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Parameter 
TM
 PGE2 Assay and the Quantikine
®
 Human Total MMP-3 Immunoassay 
(R&DSystems, USA) as described by the manufacturer.  
 
2.5. Statistical Analyses 
Data were exported to the GraphPad Prism statistics software package (GraphPad 
Prism Software, USA). The Gaussian distribution of data was verified using the 
Kolmogorov-Smirnov test. Statistics were performed using one-way analysis of 
variance (ANOVA) with post hoc Tukey tests, cross-comparing all study groups (95% 
confidence interval). p-values < 0.05 were considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
96
Specific topics - Study 6
3. Results 
3.1. HPLC analysis 
As shown in Fig.1, the isolation processes were controlled by analytic HPLC at 
280nm wave length. Fig.1A is the chromatogram of CSE, than following Fig.1B 
shown the similar chromatogram of lyophilisate from CSE water extract. In Fig.1C 
one prominent peak after preparative HPLC isolation was shown in the chromatogram, 
with retention time 14.4 min at 280nm wave length.  
 
3.2. Identification of Brazilin 
1
HNMR 
δ7.23(H-1), 6.69(H-11), 6.65(H-8), 6.51(H-2), 6.28(H-4), 3.93(S, 1H, H-12), 3.86(d, 
1H, J6a,6b=11.5Hz, H-6a), 3.56(d, 1H, J6a,6b=11.5Hz, H-6b), 2.93(d, 1H, J7a,7b=16.0Hz, 
H-7a), 2.74(dd, 1H, J7a,7b=15.5Hz, H-7b). 
13
C-NMR 
δ40.54(C-7), 48.82(C-12), 69.14(C-6), 76.9(C-6a), 103.14(C-4), 109.52(C-2), 
111.81(C-11), 112.87(C-8), 114.48(C-1a), 131.27(C-7a or 11a), 131.69(C-1), 
136.28(C-7a or 11a), 143.00, 143.34 (C-9, C-10), 153.37(C-4a), 153.16(C-3) 
The 
1
HNMR and 
13
C-NMR spectra of isolated compound coincided with brazilin 
((6aS,11bR)-7,11b-Dihydrobenz[b]indeno[1,2-d]pyran-3,6a,9,10(6H)-tetrol)(C16H14
O5) (Fig.2). In agreement with previous studies [12, 18], the isolated compound was 
identified as brazilin. 
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3.3. Effect of brazilin on cell viability 
Prior to examining the impact of brazilin on cytokine expression in chondrocytes, we 
confirmed the cytotoxicity of this compound on the primary human chondrocytes. As 
shown in Figure.3, there was no significant cytotoxicity of brazilin up to 
concentrations of 40 µg/ml in primary chondrocytes. The subsequent experiments 
were therefore performed using brazilin concentrations not higher than 20 µg/ml.  
 
3.4. Brazilin reduces TNF-α, COX-2 and MMP3 gene expression stimulated by 
IL-1ß in primary cells and SW1353 cells  
From previous studies [14, 15], we confirmed the anti-inflammatory activities of CSE 
in an osteoarthritic human chondrocytes and presented evidence that CSE inhibits 
chondrocyte catabolism via suppression of IL-1ß-induced MMPs mRNA and protein 
levels. To determine if brazilin might be the responsible compound of this 
anti-catabolic effect of CSE in chondrocytes, we performed qRT-PCR studies to 
investigate the effect of brazilin on inhibiting TNF-α, COX-2 and MMP3 gene 
expression in chondrocytes. As shown in Figure 4A and 4B, TNF-α gene expression 
in primary chondrocytes and SW1353 was markedly upregulated following 
stimulation with 10 ng/ml IL-1ß. Brazilin, particularly at concentrations of 10 µg/ml 
and 20 µg/ml, completely blocked the IL-1ß-induced TNF-α mRNA levels, 
re-establishing expression levels comparable to untreated cells. The COX-2 mRNA 
level in primary chondrocytes (Figure 4C) and SW1353 cells (Figure 4D) were 
strongly increased 76.28±9.76 fold and 25.25±2.71 fold, respectively by 10 ng/ml 
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IL-1ß, whereas pre-treatment with 5-20 µg/ml brazilin significantly reduced this 
effect. Figure 4E and 4F demonstrate that brazilin dose dependently suppressed the 
IL-1ß-mediated upregulation of MMP3 mRNA levels in primary chondrocytes and 
SW1353 cells. 5 µg/ml CSE was added in each experiment and 5-20 µg/ml CAPE, 
one well known inhibitor of NF-kappa B activation were added in the experiments 
with primary chondrocytes as positive control. Pretreatments with CSE and CAPE 
reduced the IL-1ß stimulated expression of TNF-α, COX-2 and MMP3 mRNA 
expression in chondrocytes. In the previous studies, 5, 10, or 20 µg/ml CSE showed 
significant inhibitory effect on expression of TNF-α, COX-2 and MMP3 mRNA. And 
in present study, 5µg/ml CSE in the most instances significantly inhibited the 
IL-1ß-mediated upregulation of TNF-α, COX-2 and MMP3 mRNA levels in primary 
chondrocytes and SW1353 cells, but was less effective comparing with 5µg/ml 
brazilin (Fig.4A.B.C.D.F). A similar effect with different concentrations of CAPE was 
also observed in the present study (Fig.4A,C,E). 
 
3.5. Brazilin reduces TNF-α and MMP3 production but not PGE-2 production 
To quantify the effects of brazilin on secreted levels of TNF-α, PGE2 and MMP3, the 
culture supernatants of chondrocytes were determined using ELISA assays. As shown 
in Figure 5A, 48 h treatment with IL-1ß (10 ng/ml) caused an increase of TNF-α 
expression in primary human chondrocytes from 278.37±16.33 to 396±30.85 pg/ml. 
Pretreatment with 10 µg/ml brazilin significantly suppressed the IL-1ß-induced 
TNF-α production released in cell culture. Interestingly, PGE-2 release (Figure 5B) 
99
Specific topics - Study 6
was not augmented by IL-1ß stimulation in this study in spite of the increased 
COX-2mRNA levels in presence of IL-1ß. An increase of MMP3 release following by 
IL-1ß was not observed in Figure 5C. However, the MMP3 production in primary 
cells treated with IL-1ß was down-regulated by 10 µg/ml brazilin, even lower than 
basal levels.  
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4. Discussion 
 
Overproduction of pro-inflammatory cytokines, notably IL-1ß and TNF-α is one 
characteristic feature of established OA. Evidence indicates that in response to these 
proinflammatory mediators, chondrocytes increase the synthesis of catabolic 
proteinases (such as MMPs 1, 2, 3, 8, 9, and 13), production of PGE2 by stimulating 
the expression of COX-2, PGE synthase 1, and soluble phospholipase A2, and 
production of NO via incucible nitric oxide synthetase( iNOS, or NOS2) [19,20,21]. 
Thereby, reducing or preventing the inflammatory properties within joint tissue 
represents a promising therapeutic approach to relief OA symptoms, to prevent the 
progression of OA and to restore the structure of cartilage. 
 
Brazilin, the major compound in CSE, is also known as a red dye (Natural Red 24) 
used since the middle ages in dye fabric. Although brazilin possesses defined 
chemical structure, its own IUPAC name and CAS-number, most commercial 
available “brazilin” is an extract of sappan wood consisting several undefined 
compounds, probably because of the long history of utilization of this name in dye 
fabric as dye name. To our knowlegment, pure brazilin is commercial difficult to 
available. Thus, to obtain pure brazilin, we isolated it from CSE and identified it using 
analytical HPLC and NMR methods.  
 
As noted above, TNF-α is one of the predominant proinflammatory cytokines, which 
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exert catabolic effects on chondrocyte metabolism. Our present results clearly 
demonstrate that the addition of brazilin effectively suppresses the over-expression of 
TNF-α in stimulated OA chondrocytes as well as SW1353 chondrocytes. Of note, 5 
µg/ml brazilin showed a higher inhibitory effect on TNF-α mRNA expression than 
same concentration of CSE, indicating that brazilin contributes to at least the major 
part of the inhibitory effect of CSE on TNF-α production stimulated by IL-1ß. This 
result correlates well with a study obtained in mouse macrophages by Hu and 
coworkers [22]. In contrast, Washiyama et al. compared seven compounds isolated 
from a methanolic extract of Sappan lignum in mouse macrophage-like J774.1 cells 
and demonstrated that brazilin does not significantly contribute to the inhibitory 
effects of CSE on TNF-α production [10].  
 
Furthermore, inflammatory cytokines increase the production of prostaglandins via 
the induction of COX-2 and microsomal PGE synthase 1 [3]. Evidence indicated that 
PGE2 decrease proteoglycan synthesis and enhanced matrix degradation in OA 
cartilage explants [23]. RT-qPCR results reported in the present study indicate that 
brazilin is able to attenuate IL-1ß-induced COX-2 mRNA expression in SW1353 and 
primary chondrocytes in a dose dependent manner. No significant regulation was 
observed in ELISA assay of PGE2 production in present study probably because of 
amount of PGE2 in supernatant of cell culture under detection limitation in our 
experiments. Experiments in other cell types have indicated that the 
anti-inflammatory activity of brazilin involves the reduction of PGE2 synthesis [22, 
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23]. Interestingly, Washiyama et al found that brazilin minimally inhibited COX-2 
mRNA expression and PGE2 production [10]. 
MMP3 is one of the particularly effective metalloproteinases in cartilage degradation 
because it cleaves a wide variety of matrix proteins, e.g., aggrecan, fibronection and 
several collagens, and it activates other MMPs [19]. Our previous studies revealed for 
the first time that CSE inhibits chondrocyte catabolism via suppression of 
IL-1ß-induced MMPs at mRNA and protein levels [15]. In present study, we 
demonstrated that brazilin decreased MMP3 mRNA expression and consequently 
reduced the MMP-3 synthesis. To our surprise, MMP-3 release was not induced by 
IL-1ß stimulation in ELISA assay or at least statistically not significant in this study. 
While in several studies, IL-1ß was shown to upregulate MMP-1, -3, and 13 in normal 
human chondrocytes, OA chondrocytes, and chondrosarcoma cells using Westenblot 
[19, 25, 26]. The reason might be the primary chondrocytes used in our experiments, 
were obtained from OA patients. These chondrocytes were accustomed to the milieu 
presenting with high level of IL-1ß and are not able to produce MMPs in response to 
IL-1ß stimulation. Another explains might be that ELISA assay observed only the 
protein level secreted to the cell culture. Perhaps there were upregulation existed 
intracellular and should be determined using Western blot. However, the MMP3 
production in primary cells was down-regulated by 10 µg/ml brazilin, even lower than 
basal levels. This result indicates that brazilin at least partly contribute to reduction of 
MMP-3 synthesis caused by CSE and might be able to slow down extracellular matrix 
degradation by inhibiting MMP activity. 
103
Specific topics - Study 6
One limitation of our study is the limited number of cartilage specimens and limited 
biological assays. Therefore, additional experiments on normal and OA chondrocytes 
are needed before definitive conclusions can be drawn. Further research to explore the 
mechanism underlying the anti-inflammatory effects and the inhibitory effects on 
MMPs of brazilin and CSE in cartilage is also necessary.  
 
In summary, we isolated brazilin from CSE, identified its structure, and determined its 
biological activities on OA chondrocytes in comparison to CSE. Brazilin substantially 
suppresses the expression of inflammatory mediator TNF-α, COX-2 and proteinase 
MMP3 and production of TNF-α and MMP3. The study suggests that brazilin largely 
contributes to the anti-inflammatory and anti-catabolic action of CSE in human 
chondrocytes. The data suggest that brazilin may be beneficial for future management 
of OA. 
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Glossary 
 
 
ADAMTS = A disintegrin and metalloproteinase with thrombospondin motifs 
COX-2 = Cyclooxygenase-2 
CSE = Ethanolic Caesalpinia Sappan Extract  
DMEM = Dulbecco’s modified Eagle’s medium 
ECM = Extracellular matrix 
FCS = Fetal calf serum 
GAPDH = Glyceraldehyde-3-phosphate dehydrogenase 
IL-1ß = Interleukin-1 beta 
iNOS = Inducible nitric oxide synthase 
ITS = Insulin-Transferrin-Selenium  
MMPs = Matrix metalloproteinases 
NF-κB = Nuclear factor-kappa-B 
NO = Nitric oxide 
NSAIDs = Nonsteroidal anti-inflammatory drugs 
OA = Osteoarthritis 
PGE2 = Prostaglandin E2 
RIN = RNA integrity numbers  
RT-qPCR = Quantitative real-time RT-PCR  
TNF-α = Tumor necrosis factor- alpha 
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5. Figures and Tables  
 
 
 
Table 1. Details on RT-qPCR primers. 
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Figure 1. Analytic HPLC chromatogram at 280nm  
(1A) 1mg/ml CSE (1B) 1mg/ml Lyophilisate from CSE water extract (1C) the major 
fraction collected in repeated preparative HPLC separation after lyophilisation 
107
Specific topics - Study 6
OOH
H
HO
HO
H H H H H
H
H
OH
H
H
1
2
3
4
4a
1a
5
6
6a
7
7a
8
9
10
11
11a 12
 
Figure 2. Structure of brazilin 
The structure of brazilin conducted from NMR spectra.  
 
 
co
nt
ro
l
0.
62
5
1.
25 2.
5 5
10
 
20 40
0
50
100
150
Brazilin (ug/ml)
C
e
ll
 v
ia
b
il
it
y
 %
 
Figure3. Viability of primary chondrocytes in presence of brazilin.  
Cells were incubated for 72 h with various concentrations of brazilin (0.625-40 μg/ml) 
and the viability was determined using MTT-based assays. Each value represents the 
mean ± SD. Significant differences as compared to untreated cells (p< 0.05). 
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Figure 4. Effect of brazilin on TNF-α, COX-2 and MMP3 mRNA transcription in 
primary chondrocyte and SW1353 cells. (A) Effect of brazilin on TNF-α mRNA 
transcription in primary chondrocyte (B) Effect of brazilin on TNF-α mRNA 
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transcription in SW1353 cells (C) Effect of brazilin on COX-2 mRNA transcription in 
primary chondrocyte (D) Effect of brazilin on COX-2 mRNA transcription in 
SW1353 cells (E) Effect of brazilin on MMP-3 mRNA transcription in primary 
chondrocyte (F) Effect of brazilin on MMP-3 mRNA transcription in SW1353 cells. 
Cells were preincubated with various concentration of brazilin and CAPE for 1 h prior 
to stimulation with 10 ng/ml IL-1ß for 6 h. The alteration of mRNA levels was 
analyzed using RT-qPCR. Results are expressed as fold changes (mean ± SD) versus 
controls. Asterisk indicates significant differences compared to cells treated only with 
IL-1ß 10 ng/ml (p< 0.05). 
 
 
 
 
110
Specific topics - Study 6
C 
IL
1-
B
ra
zi
lin
 1
0
0
100
200
300
400
500
g/ml

A
p
g
/m
l
co
nt
ro
l 
IL
-1
B
ra
zi
lin
10
0
2
4
6
B
g/ml
p
g
/m
l
co
nt
ro
l 
IL
-1
B
ra
zi
lin
10
0
5
10
15
20
25

C
µg/ml
n
g
/m
l
 
 
Figure 5. Effect of brazilin on TNF-α (A), PGE-2(B), and MMP3(C) production 
in primary chondrocytes. After 1 h preincubation with 10 µg/ml Brazilin, cells were 
treated with 10 ng/ml IL-1ß for additional 48 h. TNF-α, PGE2, MMP3 levels in the 
cell culture medium were analyzed using ELISA assay. Data are presented as mean ± 
SD (n=1). Asterisk indicates significant differences compared to cells treated only 
with IL-1ß (p< 0.05).  
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3. Conclusion 
 
The present thesis aimed to investigate two separate aspects of inflammation in 
human chondrocytes, the unique cell component of articular cartilage.  
 
First, we investigated the chondrocyte glycophenotype in different cell models and 
under inflammatory conditions in vitro (Study1-3). In the first study, using real-time 
qPCR, immunofluorescence, and glycosaminoglycan (GAG) staining, the glycoprofile 
of primary human chondrocytes and two chondrocyte cell lines was evaluated. The 
immortalized cell lines expressed and produced minor extracellular matrix genes and 
proteins in comparison with primary chondrocytes. Through the analysis of the 
glycosylation pattern via lectin-binding, a reduced level of high-mannose type and 
sialic acid-capped N-glycans as well as increased fucosylated O-glycosylation was 
obeserved in C-28/I2 and T/C-28a2 cell lines. Thus, it could be concluded that 
differences in the molecular chondrocyte phenotype are reflected in the 
glycophenotype of the cells. In the following 2 studies (Study 2 and 3), the regulation 
of the chondrocyte glycophenotype was monitored using quantitative PCR and 
LC–ESI-MS. Primary human chondrocytes predominantly express 
α-(2→6)-sialyltransferases (SiaT) and accordingly, α-(2→6)-linked sialic acid 
residues in glycoprotein N-glycans. In contrast, the preponderance of α-2,3-linked 
sialyl residues and, correspondingly, reduced levels of α-2,6-specific SiaTs are 
associated with the altered chondrocyte phenotype of C-28/I2 and SW1353 cells. Of 
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note, an overall shift towards α-(2→3)-sialylation of diantennary fucosylated 
N-glycans and towards α-(2→3)-SiaT mRNA levels was observed following 
stimulation of primary chondrocytes with IL-1ß or TNF-α. In addition, both cytokines 
increased overall sialylation of N- and O-glycans as well as α-(2→3)-linked sialic 
acid residues in chondrocyte glycoproteins. Moreover, a considerable shift from 
oligomannosidic glycans towards complex-type N-glycans was found in IL-1ß or 
TNF-α treated chondrocytes. In summary, inflammatory conditions induce specific 
alterations of the chondrocyte glycophenotype at mRNA and glycan levels, which 
might affect the maintenance of articular cartilage function. 
 
As inflammatory events represent interesting targets for the treatment of OA, the 
second part of this thesis evaluated the activities of Caesalpinia sappan extracts and 
the isolated compound brazilin in stimulated human chondrocytes and macrophages 
(Studies 4-6). Using preparative HPLC, we isolated brazilin from the ethanolic extract 
of Caesalpinia sappan (CSE) and identified it by NMR and HPLC (Study 6). 
Following viability tests, ELISA, and validated real-time PCR assays, we found that 
CSE and brazilin can effectively abrogate the IL-1ß-induced overexpression of 
inflammatory mediators, such as IL-1ß, TNF-α, iNOS and COX-2. We further 
observed that the levels of IL-1ß-induced MMP-1, -3, -7, -9 and -13 mRNA, but not 
TIMP (tissue inhibitors of MMPs) mRNA levels, were down-regulated in 
chondrocytes in response to CSE. Co-transfection experiments with COX-2 and 
MMP-13 luciferase reporter constructs and NF-κB p50 and p65 expression vectors 
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further showed that CSE abrogated the NF-κB (p65/p50)-driven promoter activation. 
Blockade of IL-1ß-induced NF-κB signalling and its downstream pro-inflammatory 
targets by CSE and brazilin may be beneficial for reducing cartilage breakdown in 
arthritis. 
 
In conclusion, this thesis (1) contributes to the elucidation of the chondrocyte 
glycophenotype under inflammatory conditions and (2) suggests that CSE or 
CSE-derived compounds should be further developed as therapeutically effective 
agents or lead structures for future management of inflammation in OA. 
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4. Appendix 
German Abstract- Kurzfassung 
 
Osteoarthrose ist definiert als eine progressive, degenerative Gelenkserkrankung im 
höheren Lebensalter. Im Gegensatz zur Rheumatoiden Arthritis beschreibt die 
Arthrose einen langsamen Verschleiß des Gelenksknorpels und ist als eine nicht 
entzündliche Gelenkserkrankung zu verstehen. Obwohl die entzündliche Komponente 
ein wesentliches Unterscheidungskriterium darstellt, kann auch eine Arthrose, 
insbesondere im fortgeschrittenen Stadium der Krankheit, von entzündlichen 
Prozessen begleitet sein und die klassischen Symptome einer Entzündung (Rötung, 
Schwellung und Schmerzen) aufweisen. Es ist bekannt, dass das Gelenksgewebe bei 
Arthrosepatienten eine deutlich erhöhte Produktion proinflammatorischer Zytokine, 
wie zum Beispiel IL-1ß und TNF-α, aufweist. IL-1ß und TNF-α steigern die Synthese 
matrixdegradierender Proteasen (MMPs) und inhibieren die Kollagen- und 
Aggrekansynthese. 
In der vorliegenden Dissertation wurden zwei unterschiedliche Aspekte von 
Entzündungsprozessen in Chondrozyten untersucht.  
Einerseits wurde der zelluläre Glykophänotyp in unterschiedlichen 
Chondrozytenmodellen unter Entzündungsbedingungen untergesucht. Die Studien 1-3 
fokussieren den Blick auf (1) den Zusammenhang von Glykophänotyp und 
generellem Zellphänotyp in humanen Chondrozyten, (2) Sialylisierungsmuster von N- 
und O-Glykanen in Chondrozyten, und (3) den Einfluss inflammatorischer Zytokine 
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(IL-1ß und TNF-α) auf die Glykanexpression. 
 
Weil Entzündungsprozesse immer wieder im Interesse der Erforschung neuer 
Behandlungsmöglichkeiten der OA stehen, evaluierte der zweite Teil dieser 
Dissertation die Effekte eines ethanolischen Caesalpinia sappan Extraktes (CSE) und 
einer daraus isolierten Reinsubstanz (Brazilin) auf stimulierte humane Chondrozyten 
und Macrophagen in vitro. In den Studien 4-6 konnte gezeigt werden, dass CSE und 
Brazilin anti-inflammtorische Effekte ausüben und knorpelabbauende Prozesse, 
welche durch IL-1ß induziert wurden, hemmen können. 
 
Zusammenfassend trägt diese Arbeit zur Beschreibung des 
Chondrozyten-Glycophänotyps unter entzündlichen Bedingungen bei, und weist 
darauf hin, dass CSE oder aus CSE isolierte Wirkstoffe zukünftig als therapeutisch 
wirksame Agenten oder Leitstrukturen für die Behandlung entzündlicher Prozesse bei 
der OA weiterentwickelt werden sollten. 
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